[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fJIa738B4PtuA2D50X7YqBhCwSbvLFDJWtU6NgyHvWFw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Icahn School of Medicine at Mount Sinai",[4],753,false,203,29,383037,88,497,[14,17,20,23,25,27,30,33],{"name":15,"count":16},"Coronary Artery Disease",16,{"name":18,"count":19},"Major Depressive Disorder",15,{"name":21,"count":22},"Depression",14,{"name":24,"count":22},"Obesity",{"name":26,"count":22},"Prostate Cancer",{"name":28,"count":29},"Mild Cognitive Impairment",12,{"name":31,"count":32},"Breast Cancer",10,{"name":34,"count":32},"Traumatic Brain Injury",[36,41,46,51,56,61,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT01706939","The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer","2020-04-01","Carboplatin",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06703437","Long Acting Neuraxial Peri-prostatic Block in Cancer","2023-02-23","Dehydrated alcohol",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05119140","Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis","2025-05","Hydroxychloroquine",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03781752","Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD","2025-08","Methylphenidate",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06069843","Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment","2025-09","IV Ketamine",{"nctId":62,"briefTitle":63,"date":64,"intervention":55},"NCT03781765","Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk","2025-09-25",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT04985500","ESP\u002FPIF for Sternotomy","2025-12-31","Bupivacain",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT03992469","Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease","2026-02-02","EBFAHF-2",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT05539729","Vancomycin Study in Multiple Sclerosis (MS)","2026-03","Vancomycin",{"nctId":81,"briefTitle":82,"date":78,"intervention":83},"NCT06418308","Intrathecal Dexmedetomidine vs Epinephrine","Dexmedetomidine",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,159,267,313,355,380,404,422,440,466,484,502,520,546,564,621,657,734,759,777,802,827,855,873,898,963,1020,1062,1099,1126,1165,1200,1230,1252,1285,1320,1351,1378,1396,1422,1449,1467,1485,1508,1535,1553,1571,1594,1612,1631,1649,1671,1692,1710,1733,1760,1778,1796,1814,1832,1850,1868,1892,1928,1948,1971,1989,2014,2032,2052,2072,2090,2116,2134,2158,2184,2202,2238,2299,2321,2345,2363,2387,2405,2423,2441,2486,2510,2528,2618,2668,2694,2721,2756,2788,2810,2832,2868,2893,2918,2942,2965,2989,3014,3038,3063,3087,3111,3137,3155,3180,3198,3224,3242,3260,3278,3304,3322,3340,3365,3390,3408,3435,3453,3471,3496,3520,3538,3563,3585,3608,3626,3644,3662,3687,3705,3730,3748,3774,3792,3815,3840,3868,3893,3916,3934,3952,3977,3995,4013,4037,4061,4079,4104,4122,4140,4158,4185,4203,4221,4239,4262,4286,4312,4330,4356,4374,4392,4410,4436,4454,4478,4496,4514,4539,4557,4585,4610,4634,4658,4681,4713,4742,4769,4795,4824,4856,4874,4898,4922,4946,4964,4988,5011,5035,5058,5076,5094,5112,5130,5148,5166,5189,5207,5225,5243,5261,5284,5308,5334,5352,5370,5388,5414,5432,5457,5475,5498,5516,5534,5552,5577,5595,5613,5641,5659,5685,5703,5726,5747,5771,5795,5813,5831,5849,5872,5894,5917,5935,5958,5976,5999,6017,6041,6066,6090,6113,6137,6155,6177,6199,6225,6250,6268,6291,6316,6338,6356,6374,6392,6421,6439,6457,6475,6493,6523,6547,6572,6596,6621,6645,6663,6687,6711,6738,6756,6780,6802,6829,6847,6865,6889,6974,7018,7057,7099,7125,7147,7172,7205,7231,7253,7278,7296,7320,7345,7370,7392,7417,7435,7453,7479,7497,7518,7541,7564,7587,7605,7630,7654,7678,7702,7724,7742,7764,7789,7807,7830,7853],{"intervention":55,"totalTrials":93,"cells":94},5,{"EARLY_PHASE1":95,"PHASE1":110,"PHASE2":113,"PHASE3":115,"PHASE4":117,"NA":147},{"trials":96,"activeCount":109,"soonestReadout":102},[97],{"nctId":98,"briefTitle":99,"status":100,"phases":101,"primaryCompletion":102,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":108},"NCT05978167","Targeting Drug Memories With Methylphenidate","ACTIVE_NOT_RECRUITING",[85],"2026-09-03","2023-07-05",51,[106,107],"Substance Use Disorder","Cocaine Use Disorder",[55],1,{"trials":111,"activeCount":112},[],0,{"trials":114,"activeCount":112},[],{"trials":116,"activeCount":112},[],{"trials":118,"activeCount":146,"soonestReadout":54},[119,128,140],{"nctId":52,"briefTitle":53,"status":120,"phases":121,"primaryCompletion":54,"completion":54,"start":122,"enrollment":123,"conditions":124,"interventions":127},"RECRUITING",[89],"2018-03-04",500,[125,126],"ADHD","Attention Deficit Hyperactivity Disorder",[55],{"nctId":129,"briefTitle":130,"status":131,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT00183391","Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children","COMPLETED",[89],"2011-06","2005-07",232,[137],"Attention Deficit Disorder With Hyperactivity",[139,55],"Atomoxetine",{"nctId":62,"briefTitle":63,"status":120,"phases":141,"primaryCompletion":64,"completion":64,"start":142,"enrollment":143,"conditions":144,"interventions":145},[89],"2019-06-04",44,[125,126],[55,139],2,{"trials":148,"activeCount":112},[149],{"nctId":150,"briefTitle":151,"status":131,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NCT00824317","Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD\u002FHD), Inattentive Type",[90],"2005-02","2001-10",25,[125],[158],"methylphenidate",{"intervention":160,"totalTrials":161,"cells":162},"Ketamine",9,{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":229,"PHASE4":241,"NA":265},{"trials":164,"activeCount":112},[],{"trials":166,"activeCount":112},[],{"trials":168,"activeCount":109,"soonestReadout":184},[169,180,189,200,210,219],{"nctId":170,"briefTitle":171,"status":131,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT04173962","Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects",[87],"2021-03-18","2019-08-08",24,[177],"Healthy Volunteers",[160,179],"Midazolam",{"nctId":181,"briefTitle":182,"status":120,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":188},"NCT06559826","Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression",[87],"2027-08","2025-01-10",70,[18],[160],{"nctId":190,"briefTitle":191,"status":131,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":197},"NCT03102736","Ketamine and Nitroprusside for Depression",[87],"2019-06-12","2017-02-14",40,[21],[198,160,199],"Placebos","Nitroprusside",{"nctId":201,"briefTitle":202,"status":131,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":208},"NCT01880593","Ketamine Plus Lithium in Treatment-Resistant Depression",[87],"2016-11","2013-07",34,[21],[209,160],"Lithium",{"nctId":211,"briefTitle":212,"status":131,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":16,"conditions":216,"interventions":218},"NCT04889664","Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD",[87],"2023-10-14","2021-06-04",[217],"PTSD",[160],{"nctId":220,"briefTitle":221,"status":222,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":112,"conditions":226,"interventions":228},"NCT05105061","Intramuscular Ketamine for Suicidal Ideation","WITHDRAWN",[87],"2022-03-24","2022-02",[227],"Suicidal Ideation",[160],{"trials":230,"activeCount":112},[231],{"nctId":232,"briefTitle":233,"status":131,"phases":234,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":240},"NCT02397889","Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)",[87,88],"2020-01-27","2015-05-18",30,[239],"Posttraumatic Stress Disorder (PTSD)",[160,179],{"trials":242,"activeCount":109,"soonestReadout":259},[243,255],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":109,"conditions":250,"interventions":252},"NCT00947791","Treatment Study of Bipolar Depression","TERMINATED",[89],"2009-10","2009-07",[251],"Bipolar Disorder",[253,254],"ketamine","midazolam",{"nctId":256,"briefTitle":257,"status":120,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":264},"NCT06213324","Neural Circuit Effects of Ketamine in Depression",[89],"2028-03-30","2028-04-30","2024-01-31",120,[18],[160],{"trials":266,"activeCount":112},[],{"intervention":139,"totalTrials":268,"cells":269},4,{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":299,"PHASE4":301,"NA":311},{"trials":271,"activeCount":112},[],{"trials":273,"activeCount":112},[],{"trials":275,"activeCount":109,"soonestReadout":281},[276,288],{"nctId":277,"briefTitle":278,"status":279,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":287},"NCT06899178","Atomoxetine in Melanocortin Obesity Syndrome","NOT_YET_RECRUITING",[87],"2028-07","2025-04",20,[285,286],"Melanocortin Obesity Syndrome","MCOS",[139],{"nctId":289,"briefTitle":290,"status":131,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":298},"NCT03091400","Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)",[87],"2018-06-11","2017-03-16",11,[296,297],"Memory Disorders","Multiple Sclerosis",[139],{"trials":300,"activeCount":112},[],{"trials":302,"activeCount":109,"soonestReadout":64},[303,307],{"nctId":129,"briefTitle":130,"status":131,"phases":304,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":305,"interventions":306},[89],[137],[139,55],{"nctId":62,"briefTitle":63,"status":120,"phases":308,"primaryCompletion":64,"completion":64,"start":142,"enrollment":143,"conditions":309,"interventions":310},[89],[125,126],[55,139],{"trials":312,"activeCount":112},[],{"intervention":314,"totalTrials":146,"cells":315},"Olanzapine",{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":324,"NA":353},{"trials":317,"activeCount":112},[],{"trials":319,"activeCount":112},[],{"trials":321,"activeCount":112},[],{"trials":323,"activeCount":112},[],{"trials":325,"activeCount":109,"soonestReadout":344},[326,340],{"nctId":327,"briefTitle":328,"status":131,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT00044655","Switching Medication to Treat Schizophrenia",[89],"2009-03","2001-07",219,[334],"Schizophrenia",[336,314,337,338,339],"Risperidone","Ziprasidone","Quetiapine","Aripiprazole",{"nctId":341,"briefTitle":342,"status":120,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":350},"NCT06133114","Psychopharmacological Treatment of Emotional Distress",[89],"2026-10","2024-03-13",80,[348,349],"Suicide Crisis Syndrome","Psychological Distress",[351,314,352],"Clonazepam","Buprenorphine",{"trials":354,"activeCount":112},[],{"intervention":356,"totalTrials":109,"cells":357},"Chlorthalidone",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":366,"NA":378},{"trials":359,"activeCount":112},[],{"trials":361,"activeCount":112},[],{"trials":363,"activeCount":112},[],{"trials":365,"activeCount":112},[],{"trials":367,"activeCount":109,"soonestReadout":372},[368],{"nctId":369,"briefTitle":370,"status":120,"phases":371,"primaryCompletion":372,"completion":373,"start":374,"enrollment":346,"conditions":375,"interventions":377},"NCT07225764","CaOx Stone Prevention",[89],"2027-06-01","2027-06-30","2025-10-23",[376],"Kidney Stones",[356],{"trials":379,"activeCount":112},[],{"intervention":83,"totalTrials":109,"cells":381},{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":402},{"trials":383,"activeCount":112},[],{"trials":385,"activeCount":112},[],{"trials":387,"activeCount":112},[],{"trials":389,"activeCount":112},[],{"trials":391,"activeCount":109,"soonestReadout":78},[392],{"nctId":81,"briefTitle":82,"status":120,"phases":393,"primaryCompletion":78,"completion":78,"start":394,"enrollment":395,"conditions":396,"interventions":399},[89],"2024-09-17",62,[397,398],"Cesarean Section","Anesthesia, Spinal",[83,400,401],"Epinephrine","Standardized Spinal Mixture",{"trials":403,"activeCount":112},[],{"intervention":400,"totalTrials":109,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":420},{"trials":407,"activeCount":112},[],{"trials":409,"activeCount":112},[],{"trials":411,"activeCount":112},[],{"trials":413,"activeCount":112},[],{"trials":415,"activeCount":109,"soonestReadout":78},[416],{"nctId":81,"briefTitle":82,"status":120,"phases":417,"primaryCompletion":78,"completion":78,"start":394,"enrollment":395,"conditions":418,"interventions":419},[89],[397,398],[83,400,401],{"trials":421,"activeCount":112},[],{"intervention":401,"totalTrials":109,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":438},{"trials":425,"activeCount":112},[],{"trials":427,"activeCount":112},[],{"trials":429,"activeCount":112},[],{"trials":431,"activeCount":112},[],{"trials":433,"activeCount":109,"soonestReadout":78},[434],{"nctId":81,"briefTitle":82,"status":120,"phases":435,"primaryCompletion":78,"completion":78,"start":394,"enrollment":395,"conditions":436,"interventions":437},[89],[397,398],[83,400,401],{"trials":439,"activeCount":112},[],{"intervention":441,"totalTrials":109,"cells":442},"Ephedrine",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":464},{"trials":444,"activeCount":112},[],{"trials":446,"activeCount":112},[],{"trials":448,"activeCount":112},[],{"trials":450,"activeCount":112},[],{"trials":452,"activeCount":109,"soonestReadout":457},[453],{"nctId":454,"briefTitle":455,"status":120,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":462},"NCT05873218","Impact of Prophylactic Ephedrine on Fetal Heart Tracing and Uterine Tetanic Contraction After CSE",[89],"2027-05","2023-06-26",100,[461],"Labor",[441,463],"Normal Saline Placebo",{"trials":465,"activeCount":112},[],{"intervention":463,"totalTrials":109,"cells":467},{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":474,"PHASE4":476,"NA":482},{"trials":469,"activeCount":112},[],{"trials":471,"activeCount":112},[],{"trials":473,"activeCount":112},[],{"trials":475,"activeCount":112},[],{"trials":477,"activeCount":109,"soonestReadout":457},[478],{"nctId":454,"briefTitle":455,"status":120,"phases":479,"primaryCompletion":457,"completion":457,"start":458,"enrollment":459,"conditions":480,"interventions":481},[89],[461],[441,463],{"trials":483,"activeCount":112},[],{"intervention":351,"totalTrials":109,"cells":485},{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":492,"PHASE4":494,"NA":500},{"trials":487,"activeCount":112},[],{"trials":489,"activeCount":112},[],{"trials":491,"activeCount":112},[],{"trials":493,"activeCount":112},[],{"trials":495,"activeCount":109,"soonestReadout":344},[496],{"nctId":341,"briefTitle":342,"status":120,"phases":497,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":498,"interventions":499},[89],[348,349],[351,314,352],{"trials":501,"activeCount":112},[],{"intervention":352,"totalTrials":109,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":518},{"trials":505,"activeCount":112},[],{"trials":507,"activeCount":112},[],{"trials":509,"activeCount":112},[],{"trials":511,"activeCount":112},[],{"trials":513,"activeCount":109,"soonestReadout":344},[514],{"nctId":341,"briefTitle":342,"status":120,"phases":515,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":516,"interventions":517},[89],[348,349],[351,314,352],{"trials":519,"activeCount":112},[],{"intervention":521,"totalTrials":109,"cells":522},"Atezolizumab",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":531,"NA":544},{"trials":524,"activeCount":112},[],{"trials":526,"activeCount":112},[],{"trials":528,"activeCount":112},[],{"trials":530,"activeCount":112},[],{"trials":532,"activeCount":109,"soonestReadout":537},[533],{"nctId":534,"briefTitle":535,"status":120,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":195,"conditions":540,"interventions":542},"NCT07059494","Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant",[89],"2027-08-01","2028-08-01","2026-06",[541],"Hepatocellular Carcinoma",[521,543],"Bevacizumab",{"trials":545,"activeCount":112},[],{"intervention":543,"totalTrials":109,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":556,"NA":562},{"trials":549,"activeCount":112},[],{"trials":551,"activeCount":112},[],{"trials":553,"activeCount":112},[],{"trials":555,"activeCount":112},[],{"trials":557,"activeCount":109,"soonestReadout":537},[558],{"nctId":534,"briefTitle":535,"status":120,"phases":559,"primaryCompletion":537,"completion":538,"start":539,"enrollment":195,"conditions":560,"interventions":561},[89],[541],[521,543],{"trials":563,"activeCount":112},[],{"intervention":565,"totalTrials":268,"cells":566},"Cannabidiol",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":580,"PHASE3":604,"PHASE4":617,"NA":619},{"trials":568,"activeCount":112},[],{"trials":570,"activeCount":112},[571],{"nctId":572,"briefTitle":573,"status":131,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":175,"conditions":577,"interventions":579},"NCT05023070","Investigation of the Pharmacokinetic Profile of CBD - Phase 1 ANANDA",[86],"2023-02-16","2021-07-22",[578],"Healthy",[565,565,565,565],{"trials":581,"activeCount":146,"soonestReadout":586},[582,592],{"nctId":583,"briefTitle":584,"status":120,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT06930703","Cannabidiol in Sickle Cell Disease",[86,87],"2027-02-01","2025-04-03",52,[590],"Sickle Cell Disease",[565],{"nctId":593,"briefTitle":594,"status":120,"phases":595,"primaryCompletion":596,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":603},"NCT07278505","Study of Cannabidiol and Neuroimaging on Stress",[86,87],"2030-02-28","2025-10-28",160,[600,601,602],"Early Life Adversity","Trauma","Stress",[565],{"trials":605,"activeCount":109,"soonestReadout":610},[606],{"nctId":607,"briefTitle":608,"status":120,"phases":609,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":616},"NCT06940674","Adjunctive Cannabidiol for Recovery From Opioid Study",[88],"2027-07-15","2027-08-15","2025-06-13",450,[615],"Opioid Use Disorder (OUD)",[565],{"trials":618,"activeCount":112},[],{"trials":620,"activeCount":112},[],{"intervention":622,"totalTrials":146,"cells":623},"Suzetrigine",{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":653,"NA":655},{"trials":625,"activeCount":112},[],{"trials":627,"activeCount":112},[],{"trials":629,"activeCount":112},[],{"trials":631,"activeCount":146,"soonestReadout":647},[632,643],{"nctId":633,"briefTitle":634,"status":120,"phases":635,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":642},"NCT07548385","Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN",[88],"2027-02-23","2026-04",235,[640,641],"Total Knee Replacement Surgery","Post-operative Pain",[622],{"nctId":644,"briefTitle":645,"status":120,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":638,"conditions":649,"interventions":652},"NCT07539623","Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery",[88],"2026-12-22","2026-05-01",[650,651,641],"Bariatric Surgery","Cardiac Surgery With Sternotomy",[622],{"trials":654,"activeCount":112},[],{"trials":656,"activeCount":112},[],{"intervention":40,"totalTrials":93,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":720,"PHASE4":730,"NA":732},{"trials":660,"activeCount":112},[],{"trials":662,"activeCount":112},[],{"trials":664,"activeCount":112},[665,680,693,709],{"nctId":666,"briefTitle":667,"status":668,"phases":669,"primaryCompletion":54,"completion":54,"start":670,"enrollment":9,"conditions":671,"interventions":674},"NCT04308837","A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation","UNKNOWN",[87],"2018-12-03",[672,673],"Gastric Cancer","Stomach Cancer",[675,40,676,677,678,679],"Paclitaxel","Dexamethasone","Diphenhydramine","Famotidine","Palonosetron",{"nctId":681,"briefTitle":682,"status":131,"phases":683,"primaryCompletion":684,"completion":684,"start":685,"enrollment":195,"conditions":686,"interventions":687},"NCT02903160","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",[87],"2021-11-15","2017-01-13",[26],[688,689,690,691,40,692],"Abiraterone acetate","Prednisone","Radium-223 dichloride","cabazitaxel","Enzalutamide",{"nctId":694,"briefTitle":695,"status":246,"phases":696,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":700,"interventions":702},"NCT03329378","Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer",[87],"2021-03-07","2019-01-24",7,[701],"Locally Advanced Breast Cancer",[703,40,704,705,706,704,675,707,708,675],"Docetaxel","Trastuzumab","Pertuzumab","Pegfilgrastim","Doxorubicin","Cyclophosphamide",{"nctId":710,"briefTitle":711,"status":222,"phases":712,"primaryCompletion":713,"completion":713,"start":713,"enrollment":112,"conditions":714,"interventions":717},"NCT04849377","RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC",[87],"2022-06-14",[715,716],"Human Papillomavirus (HPV)","Head and Neck Squamous Cell Carcinoma (HNSCC)",[40,718,719],"Cisplatin 200","Cisplatin 240",{"trials":721,"activeCount":109,"soonestReadout":39},[722],{"nctId":37,"briefTitle":38,"status":100,"phases":723,"primaryCompletion":39,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":729},[88],"2035-05-01","2012-09-01",23,[728],"Squamous Cell Carcinomas",[40],{"trials":731,"activeCount":112},[],{"trials":733,"activeCount":112},[],{"intervention":735,"totalTrials":109,"cells":736},"Misoprostol",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":755,"NA":757},{"trials":738,"activeCount":112},[],{"trials":740,"activeCount":112},[],{"trials":742,"activeCount":112},[],{"trials":744,"activeCount":109,"soonestReadout":539},[745],{"nctId":746,"briefTitle":747,"status":120,"phases":748,"primaryCompletion":539,"completion":539,"start":749,"enrollment":750,"conditions":751,"interventions":753},"NCT06259097","Different Medications to Induce Labor",[88],"2024-07-02",300,[752,461],"Pregnancy",[735,754],"Pitocin",{"trials":756,"activeCount":112},[],{"trials":758,"activeCount":112},[],{"intervention":754,"totalTrials":109,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":773,"NA":775},{"trials":762,"activeCount":112},[],{"trials":764,"activeCount":112},[],{"trials":766,"activeCount":112},[],{"trials":768,"activeCount":109,"soonestReadout":539},[769],{"nctId":746,"briefTitle":747,"status":120,"phases":770,"primaryCompletion":539,"completion":539,"start":749,"enrollment":750,"conditions":771,"interventions":772},[88],[752,461],[735,754],{"trials":774,"activeCount":112},[],{"trials":776,"activeCount":112},[],{"intervention":778,"totalTrials":109,"cells":779},"Low-dose sirolimus",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":798,"NA":800},{"trials":781,"activeCount":112},[],{"trials":783,"activeCount":112},[],{"trials":785,"activeCount":112},[],{"trials":787,"activeCount":109,"soonestReadout":792},[788],{"nctId":789,"briefTitle":790,"status":120,"phases":791,"primaryCompletion":792,"completion":793,"start":794,"enrollment":346,"conditions":795,"interventions":797},"NCT06960928","Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19",[88],"2026-12-31","2027-05-31","2025-04-18",[796],"Long COVID-19",[778],{"trials":799,"activeCount":112},[],{"trials":801,"activeCount":112},[],{"intervention":803,"totalTrials":109,"cells":804},"Inclisiran",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":823,"NA":825},{"trials":806,"activeCount":112},[],{"trials":808,"activeCount":112},[],{"trials":810,"activeCount":112},[],{"trials":812,"activeCount":109,"soonestReadout":817},[813],{"nctId":814,"briefTitle":815,"status":120,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":822},"NCT06494501","The Prevent Coronary Artery Disease Trial",[88],"2032-06-30","2024-09-12",1600,[821],"Atherosclerotic Cardiovascular Disease",[803],{"trials":824,"activeCount":112},[],{"trials":826,"activeCount":112},[],{"intervention":828,"totalTrials":109,"cells":829},"Antiplatelet-only strategy",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":851,"NA":853},{"trials":831,"activeCount":112},[],{"trials":833,"activeCount":112},[],{"trials":835,"activeCount":112},[],{"trials":837,"activeCount":109,"soonestReadout":842},[838],{"nctId":839,"briefTitle":840,"status":120,"phases":841,"primaryCompletion":842,"completion":842,"start":843,"enrollment":844,"conditions":845,"interventions":849},"NCT04045665","Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG",[88],"2026-08-31","2019-12-13",3200,[846,847,848],"Atrial Fibrillation","Stroke","Bleeding",[828,850],"Oral Anticoagulant plus background antiplatelet therapy",{"trials":852,"activeCount":112},[],{"trials":854,"activeCount":112},[],{"intervention":850,"totalTrials":109,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":869,"NA":871},{"trials":858,"activeCount":112},[],{"trials":860,"activeCount":112},[],{"trials":862,"activeCount":112},[],{"trials":864,"activeCount":109,"soonestReadout":842},[865],{"nctId":839,"briefTitle":840,"status":120,"phases":866,"primaryCompletion":842,"completion":842,"start":843,"enrollment":844,"conditions":867,"interventions":868},[88],[846,847,848],[828,850],{"trials":870,"activeCount":112},[],{"trials":872,"activeCount":112},[],{"intervention":874,"totalTrials":109,"cells":875},"SAFE",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":882,"PHASE4":894,"NA":896},{"trials":877,"activeCount":112},[],{"trials":879,"activeCount":112},[],{"trials":881,"activeCount":112},[],{"trials":883,"activeCount":109,"soonestReadout":888},[884],{"nctId":885,"briefTitle":886,"status":120,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":890,"conditions":891,"interventions":893},"NCT06945315","SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)",[88],"2027-07-14","2023-11-14",196,[26,892],"Erectile Dysfunction",[874],{"trials":895,"activeCount":112},[],{"trials":897,"activeCount":112},[],{"intervention":899,"totalTrials":268,"cells":900},"Pembrolizumab",{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":902,"activeCount":112},[],{"trials":904,"activeCount":112},[],{"trials":906,"activeCount":956,"soonestReadout":948},[907,922,932,944],{"nctId":908,"briefTitle":909,"status":131,"phases":910,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":915,"interventions":919},"NCT03789097","Vaccination With Flt3L, Radiation, and Poly-ICLC",[86,87],"2023-12-21","2025-09-22","2019-04-05",17,[916,917,918],"Non-Hodgkin's Lymphoma","Metastatic Breast Cancer","Head and Neck Squamous Cell Carcinoma",[899,920,921],"Flt3L","Poly ICLC",{"nctId":923,"briefTitle":924,"status":120,"phases":925,"primaryCompletion":457,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":931},"NCT05589818","Pembrolizumab for Advanced NSCLC and PS 2-3",[87],"2028-05","2023-05-26",45,[930],"Non-Small Cell Lung Cancer (NSCLC)",[899],{"nctId":933,"briefTitle":934,"status":120,"phases":935,"primaryCompletion":184,"completion":936,"start":937,"enrollment":155,"conditions":938,"interventions":940},"NCT05462496","Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer",[87],"2028-04","2023-03-16",[939],"Pancreatic Cancer",[941,942,943,899],"FOLFIRINOX","Ciprofloxacin","Metronidazole",{"nctId":945,"briefTitle":946,"status":120,"phases":947,"primaryCompletion":948,"completion":949,"start":950,"enrollment":195,"conditions":951,"interventions":953},"NCT07027124","Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer",[87],"2026-12-01","2031-05-02","2026-03-19",[26,952],"High-risk Prostate Cancer",[954,899,955],"Darolutamide","Lupron",3,{"trials":958,"activeCount":112},[],{"trials":960,"activeCount":112},[],{"trials":962,"activeCount":112},[],{"intervention":964,"totalTrials":268,"cells":965},"Dupilumab",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":1005,"PHASE4":1007,"NA":1018},{"trials":967,"activeCount":112},[],{"trials":969,"activeCount":112},[],{"trials":971,"activeCount":146,"soonestReadout":997},[972,983,993],{"nctId":973,"briefTitle":974,"status":120,"phases":975,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":982},"NCT05866562","Dupilumab in the Treatment of Pediatric Alopecia Areata",[87],"2028-08-17","2029-04-30","2024-07-11",76,[981],"Alopecia Areata",[964],{"nctId":984,"briefTitle":985,"status":131,"phases":986,"primaryCompletion":987,"completion":988,"start":989,"enrollment":990,"conditions":991,"interventions":992},"NCT03359356","Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)",[87],"2020-01-14","2020-12-17","2018-01-09",60,[981],[964],{"nctId":994,"briefTitle":995,"status":120,"phases":996,"primaryCompletion":997,"completion":998,"start":999,"enrollment":1000,"conditions":1001,"interventions":1003},"NCT06088771","Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC",[86,87],"2026-04-15","2027-04-22","2024-03-08",21,[1002],"Non-Small Cell Lung Cancer",[964,1004],"Cemiplimab",{"trials":1006,"activeCount":112},[],{"trials":1008,"activeCount":112},[1009],{"nctId":1010,"briefTitle":1011,"status":131,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":143,"conditions":1015,"interventions":1017},"NCT04988022","Dupilumab in the Treatment of Keloids",[89],"2025-03-24","2021-05-25",[1016],"Keloid",[964],{"trials":1019,"activeCount":112},[],{"intervention":198,"totalTrials":956,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1045,"PHASE4":1047,"NA":1060},{"trials":1023,"activeCount":112},[],{"trials":1025,"activeCount":112},[],{"trials":1027,"activeCount":109,"soonestReadout":1036},[1028,1032],{"nctId":190,"briefTitle":191,"status":131,"phases":1029,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":1030,"interventions":1031},[87],[21],[198,160,199],{"nctId":1033,"briefTitle":1034,"status":120,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1043},"NCT04353778","Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV",[86,87],"2026-09-16","2020-08-03",207,[1040,1041,1042],"HIV","Non-HIV","Vagus Nerve Dysfunction",[1044,198],"Pyridostigmine",{"trials":1046,"activeCount":112},[],{"trials":1048,"activeCount":112},[1049],{"nctId":1050,"briefTitle":1051,"status":131,"phases":1052,"primaryCompletion":1053,"completion":1053,"start":1054,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT03485222","Are the \"Cardiac Benefits\" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).",[89],"2020-02-13","2018-05-21",84,[1057],"Cardiovascular Diseases",[1059,198],"Empagliflozin",{"trials":1061,"activeCount":112},[],{"intervention":1063,"totalTrials":146,"cells":1064},"Sotagliflozin",{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1084,"PHASE4":1086,"NA":1097},{"trials":1066,"activeCount":112},[],{"trials":1068,"activeCount":112},[],{"trials":1070,"activeCount":109,"soonestReadout":1075},[1071],{"nctId":1072,"briefTitle":1073,"status":279,"phases":1074,"primaryCompletion":1075,"completion":1076,"start":1077,"enrollment":990,"conditions":1078,"interventions":1083},"NCT07572175","Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity",[87],"2029-06","2029-10","2026-07",[1079,1080,1081,1082],"Anthracycline-induced Cardiotoxicity","Lymphoma","Chemotherapy","Cardiotoxicity",[1063],{"trials":1085,"activeCount":112},[],{"trials":1087,"activeCount":112},[1088],{"nctId":1089,"briefTitle":1090,"status":131,"phases":1091,"primaryCompletion":1092,"completion":1092,"start":1093,"enrollment":914,"conditions":1094,"interventions":1096},"NCT06618976","Antithrombotic Activities of Sotagliflozin vs. Empagliflozin",[89],"2026-02-10","2025-02-25",[1095],"Thrombosis",[1063,1059],{"trials":1098,"activeCount":112},[],{"intervention":1044,"totalTrials":146,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1112,"PHASE2":1114,"PHASE3":1120,"PHASE4":1122,"NA":1124},{"trials":1102,"activeCount":112},[1103],{"nctId":1104,"briefTitle":1105,"status":131,"phases":1106,"primaryCompletion":1107,"completion":1107,"start":1108,"enrollment":979,"conditions":1109,"interventions":1111},"NCT02850276","Autonomic Neuropathy, GI Motility, and Inflammation in HIV",[85],"2018-06-01","2015-11",[1110],"HIV Disease",[1044],{"trials":1113,"activeCount":112},[],{"trials":1115,"activeCount":109,"soonestReadout":1036},[1116],{"nctId":1033,"briefTitle":1034,"status":120,"phases":1117,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":1038,"conditions":1118,"interventions":1119},[86,87],[1040,1041,1042],[1044,198],{"trials":1121,"activeCount":112},[],{"trials":1123,"activeCount":112},[],{"trials":1125,"activeCount":112},[],{"intervention":1127,"totalTrials":146,"cells":1128},"cisplatin",{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1133,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1130,"activeCount":112},[],{"trials":1132,"activeCount":112},[],{"trials":1134,"activeCount":109,"soonestReadout":1149},[1135,1145],{"nctId":1136,"briefTitle":1137,"status":131,"phases":1138,"completion":1139,"start":1140,"conditions":1141,"interventions":1143},"NCT00005965","Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix",[87],"2004-04","2000-08",[1142],"Cervical Cancer",[1144,1127],"bryostatin 1",{"nctId":1146,"briefTitle":1147,"status":120,"phases":1148,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1152,"conditions":1153,"interventions":1156},"NCT06040970","Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer",[86,87],"2026-07-01","2027-07-01","2024-10-23",54,[1154,1155],"Ovarian Cancer","Malignant Neoplasm of Uterus",[1157,1158],"Sacituzumab","Cisplatin",{"trials":1160,"activeCount":112},[],{"trials":1162,"activeCount":112},[],{"trials":1164,"activeCount":112},[],{"intervention":1166,"totalTrials":146,"cells":1167},"Deucravacitinib",{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1172,"PHASE3":1194,"PHASE4":1196,"NA":1198},{"trials":1169,"activeCount":112},[],{"trials":1171,"activeCount":112},[],{"trials":1173,"activeCount":109,"soonestReadout":1178},[1174,1185],{"nctId":1175,"briefTitle":1176,"status":120,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":283,"conditions":1181,"interventions":1184},"NCT07508488","Deucravacitinib in the Treatment of Cicatricial Alopecias",[87],"2028-06-30","2028-09-30","2026-05-11",[1182,1183],"Central Centrifugal Cicatricial Alopecia","Frontal Fibrosing Alopecia",[1166],{"nctId":1186,"briefTitle":1187,"status":222,"phases":1188,"primaryCompletion":1189,"completion":1189,"start":1190,"enrollment":112,"conditions":1191,"interventions":1193},"NCT06532136","Deucravacitinib Rosacea",[87],"2026-01","2024-11",[1192],"Papulopustular Rosacea",[1166],{"trials":1195,"activeCount":112},[],{"trials":1197,"activeCount":112},[],{"trials":1199,"activeCount":112},[],{"intervention":704,"totalTrials":146,"cells":1201},{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1206,"PHASE3":1224,"PHASE4":1226,"NA":1228},{"trials":1203,"activeCount":112},[],{"trials":1205,"activeCount":112},[],{"trials":1207,"activeCount":109,"soonestReadout":1212},[1208,1220],{"nctId":1209,"briefTitle":1210,"status":100,"phases":1211,"primaryCompletion":1212,"completion":792,"start":1213,"enrollment":143,"conditions":1214,"interventions":1217},"NCT03304080","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast",[86,87],"2026-07-31","2017-12-20",[1215,1216],"Breast Neoplasms","Breast Diseases",[1218,1219,704,705],"Anastrozole","Palbociclib",{"nctId":694,"briefTitle":695,"status":246,"phases":1221,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":1222,"interventions":1223},[87],[701],[703,40,704,705,706,704,675,707,708,675],{"trials":1225,"activeCount":112},[],{"trials":1227,"activeCount":112},[],{"trials":1229,"activeCount":112},[],{"intervention":705,"totalTrials":146,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1233,"activeCount":112},[],{"trials":1235,"activeCount":112},[],{"trials":1237,"activeCount":109,"soonestReadout":1212},[1238,1242],{"nctId":1209,"briefTitle":1210,"status":100,"phases":1239,"primaryCompletion":1212,"completion":792,"start":1213,"enrollment":143,"conditions":1240,"interventions":1241},[86,87],[1215,1216],[1218,1219,704,705],{"nctId":694,"briefTitle":695,"status":246,"phases":1243,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":1244,"interventions":1245},[87],[701],[703,40,704,705,706,704,675,707,708,675],{"trials":1247,"activeCount":112},[],{"trials":1249,"activeCount":112},[],{"trials":1251,"activeCount":112},[],{"intervention":1253,"totalTrials":146,"cells":1254},"Ritlecitinib",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1279,"PHASE4":1281,"NA":1283},{"trials":1256,"activeCount":112},[],{"trials":1258,"activeCount":112},[],{"trials":1260,"activeCount":109,"soonestReadout":184},[1261,1272],{"nctId":1262,"briefTitle":1263,"status":246,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":699,"conditions":1267,"interventions":1271},"NCT05879458","Ritlecitinib in CTCL",[87],"2025-06-25","2023-05-17",[1268,1269,1270],"CTCL","Mycosis Fungoides","Sezary Syndrome",[1253],{"nctId":1273,"briefTitle":1274,"status":120,"phases":1275,"primaryCompletion":184,"completion":184,"start":1276,"enrollment":237,"conditions":1277,"interventions":1278},"NCT06373458","Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy",[87],"2024-08-13",[1016],[1253],{"trials":1280,"activeCount":112},[],{"trials":1282,"activeCount":112},[],{"trials":1284,"activeCount":112},[],{"intervention":1286,"totalTrials":146,"cells":1287},"Abrocitinib",{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1301,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1289,"activeCount":112},[],{"trials":1291,"activeCount":112},[1292],{"nctId":1293,"briefTitle":1294,"status":131,"phases":1295,"primaryCompletion":612,"completion":612,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1300},"NCT05069831","JAK Inhibition in Food Allergy",[86],"2022-05-16",71,[1299],"Food Allergy",[1286],{"trials":1302,"activeCount":109,"soonestReadout":1307},[1303],{"nctId":1304,"briefTitle":1305,"status":120,"phases":1306,"primaryCompletion":1307,"completion":1308,"start":1309,"enrollment":1310,"conditions":1311,"interventions":1313},"NCT07242638","Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome",[87],"2027-03-01","2028-03-03","2026-01-12",56,[1312,981],"Atopic Dermatitis",[1286],{"trials":1315,"activeCount":112},[],{"trials":1317,"activeCount":112},[],{"trials":1319,"activeCount":112},[],{"intervention":955,"totalTrials":146,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1345,"PHASE4":1347,"NA":1349},{"trials":1323,"activeCount":112},[],{"trials":1325,"activeCount":112},[],{"trials":1327,"activeCount":109,"soonestReadout":948},[1328,1332],{"nctId":945,"briefTitle":946,"status":120,"phases":1329,"primaryCompletion":948,"completion":949,"start":950,"enrollment":195,"conditions":1330,"interventions":1331},[87],[26,952],[954,899,955],{"nctId":1333,"briefTitle":1334,"status":131,"phases":1335,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":22,"conditions":1339,"interventions":1342},"NCT03572387","A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment",[87],"2022-06-19","2022-07-08","2018-08-20",[1340,1341,26],"Prostatic Neoplasms","Prostate Neoplasms",[1343,1344,955],"5-Azacitidine","all trans retinoic acid",{"trials":1346,"activeCount":112},[],{"trials":1348,"activeCount":112},[],{"trials":1350,"activeCount":112},[],{"intervention":1352,"totalTrials":109,"cells":1353},"Abemaciclib",{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1358,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1355,"activeCount":112},[],{"trials":1357,"activeCount":112},[],{"trials":1359,"activeCount":109,"soonestReadout":1364},[1360],{"nctId":1361,"briefTitle":1362,"status":120,"phases":1363,"primaryCompletion":1364,"completion":1365,"start":1366,"enrollment":1367,"conditions":1368,"interventions":1370},"NCT05095207","Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",[86,87],"2027-06","2028-06","2021-09-20",42,[31,1369],"Metastasis",[1352,1371],"Bicalutamide",{"trials":1373,"activeCount":112},[],{"trials":1375,"activeCount":112},[],{"trials":1377,"activeCount":112},[],{"intervention":1371,"totalTrials":109,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1381,"activeCount":112},[],{"trials":1383,"activeCount":112},[],{"trials":1385,"activeCount":109,"soonestReadout":1364},[1386],{"nctId":1361,"briefTitle":1362,"status":120,"phases":1387,"primaryCompletion":1364,"completion":1365,"start":1366,"enrollment":1367,"conditions":1388,"interventions":1389},[86,87],[31,1369],[1352,1371],{"trials":1391,"activeCount":112},[],{"trials":1393,"activeCount":112},[],{"trials":1395,"activeCount":112},[],{"intervention":1397,"totalTrials":109,"cells":1398},"Methotrexate",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1400,"activeCount":112},[],{"trials":1402,"activeCount":112},[],{"trials":1404,"activeCount":109,"soonestReadout":1364},[1405],{"nctId":1406,"briefTitle":1407,"status":120,"phases":1408,"primaryCompletion":1364,"completion":1409,"start":1410,"enrollment":1152,"conditions":1411,"interventions":1415},"NCT06541249","MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial",[87],"2027-12","2024-10-02",[1412,1413,1414],"Polycythemia Vera (PV)","Essential Thrombocythemia (ET)","Myelofibrosis (MF)",[1397],{"trials":1417,"activeCount":112},[],{"trials":1419,"activeCount":112},[],{"trials":1421,"activeCount":112},[],{"intervention":1423,"totalTrials":109,"cells":1424},"reparixin",{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1429,"PHASE3":1443,"PHASE4":1445,"NA":1447},{"trials":1426,"activeCount":112},[],{"trials":1428,"activeCount":112},[],{"trials":1430,"activeCount":109,"soonestReadout":1435},[1431],{"nctId":1432,"briefTitle":1433,"status":120,"phases":1434,"primaryCompletion":1435,"completion":1436,"start":1437,"enrollment":32,"conditions":1438,"interventions":1442},"NCT05835466","Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)",[87],"2027-12-31","2028-12-01","2023-07-24",[1439,1440,1441],"Myelofibrosis (PMF)","Post Essential Thrombocythemia Myelofibrosis (ET-MF)","Post Polycythemia Vera Related Myelofibrosis (PV-MF)",[1423],{"trials":1444,"activeCount":112},[],{"trials":1446,"activeCount":112},[],{"trials":1448,"activeCount":112},[],{"intervention":1218,"totalTrials":109,"cells":1450},{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1452,"activeCount":112},[],{"trials":1454,"activeCount":112},[],{"trials":1456,"activeCount":109,"soonestReadout":1212},[1457],{"nctId":1209,"briefTitle":1210,"status":100,"phases":1458,"primaryCompletion":1212,"completion":792,"start":1213,"enrollment":143,"conditions":1459,"interventions":1460},[86,87],[1215,1216],[1218,1219,704,705],{"trials":1462,"activeCount":112},[],{"trials":1464,"activeCount":112},[],{"trials":1466,"activeCount":112},[],{"intervention":1219,"totalTrials":109,"cells":1468},{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1470,"activeCount":112},[],{"trials":1472,"activeCount":112},[],{"trials":1474,"activeCount":109,"soonestReadout":1212},[1475],{"nctId":1209,"briefTitle":1210,"status":100,"phases":1476,"primaryCompletion":1212,"completion":792,"start":1213,"enrollment":143,"conditions":1477,"interventions":1478},[86,87],[1215,1216],[1218,1219,704,705],{"trials":1480,"activeCount":112},[],{"trials":1482,"activeCount":112},[],{"trials":1484,"activeCount":112},[],{"intervention":1486,"totalTrials":109,"cells":1487},"Dronabinol",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1502,"PHASE4":1504,"NA":1506},{"trials":1489,"activeCount":112},[],{"trials":1491,"activeCount":112},[],{"trials":1493,"activeCount":109,"soonestReadout":1498},[1494],{"nctId":1495,"briefTitle":1496,"status":120,"phases":1497,"primaryCompletion":1498,"completion":1499,"start":587,"enrollment":990,"conditions":1500,"interventions":1501},"NCT05519111","Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain",[87],"2027-04-01","2027-05-01",[590],[1486],{"trials":1503,"activeCount":112},[],{"trials":1505,"activeCount":112},[],{"trials":1507,"activeCount":112},[],{"intervention":1509,"totalTrials":109,"cells":1510},"tenofovir disoproxil\u002Femtricitabine",{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1529,"PHASE4":1531,"NA":1533},{"trials":1512,"activeCount":112},[],{"trials":1514,"activeCount":112},[],{"trials":1516,"activeCount":109,"soonestReadout":1521},[1517],{"nctId":1518,"briefTitle":1519,"status":120,"phases":1520,"primaryCompletion":1521,"completion":1522,"start":1523,"enrollment":1524,"conditions":1525,"interventions":1527},"NCT06511063","Antiviral Clinical Trial for Long Covid-19",[87],"2026-11","2026-12","2024-10-01",90,[1526],"Long Covid",[1509,1528],"Selzentry",{"trials":1530,"activeCount":112},[],{"trials":1532,"activeCount":112},[],{"trials":1534,"activeCount":112},[],{"intervention":1528,"totalTrials":109,"cells":1536},{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1538,"activeCount":112},[],{"trials":1540,"activeCount":112},[],{"trials":1542,"activeCount":109,"soonestReadout":1521},[1543],{"nctId":1518,"briefTitle":1519,"status":120,"phases":1544,"primaryCompletion":1521,"completion":1522,"start":1523,"enrollment":1524,"conditions":1545,"interventions":1546},[87],[1526],[1509,1528],{"trials":1548,"activeCount":112},[],{"trials":1550,"activeCount":112},[],{"trials":1552,"activeCount":112},[],{"intervention":1004,"totalTrials":109,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1565,"PHASE4":1567,"NA":1569},{"trials":1556,"activeCount":112},[],{"trials":1558,"activeCount":112},[],{"trials":1560,"activeCount":109,"soonestReadout":997},[1561],{"nctId":994,"briefTitle":995,"status":120,"phases":1562,"primaryCompletion":997,"completion":998,"start":999,"enrollment":1000,"conditions":1563,"interventions":1564},[86,87],[1002],[964,1004],{"trials":1566,"activeCount":112},[],{"trials":1568,"activeCount":112},[],{"trials":1570,"activeCount":112},[],{"intervention":1572,"totalTrials":109,"cells":1573},"Psilocybin",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1588,"PHASE4":1590,"NA":1592},{"trials":1575,"activeCount":112},[],{"trials":1577,"activeCount":112},[],{"trials":1579,"activeCount":109,"soonestReadout":1584},[1580],{"nctId":1581,"briefTitle":1582,"status":120,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1093,"enrollment":990,"conditions":1585,"interventions":1586},"NCT06592833","Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder",[87],"2028-03-01",[18],[1572,1587],"Pimavanserin",{"trials":1589,"activeCount":112},[],{"trials":1591,"activeCount":112},[],{"trials":1593,"activeCount":112},[],{"intervention":1587,"totalTrials":109,"cells":1595},{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1597,"activeCount":112},[],{"trials":1599,"activeCount":112},[],{"trials":1601,"activeCount":109,"soonestReadout":1584},[1602],{"nctId":1581,"briefTitle":1582,"status":120,"phases":1603,"primaryCompletion":1584,"completion":1584,"start":1093,"enrollment":990,"conditions":1604,"interventions":1605},[87],[18],[1572,1587],{"trials":1607,"activeCount":112},[],{"trials":1609,"activeCount":112},[],{"trials":1611,"activeCount":112},[],{"intervention":60,"totalTrials":109,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1615,"activeCount":112},[],{"trials":1617,"activeCount":112},[],{"trials":1619,"activeCount":109,"soonestReadout":59},[1620],{"nctId":57,"briefTitle":58,"status":100,"phases":1621,"primaryCompletion":59,"completion":59,"start":1622,"enrollment":19,"conditions":1623,"interventions":1624},[87],"2024-11-01",[21,28],[60],{"trials":1626,"activeCount":112},[],{"trials":1628,"activeCount":112},[],{"trials":1630,"activeCount":112},[],{"intervention":1157,"totalTrials":109,"cells":1632},{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1634,"activeCount":112},[],{"trials":1636,"activeCount":112},[],{"trials":1638,"activeCount":109,"soonestReadout":1149},[1639],{"nctId":1146,"briefTitle":1147,"status":120,"phases":1640,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1152,"conditions":1641,"interventions":1642},[86,87],[1154,1155],[1157,1158],{"trials":1644,"activeCount":112},[],{"trials":1646,"activeCount":112},[],{"trials":1648,"activeCount":112},[],{"intervention":1650,"totalTrials":109,"cells":1651},"Flotufolastat F18",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1653,"activeCount":112},[],{"trials":1655,"activeCount":112},[],{"trials":1657,"activeCount":109,"soonestReadout":1499},[1658],{"nctId":1659,"briefTitle":1660,"status":120,"phases":1661,"primaryCompletion":1499,"completion":1499,"start":1092,"enrollment":262,"conditions":1662,"interventions":1664},"NCT07285057","Diagnostic Utility of rhPSMA-7.3 (18F) PET\u002FCT in Men With Prostate Cancer on Active Surveillance",[87],[1340,26,1663],"Prostate Adenocarcinoma",[1650],{"trials":1666,"activeCount":112},[],{"trials":1668,"activeCount":112},[],{"trials":1670,"activeCount":112},[],{"intervention":50,"totalTrials":109,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1674,"activeCount":112},[],{"trials":1676,"activeCount":112},[],{"trials":1678,"activeCount":109,"soonestReadout":49},[1679],{"nctId":47,"briefTitle":48,"status":100,"phases":1680,"primaryCompletion":49,"completion":49,"start":1681,"enrollment":956,"conditions":1682,"interventions":1684},[86,87],"2022-06-10",[1683],"Ulcerative Colitis (Disorder)",[50,1685],"Mesalamine",{"trials":1687,"activeCount":112},[],{"trials":1689,"activeCount":112},[],{"trials":1691,"activeCount":112},[],{"intervention":1685,"totalTrials":109,"cells":1693},{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1695,"activeCount":112},[],{"trials":1697,"activeCount":112},[],{"trials":1699,"activeCount":109,"soonestReadout":49},[1700],{"nctId":47,"briefTitle":48,"status":100,"phases":1701,"primaryCompletion":49,"completion":49,"start":1681,"enrollment":956,"conditions":1702,"interventions":1703},[86,87],[1683],[50,1685],{"trials":1705,"activeCount":112},[],{"trials":1707,"activeCount":112},[],{"trials":1709,"activeCount":112},[],{"intervention":1711,"totalTrials":109,"cells":1712},"Tocilizumab",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1714,"activeCount":112},[],{"trials":1716,"activeCount":112},[],{"trials":1718,"activeCount":109,"soonestReadout":1723},[1719],{"nctId":1720,"briefTitle":1721,"status":120,"phases":1722,"primaryCompletion":1723,"completion":1723,"start":1724,"enrollment":990,"conditions":1725,"interventions":1726},"NCT07493317","Neutralizing Interleukin (IL)-6",[87],"2031-02-06","2026-03-26",[18],[1711],{"trials":1728,"activeCount":112},[],{"trials":1730,"activeCount":112},[],{"trials":1732,"activeCount":112},[],{"intervention":1734,"totalTrials":109,"cells":1735},"Valacyclovir",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1737,"activeCount":112},[],{"trials":1739,"activeCount":112},[],{"trials":1741,"activeCount":109,"soonestReadout":1178},[1742],{"nctId":1743,"briefTitle":1744,"status":279,"phases":1745,"primaryCompletion":1178,"completion":1178,"start":1746,"enrollment":1747,"conditions":1748,"interventions":1751},"NCT07597902","SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction",[87],"2026-06-01",150,[1749,1750],"Post-acute Sequelae of COVID-19","Long COVID",[1734,1752,1753],"Celecoxib","Paxlovid",{"trials":1755,"activeCount":112},[],{"trials":1757,"activeCount":112},[],{"trials":1759,"activeCount":112},[],{"intervention":1752,"totalTrials":109,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1763,"activeCount":112},[],{"trials":1765,"activeCount":112},[],{"trials":1767,"activeCount":109,"soonestReadout":1178},[1768],{"nctId":1743,"briefTitle":1744,"status":279,"phases":1769,"primaryCompletion":1178,"completion":1178,"start":1746,"enrollment":1747,"conditions":1770,"interventions":1771},[87],[1749,1750],[1734,1752,1753],{"trials":1773,"activeCount":112},[],{"trials":1775,"activeCount":112},[],{"trials":1777,"activeCount":112},[],{"intervention":1753,"totalTrials":109,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1781,"activeCount":112},[],{"trials":1783,"activeCount":112},[],{"trials":1785,"activeCount":109,"soonestReadout":1178},[1786],{"nctId":1743,"briefTitle":1744,"status":279,"phases":1787,"primaryCompletion":1178,"completion":1178,"start":1746,"enrollment":1747,"conditions":1788,"interventions":1789},[87],[1749,1750],[1734,1752,1753],{"trials":1791,"activeCount":112},[],{"trials":1793,"activeCount":112},[],{"trials":1795,"activeCount":112},[],{"intervention":941,"totalTrials":109,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1799,"activeCount":112},[],{"trials":1801,"activeCount":112},[],{"trials":1803,"activeCount":109,"soonestReadout":184},[1804],{"nctId":933,"briefTitle":934,"status":120,"phases":1805,"primaryCompletion":184,"completion":936,"start":937,"enrollment":155,"conditions":1806,"interventions":1807},[87],[939],[941,942,943,899],{"trials":1809,"activeCount":112},[],{"trials":1811,"activeCount":112},[],{"trials":1813,"activeCount":112},[],{"intervention":942,"totalTrials":109,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":112},[],{"trials":1819,"activeCount":112},[],{"trials":1821,"activeCount":109,"soonestReadout":184},[1822],{"nctId":933,"briefTitle":934,"status":120,"phases":1823,"primaryCompletion":184,"completion":936,"start":937,"enrollment":155,"conditions":1824,"interventions":1825},[87],[939],[941,942,943,899],{"trials":1827,"activeCount":112},[],{"trials":1829,"activeCount":112},[],{"trials":1831,"activeCount":112},[],{"intervention":943,"totalTrials":109,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1844,"PHASE4":1846,"NA":1848},{"trials":1835,"activeCount":112},[],{"trials":1837,"activeCount":112},[],{"trials":1839,"activeCount":109,"soonestReadout":184},[1840],{"nctId":933,"briefTitle":934,"status":120,"phases":1841,"primaryCompletion":184,"completion":936,"start":937,"enrollment":155,"conditions":1842,"interventions":1843},[87],[939],[941,942,943,899],{"trials":1845,"activeCount":112},[],{"trials":1847,"activeCount":112},[],{"trials":1849,"activeCount":112},[],{"intervention":954,"totalTrials":109,"cells":1851},{"EARLY_PHASE1":1852,"PHASE1":1854,"PHASE2":1856,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1853,"activeCount":112},[],{"trials":1855,"activeCount":112},[],{"trials":1857,"activeCount":109,"soonestReadout":948},[1858],{"nctId":945,"briefTitle":946,"status":120,"phases":1859,"primaryCompletion":948,"completion":949,"start":950,"enrollment":195,"conditions":1860,"interventions":1861},[87],[26,952],[954,899,955],{"trials":1863,"activeCount":112},[],{"trials":1865,"activeCount":112},[],{"trials":1867,"activeCount":112},[],{"intervention":1869,"totalTrials":109,"cells":1870},"Delgocitinib",{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1886,"PHASE4":1888,"NA":1890},{"trials":1872,"activeCount":112},[],{"trials":1874,"activeCount":112},[],{"trials":1876,"activeCount":109,"soonestReadout":1881},[1877],{"nctId":1878,"briefTitle":1879,"status":120,"phases":1880,"primaryCompletion":1881,"completion":1435,"start":1882,"enrollment":237,"conditions":1883,"interventions":1885},"NCT07487948","Safety and Biomarker Responses of Delgocitinib (JAK1,2,3\u002FTYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris",[87],"2027-04-05","2026-05",[1182,1884],"Lichen Planopilaris",[1869],{"trials":1887,"activeCount":112},[],{"trials":1889,"activeCount":112},[],{"trials":1891,"activeCount":112},[],{"intervention":1893,"totalTrials":146,"cells":1894},"Lidocaine",{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1896,"activeCount":112},[],{"trials":1898,"activeCount":109,"soonestReadout":1912},[1899,1908],{"nctId":1900,"briefTitle":1901,"status":131,"phases":1902,"primaryCompletion":1107,"completion":1107,"start":1903,"enrollment":32,"conditions":1904,"interventions":1906},"NCT02838758","Compare Ultrasound Assisted Cold Therapy and Lidocaine Injection to Treat Morton's Neuroma",[86],"2016-07",[1905],"Intermetatarsal Neuroma",[1893,1907],"Saline",{"nctId":1909,"briefTitle":1910,"status":120,"phases":1911,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":990,"conditions":1914,"interventions":1918},"NCT06653400","Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy",[86],"2026-09-01","2025-02-27",[1915,1916,1917],"Abnormal Uterine Bleeding","Analgesia","Paracervical Block",[1893,1919],"ketorolac",{"trials":1921,"activeCount":112},[],{"trials":1923,"activeCount":112},[],{"trials":1925,"activeCount":112},[],{"trials":1927,"activeCount":112},[],{"intervention":74,"totalTrials":109,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1946},{"trials":1931,"activeCount":112},[],{"trials":1933,"activeCount":109,"soonestReadout":73},[1934],{"nctId":71,"briefTitle":72,"status":100,"phases":1935,"primaryCompletion":73,"completion":73,"start":1936,"enrollment":699,"conditions":1937,"interventions":1939},[86],"2023-02-15",[1938],"Crohn's Disease",[74],{"trials":1941,"activeCount":112},[],{"trials":1943,"activeCount":112},[],{"trials":1945,"activeCount":112},[],{"trials":1947,"activeCount":112},[],{"intervention":1949,"totalTrials":109,"cells":1950},"MDMA-AT",{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1963,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1952,"activeCount":112},[],{"trials":1954,"activeCount":109,"soonestReadout":260},[1955],{"nctId":1956,"briefTitle":1957,"status":279,"phases":1958,"primaryCompletion":260,"completion":260,"start":1882,"enrollment":195,"conditions":1959,"interventions":1961},"NCT07542145","MDMA Assisted Therapy for BN",[86],[1960],"Bulimia Nervosa",[1949,1962],"MDMA-AT-BN",{"trials":1964,"activeCount":112},[],{"trials":1966,"activeCount":112},[],{"trials":1968,"activeCount":112},[],{"trials":1970,"activeCount":112},[],{"intervention":1962,"totalTrials":109,"cells":1972},{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":1981,"PHASE3":1983,"PHASE4":1985,"NA":1987},{"trials":1974,"activeCount":112},[],{"trials":1976,"activeCount":109,"soonestReadout":260},[1977],{"nctId":1956,"briefTitle":1957,"status":279,"phases":1978,"primaryCompletion":260,"completion":260,"start":1882,"enrollment":195,"conditions":1979,"interventions":1980},[86],[1960],[1949,1962],{"trials":1982,"activeCount":112},[],{"trials":1984,"activeCount":112},[],{"trials":1986,"activeCount":112},[],{"trials":1988,"activeCount":112},[],{"intervention":1990,"totalTrials":109,"cells":1991},"MTC 01",{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":2006,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":1993,"activeCount":112},[],{"trials":1995,"activeCount":109,"soonestReadout":2000},[1996],{"nctId":1997,"briefTitle":1998,"status":120,"phases":1999,"primaryCompletion":2000,"completion":2000,"start":2001,"enrollment":990,"conditions":2002,"interventions":2004},"NCT05911997","MTC Versus FMT in for RCDI",[86],"2026-07-25","2024-01-08",[2003],"Clostridiodies Difficile Infections",[1990,2005],"Fecal Microbiota Transplantation",{"trials":2007,"activeCount":112},[],{"trials":2009,"activeCount":112},[],{"trials":2011,"activeCount":112},[],{"trials":2013,"activeCount":112},[],{"intervention":2005,"totalTrials":109,"cells":2015},{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2024,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2017,"activeCount":112},[],{"trials":2019,"activeCount":109,"soonestReadout":2000},[2020],{"nctId":1997,"briefTitle":1998,"status":120,"phases":2021,"primaryCompletion":2000,"completion":2000,"start":2001,"enrollment":990,"conditions":2022,"interventions":2023},[86],[2003],[1990,2005],{"trials":2025,"activeCount":112},[],{"trials":2027,"activeCount":112},[],{"trials":2029,"activeCount":112},[],{"trials":2031,"activeCount":112},[],{"intervention":79,"totalTrials":109,"cells":2033},{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2044,"PHASE3":2046,"PHASE4":2048,"NA":2050},{"trials":2035,"activeCount":112},[],{"trials":2037,"activeCount":109,"soonestReadout":78},[2038],{"nctId":76,"briefTitle":77,"status":120,"phases":2039,"primaryCompletion":78,"completion":2040,"start":2041,"enrollment":29,"conditions":2042,"interventions":2043},[86],"2026-09","2023-01-31",[297],[79],{"trials":2045,"activeCount":112},[],{"trials":2047,"activeCount":112},[],{"trials":2049,"activeCount":112},[],{"trials":2051,"activeCount":112},[],{"intervention":45,"totalTrials":109,"cells":2053},{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2064,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2055,"activeCount":112},[],{"trials":2057,"activeCount":109,"soonestReadout":44},[2058],{"nctId":42,"briefTitle":43,"status":100,"phases":2059,"primaryCompletion":44,"completion":1746,"start":2060,"enrollment":29,"conditions":2061,"interventions":2062},[86],"2022-12-13",[26],[45,2063],"Lidocaine IV",{"trials":2065,"activeCount":112},[],{"trials":2067,"activeCount":112},[],{"trials":2069,"activeCount":112},[],{"trials":2071,"activeCount":112},[],{"intervention":2063,"totalTrials":109,"cells":2073},{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2082,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2075,"activeCount":112},[],{"trials":2077,"activeCount":109,"soonestReadout":44},[2078],{"nctId":42,"briefTitle":43,"status":100,"phases":2079,"primaryCompletion":44,"completion":1746,"start":2060,"enrollment":29,"conditions":2080,"interventions":2081},[86],[26],[45,2063],{"trials":2083,"activeCount":112},[],{"trials":2085,"activeCount":112},[],{"trials":2087,"activeCount":112},[],{"trials":2089,"activeCount":112},[],{"intervention":2091,"totalTrials":109,"cells":2092},"lamivudine",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2094,"activeCount":112},[],{"trials":2096,"activeCount":109,"soonestReadout":1149},[2097],{"nctId":2098,"briefTitle":2099,"status":120,"phases":2100,"primaryCompletion":1149,"completion":1149,"start":2101,"enrollment":2102,"conditions":2103,"interventions":2106},"NCT07058974","A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation",[86],"2025-08-25",22,[2104,2105],"Smokers","Former Smokers",[2091,2107],"rapamycin",{"trials":2109,"activeCount":112},[],{"trials":2111,"activeCount":112},[],{"trials":2113,"activeCount":112},[],{"trials":2115,"activeCount":112},[],{"intervention":2107,"totalTrials":109,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2119,"activeCount":112},[],{"trials":2121,"activeCount":109,"soonestReadout":1149},[2122],{"nctId":2098,"briefTitle":2099,"status":120,"phases":2123,"primaryCompletion":1149,"completion":1149,"start":2101,"enrollment":2102,"conditions":2124,"interventions":2125},[86],[2104,2105],[2091,2107],{"trials":2127,"activeCount":112},[],{"trials":2129,"activeCount":112},[],{"trials":2131,"activeCount":112},[],{"trials":2133,"activeCount":112},[],{"intervention":2135,"totalTrials":109,"cells":2136},"Alnuctamab",{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2150,"PHASE3":2152,"PHASE4":2154,"NA":2156},{"trials":2138,"activeCount":112},[],{"trials":2140,"activeCount":109,"soonestReadout":2145},[2141],{"nctId":2142,"briefTitle":2143,"status":120,"phases":2144,"primaryCompletion":2145,"completion":2145,"start":2146,"enrollment":1000,"conditions":2147,"interventions":2149},"NCT07219563","Alnuctamab for Refractory SLE (LATTE Study)",[86],"2027-12-01","2026-03-17",[2148],"Systemic Lupus Erythematosus",[2135],{"trials":2151,"activeCount":112},[],{"trials":2153,"activeCount":112},[],{"trials":2155,"activeCount":112},[],{"trials":2157,"activeCount":112},[],{"intervention":2159,"totalTrials":109,"cells":2160},"Timolol Maleate Solution",{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2162,"activeCount":112},[],{"trials":2164,"activeCount":109,"soonestReadout":2169},[2165],{"nctId":2166,"briefTitle":2167,"status":120,"phases":2168,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":2171,"conditions":2172,"interventions":2175},"NCT06941467","Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds",[86],"2026-04-01","2025-01-03",102,[2173,2174],"Wound Healing","Mohs Micrographic Surgery",[2159],{"trials":2177,"activeCount":112},[],{"trials":2179,"activeCount":112},[],{"trials":2181,"activeCount":112},[],{"trials":2183,"activeCount":112},[],{"intervention":1919,"totalTrials":109,"cells":2185},{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2194,"PHASE3":2196,"PHASE4":2198,"NA":2200},{"trials":2187,"activeCount":112},[],{"trials":2189,"activeCount":109,"soonestReadout":1912},[2190],{"nctId":1909,"briefTitle":1910,"status":120,"phases":2191,"primaryCompletion":1912,"completion":1912,"start":1913,"enrollment":990,"conditions":2192,"interventions":2193},[86],[1915,1916,1917],[1893,1919],{"trials":2195,"activeCount":112},[],{"trials":2197,"activeCount":112},[],{"trials":2199,"activeCount":112},[],{"trials":2201,"activeCount":112},[],{"intervention":69,"totalTrials":146,"cells":2203},{"EARLY_PHASE1":2204,"PHASE1":2214,"PHASE2":2216,"PHASE3":2218,"PHASE4":2234,"NA":2236},{"trials":2205,"activeCount":109,"soonestReadout":68},[2206],{"nctId":66,"briefTitle":67,"status":100,"phases":2207,"primaryCompletion":68,"completion":68,"start":2208,"enrollment":2209,"conditions":2210,"interventions":2213},[85],"2021-07-09",225,[2211,2212],"Cardiac Surgery","Sternotomy",[69],{"trials":2215,"activeCount":112},[],{"trials":2217,"activeCount":112},[],{"trials":2219,"activeCount":112},[2220],{"nctId":2221,"briefTitle":2222,"status":131,"phases":2223,"primaryCompletion":2224,"completion":2224,"start":2225,"enrollment":2226,"conditions":2227,"interventions":2231},"NCT04426500","Use of Perioperative Pain Blocks In Urological Surgery",[88],"2021-02-13","2019-11-11",148,[2228,2229,2230],"Pain, Postoperative","Nerve Block","Robotic Surgical Procedures",[69,2232,2233],"Ultrasound-guided transversus abdominus plane block","Laparoscopic-guided transversus abdominus plane block",{"trials":2235,"activeCount":112},[],{"trials":2237,"activeCount":112},[],{"intervention":2239,"totalTrials":268,"cells":2240},"Nivolumab",{"EARLY_PHASE1":2241,"PHASE1":2254,"PHASE2":2267,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2242,"activeCount":109,"soonestReadout":2040},[2243],{"nctId":2244,"briefTitle":2245,"status":120,"phases":2246,"primaryCompletion":2040,"completion":1522,"start":1936,"enrollment":283,"conditions":2247,"interventions":2249},"NCT05188118","Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma",[85],[2248],"Renal Cell Carcinoma",[2250,2251,2239,2252,2253],"Cabozantinib","Ipilimumab","Lenvatinib","Everolimus",{"trials":2255,"activeCount":112},[2256],{"nctId":2257,"briefTitle":2258,"status":131,"phases":2259,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":2263,"interventions":2266},"NCT03305445","Nivolumab\u002FIpilimumab-Primed Immunotransplant for DLBCL",[86],"2021-04-01","2018-05-14",6,[2264,2265],"Relapsed Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma",[2251,2239],{"trials":2268,"activeCount":112},[2269,2281],{"nctId":2270,"briefTitle":2271,"status":131,"phases":2272,"primaryCompletion":2273,"completion":2273,"start":2274,"enrollment":155,"conditions":2275,"interventions":2279},"NCT04263090","Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment",[86,87],"2023-12-20","2020-06-29",[2276,2277,2278],"Non-small Cell Lung Cancer","Adenocarcinoma","Stage IV",[2280,2239],"Rigosertib",{"nctId":2282,"briefTitle":2283,"status":131,"phases":2284,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":2289,"interventions":2290},"NCT04123379","Neoadjuvant Nivolumab With CCR2\u002F5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)",[87],"2023-08-24","2025-08-24","2020-03-05",48,[2276,541],[2239,2291,2292],"BMS-813160","BMS-986253",{"trials":2294,"activeCount":112},[],{"trials":2296,"activeCount":112},[],{"trials":2298,"activeCount":112},[],{"intervention":2251,"totalTrials":146,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2307,"PHASE2":2313,"PHASE3":2315,"PHASE4":2317,"NA":2319},{"trials":2302,"activeCount":109,"soonestReadout":2040},[2303],{"nctId":2244,"briefTitle":2245,"status":120,"phases":2304,"primaryCompletion":2040,"completion":1522,"start":1936,"enrollment":283,"conditions":2305,"interventions":2306},[85],[2248],[2250,2251,2239,2252,2253],{"trials":2308,"activeCount":112},[2309],{"nctId":2257,"briefTitle":2258,"status":131,"phases":2310,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":2311,"interventions":2312},[86],[2264,2265],[2251,2239],{"trials":2314,"activeCount":112},[],{"trials":2316,"activeCount":112},[],{"trials":2318,"activeCount":112},[],{"trials":2320,"activeCount":112},[],{"intervention":2322,"totalTrials":109,"cells":2323},"Iberdomide",{"EARLY_PHASE1":2324,"PHASE1":2335,"PHASE2":2337,"PHASE3":2339,"PHASE4":2341,"NA":2343},{"trials":2325,"activeCount":109,"soonestReadout":1521},[2326],{"nctId":2327,"briefTitle":2328,"status":100,"phases":2329,"primaryCompletion":1521,"completion":1522,"start":2330,"enrollment":699,"conditions":2331,"interventions":2333},"NCT05560399","A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed\u002FRefractory Multiple Myeloma",[85],"2023-02-06",[2332],"Multiple Myeloma",[2322,2334,676],"Elotuzumab",{"trials":2336,"activeCount":112},[],{"trials":2338,"activeCount":112},[],{"trials":2340,"activeCount":112},[],{"trials":2342,"activeCount":112},[],{"trials":2344,"activeCount":112},[],{"intervention":2334,"totalTrials":109,"cells":2346},{"EARLY_PHASE1":2347,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2359,"NA":2361},{"trials":2348,"activeCount":109,"soonestReadout":1521},[2349],{"nctId":2327,"briefTitle":2328,"status":100,"phases":2350,"primaryCompletion":1521,"completion":1522,"start":2330,"enrollment":699,"conditions":2351,"interventions":2352},[85],[2332],[2322,2334,676],{"trials":2354,"activeCount":112},[],{"trials":2356,"activeCount":112},[],{"trials":2358,"activeCount":112},[],{"trials":2360,"activeCount":112},[],{"trials":2362,"activeCount":112},[],{"intervention":2364,"totalTrials":109,"cells":2365},"Corticosteroid",{"EARLY_PHASE1":2366,"PHASE1":2377,"PHASE2":2379,"PHASE3":2381,"PHASE4":2383,"NA":2385},{"trials":2367,"activeCount":109,"soonestReadout":2372},[2368],{"nctId":2369,"briefTitle":2370,"status":120,"phases":2371,"primaryCompletion":2372,"completion":2372,"start":2373,"enrollment":195,"conditions":2374,"interventions":2376},"NCT07039019","Study of the Feasibility and Efficacy of PrednisonE for Non-specifiC pleuriTis",[85],"2026-11-19","2025-06-04",[2375],"Pleuritis, Non-specific",[2364],{"trials":2378,"activeCount":112},[],{"trials":2380,"activeCount":112},[],{"trials":2382,"activeCount":112},[],{"trials":2384,"activeCount":112},[],{"trials":2386,"activeCount":112},[],{"intervention":2250,"totalTrials":109,"cells":2388},{"EARLY_PHASE1":2389,"PHASE1":2395,"PHASE2":2397,"PHASE3":2399,"PHASE4":2401,"NA":2403},{"trials":2390,"activeCount":109,"soonestReadout":2040},[2391],{"nctId":2244,"briefTitle":2245,"status":120,"phases":2392,"primaryCompletion":2040,"completion":1522,"start":1936,"enrollment":283,"conditions":2393,"interventions":2394},[85],[2248],[2250,2251,2239,2252,2253],{"trials":2396,"activeCount":112},[],{"trials":2398,"activeCount":112},[],{"trials":2400,"activeCount":112},[],{"trials":2402,"activeCount":112},[],{"trials":2404,"activeCount":112},[],{"intervention":2252,"totalTrials":109,"cells":2406},{"EARLY_PHASE1":2407,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2419,"NA":2421},{"trials":2408,"activeCount":109,"soonestReadout":2040},[2409],{"nctId":2244,"briefTitle":2245,"status":120,"phases":2410,"primaryCompletion":2040,"completion":1522,"start":1936,"enrollment":283,"conditions":2411,"interventions":2412},[85],[2248],[2250,2251,2239,2252,2253],{"trials":2414,"activeCount":112},[],{"trials":2416,"activeCount":112},[],{"trials":2418,"activeCount":112},[],{"trials":2420,"activeCount":112},[],{"trials":2422,"activeCount":112},[],{"intervention":2253,"totalTrials":109,"cells":2424},{"EARLY_PHASE1":2425,"PHASE1":2431,"PHASE2":2433,"PHASE3":2435,"PHASE4":2437,"NA":2439},{"trials":2426,"activeCount":109,"soonestReadout":2040},[2427],{"nctId":2244,"briefTitle":2245,"status":120,"phases":2428,"primaryCompletion":2040,"completion":1522,"start":1936,"enrollment":283,"conditions":2429,"interventions":2430},[85],[2248],[2250,2251,2239,2252,2253],{"trials":2432,"activeCount":112},[],{"trials":2434,"activeCount":112},[],{"trials":2436,"activeCount":112},[],{"trials":2438,"activeCount":112},[],{"trials":2440,"activeCount":112},[],{"intervention":676,"totalTrials":268,"cells":2442},{"EARLY_PHASE1":2443,"PHASE1":2449,"PHASE2":2451,"PHASE3":2468,"PHASE4":2470,"NA":2472},{"trials":2444,"activeCount":109,"soonestReadout":1521},[2445],{"nctId":2327,"briefTitle":2328,"status":100,"phases":2446,"primaryCompletion":1521,"completion":1522,"start":2330,"enrollment":699,"conditions":2447,"interventions":2448},[85],[2332],[2322,2334,676],{"trials":2450,"activeCount":112},[],{"trials":2452,"activeCount":112},[2453,2457],{"nctId":666,"briefTitle":667,"status":668,"phases":2454,"primaryCompletion":54,"completion":54,"start":670,"enrollment":9,"conditions":2455,"interventions":2456},[87],[672,673],[675,40,676,677,678,679],{"nctId":2458,"briefTitle":2459,"status":131,"phases":2460,"primaryCompletion":2461,"completion":2461,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2466},"NCT03236792","Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis",[86,87],"2022-09-20","2017-06-12",28,[2465],"AL Amyloidosis",[2467,708,676],"Ixazomib",{"trials":2469,"activeCount":112},[],{"trials":2471,"activeCount":112},[],{"trials":2473,"activeCount":112},[2474],{"nctId":2475,"briefTitle":2476,"status":131,"phases":2477,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":1524,"conditions":2480,"interventions":2483},"NCT03969875","Comparison of Analgesic Efficacy Between of Interscalene Block With Liposomal Bupivacaine With Bupivacaine and Dexamethasone",[],"2022-04-05","2018-08-18",[2481,2482],"Total Shoulder Arthroplasty","Shoulder Osteoarthritis",[2484,676,2485],"Liposomal bupivacaine","Bupivacaine",{"intervention":2487,"totalTrials":109,"cells":2488},"Antipsychotics",{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2499},{"trials":2490,"activeCount":112},[],{"trials":2492,"activeCount":112},[],{"trials":2494,"activeCount":112},[],{"trials":2496,"activeCount":112},[],{"trials":2498,"activeCount":112},[],{"trials":2500,"activeCount":109,"soonestReadout":372},[2501],{"nctId":2502,"briefTitle":2503,"status":120,"phases":2504,"primaryCompletion":372,"completion":2145,"start":2505,"enrollment":2506,"conditions":2507,"interventions":2508},"NCT06049953","Maternal And Infant Antipsychotic Study",[],"2023-09-29",200,[2487,752],[2487,2509],"Non-antipsychotic medication",{"intervention":2509,"totalTrials":109,"cells":2511},{"EARLY_PHASE1":2512,"PHASE1":2514,"PHASE2":2516,"PHASE3":2518,"PHASE4":2520,"NA":2522},{"trials":2513,"activeCount":112},[],{"trials":2515,"activeCount":112},[],{"trials":2517,"activeCount":112},[],{"trials":2519,"activeCount":112},[],{"trials":2521,"activeCount":112},[],{"trials":2523,"activeCount":109,"soonestReadout":372},[2524],{"nctId":2502,"briefTitle":2503,"status":120,"phases":2525,"primaryCompletion":372,"completion":2145,"start":2505,"enrollment":2506,"conditions":2526,"interventions":2527},[],[2487,752],[2487,2509],{"intervention":1907,"totalTrials":699,"cells":2529},{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2538,"PHASE3":2563,"PHASE4":2565,"NA":2616},{"trials":2531,"activeCount":112},[],{"trials":2533,"activeCount":112},[2534],{"nctId":1900,"briefTitle":1901,"status":131,"phases":2535,"primaryCompletion":1107,"completion":1107,"start":1903,"enrollment":32,"conditions":2536,"interventions":2537},[86],[1905],[1893,1907],{"trials":2539,"activeCount":112},[2540,2553],{"nctId":2541,"briefTitle":2542,"status":131,"phases":2543,"primaryCompletion":2544,"completion":2545,"start":2546,"enrollment":2547,"conditions":2548,"interventions":2551},"NCT05187377","A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism",[87],"2025-01-28","2025-02-05","2022-01-19",32,[2549,2550],"Phelan-McDermid Syndrome","Autism Spectrum Disorder (ASD)",[2552,1907],"Growth Hormone",{"nctId":2554,"briefTitle":2555,"status":131,"phases":2556,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":1367,"conditions":2559,"interventions":2561},"NCT02623829","Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)",[87],"2019-03-01","2015-12-01",[2560],"Post-operative Excessive Scarring",[2562,1907],"Botulinum Toxin",{"trials":2564,"activeCount":112},[],{"trials":2566,"activeCount":112},[2567,2578,2592,2604],{"nctId":2568,"briefTitle":2569,"status":131,"phases":2570,"primaryCompletion":2571,"completion":2571,"start":2572,"enrollment":2573,"conditions":2574,"interventions":2577},"NCT03856788","Unilateral TAP Block for Laparoscopic Gastric Sleeve Surgery",[89],"2021-03-25","2018-12-10",43,[2575,2576],"Laparoscopic Sleeve Gastrectomy","Subcostal Transversus Abdominis Plane Block",[1907,2485],{"nctId":2579,"briefTitle":2580,"status":246,"phases":2581,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":2102,"conditions":2584,"interventions":2589},"NCT02643979","Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy",[89],"2019-01-05","2016-01-01",[24,2585,2586,2587,2588],"Bariatrics","Sleep Apnea Syndromes","Gastric Bypass","Endoscopy",[2590,2591,1907],"Ketofol","Propofol",{"nctId":2593,"briefTitle":2594,"status":131,"phases":2595,"primaryCompletion":2596,"completion":2596,"start":2597,"enrollment":598,"conditions":2598,"interventions":2602},"NCT04017442","Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery",[89],"2023-08-31","2019-10-19",[2599,2600,2601],"Postpartum Pain","Postpartum Depression","Opioid Consumption",[2603,1907],"Preservative Free Morphine",{"nctId":2605,"briefTitle":2606,"status":131,"phases":2607,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":990,"conditions":2610,"interventions":2613},"NCT03326999","Does Adding an Additional Numbing Medication Injection in the Thigh Help With Pain Control After Knee Replacement Surgery?",[89],"2018-12-18","2017-12-11",[2611,2612],"Knee Osteoarthritis","Knee Rheumatism",[2614,2615,1907],"Obturator nerve regional block","Adductor canal regional block",{"trials":2617,"activeCount":112},[],{"intervention":2619,"totalTrials":956,"cells":2620},"Aspirin",{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2637,"PHASE4":2652,"NA":2666},{"trials":2622,"activeCount":112},[],{"trials":2624,"activeCount":112},[],{"trials":2626,"activeCount":112},[2627],{"nctId":2628,"briefTitle":2629,"status":131,"phases":2630,"primaryCompletion":204,"completion":204,"start":2631,"enrollment":2632,"conditions":2633,"interventions":2635},"NCT02578706","Targeting Platelets in Chronic HIV Infection",[87],"2015-10",27,[2634],"HIV-1 Infection",[2636,2619],"Clopidogrel",{"trials":2638,"activeCount":112},[2639],{"nctId":2640,"briefTitle":2641,"status":131,"phases":2642,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":186,"conditions":2645,"interventions":2648},"NCT02325466","Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes",[88],"2018-05-04","2015-04",[2646,2647],"Peripheral Artery Disease","Type 2 Diabetes",[2619,2649,2650,2651],"Ticagrelor","Aspirin Placebo","Ticagrelor Placebo",{"trials":2653,"activeCount":112},[2654],{"nctId":2655,"briefTitle":2656,"status":131,"phases":2657,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":2660,"conditions":2661,"interventions":2664},"NCT02270242","Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention",[89],"2019-07-10","2015-07",9006,[2662,2663],"Cardiovascular Disease","Interventional Cardiology",[2619,2665],"ticagrelor",{"trials":2667,"activeCount":112},[],{"intervention":179,"totalTrials":956,"cells":2669},{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2680,"PHASE4":2686,"NA":2692},{"trials":2671,"activeCount":112},[],{"trials":2673,"activeCount":112},[],{"trials":2675,"activeCount":112},[2676],{"nctId":170,"briefTitle":171,"status":131,"phases":2677,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":2678,"interventions":2679},[87],[177],[160,179],{"trials":2681,"activeCount":112},[2682],{"nctId":232,"briefTitle":233,"status":131,"phases":2683,"primaryCompletion":235,"completion":235,"start":236,"enrollment":237,"conditions":2684,"interventions":2685},[87,88],[239],[160,179],{"trials":2687,"activeCount":112},[2688],{"nctId":244,"briefTitle":245,"status":246,"phases":2689,"primaryCompletion":248,"completion":248,"start":249,"enrollment":109,"conditions":2690,"interventions":2691},[89],[251],[253,254],{"trials":2693,"activeCount":112},[],{"intervention":689,"totalTrials":146,"cells":2695},{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2706,"PHASE4":2708,"NA":2719},{"trials":2697,"activeCount":112},[],{"trials":2699,"activeCount":112},[],{"trials":2701,"activeCount":112},[2702],{"nctId":681,"briefTitle":682,"status":131,"phases":2703,"primaryCompletion":684,"completion":684,"start":685,"enrollment":195,"conditions":2704,"interventions":2705},[87],[26],[688,689,690,691,40,692],{"trials":2707,"activeCount":112},[],{"trials":2709,"activeCount":112},[2710],{"nctId":2711,"briefTitle":2712,"status":246,"phases":2713,"primaryCompletion":2714,"completion":2714,"start":2715,"enrollment":109,"conditions":2716,"interventions":2717},"NCT02324699","Corticosteroids With Vedolizumab in Crohn's Disease",[89],"2018-02-08","2016-04",[1938],[689,2718],"Vedolizumab",{"trials":2720,"activeCount":112},[],{"intervention":2722,"totalTrials":146,"cells":2723},"Bupivacaine liposome",{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2730,"PHASE4":2732,"NA":2754},{"trials":2725,"activeCount":112},[],{"trials":2727,"activeCount":112},[],{"trials":2729,"activeCount":112},[],{"trials":2731,"activeCount":112},[],{"trials":2733,"activeCount":112},[2734,2744],{"nctId":2735,"briefTitle":2736,"status":246,"phases":2737,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":2740,"conditions":2741,"interventions":2743},"NCT03642457","Efficacy Between Serratus Plane Block And Local Infiltration In Vats",[89],"2018-12-31","2018-03-01",65,[2742],"Lung Cancer",[2485,2722],{"nctId":2745,"briefTitle":2746,"status":131,"phases":2747,"primaryCompletion":597,"completion":597,"start":2748,"enrollment":2749,"conditions":2750,"interventions":2752},"NCT04272086","Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy",[89],"2020-11-09",140,[2751],"Fibroid Uterus",[2485,2722,2753],"normal saline",{"trials":2755,"activeCount":112},[],{"intervention":2757,"totalTrials":146,"cells":2758},"Modafinil",{"EARLY_PHASE1":2759,"PHASE1":2761,"PHASE2":2763,"PHASE3":2773,"PHASE4":2775,"NA":2786},{"trials":2760,"activeCount":112},[],{"trials":2762,"activeCount":112},[],{"trials":2764,"activeCount":112},[2765],{"nctId":2766,"briefTitle":2767,"status":246,"phases":2768,"primaryCompletion":2769,"completion":2769,"start":134,"enrollment":1000,"conditions":2770,"interventions":2772},"NCT00233090","Post-Traumatic Brain Injury (Post-TBI) Fatigue and Its Treatment",[87],"2008-12",[2771],"Fatigue",[2757],{"trials":2774,"activeCount":112},[],{"trials":2776,"activeCount":112},[2777],{"nctId":2778,"briefTitle":2779,"status":131,"phases":2780,"primaryCompletion":2781,"completion":2781,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2785},"NCT01965925","Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil",[89],"2017-11-09","2014-01",18,[251],[2757],{"trials":2787,"activeCount":112},[],{"intervention":1059,"totalTrials":146,"cells":2789},{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2796,"PHASE4":2798,"NA":2808},{"trials":2791,"activeCount":112},[],{"trials":2793,"activeCount":112},[],{"trials":2795,"activeCount":112},[],{"trials":2797,"activeCount":112},[],{"trials":2799,"activeCount":112},[2800,2804],{"nctId":1089,"briefTitle":1090,"status":131,"phases":2801,"primaryCompletion":1092,"completion":1092,"start":1093,"enrollment":914,"conditions":2802,"interventions":2803},[89],[1095],[1063,1059],{"nctId":1050,"briefTitle":1051,"status":131,"phases":2805,"primaryCompletion":1053,"completion":1053,"start":1054,"enrollment":1055,"conditions":2806,"interventions":2807},[89],[1057],[1059,198],{"trials":2809,"activeCount":112},[],{"intervention":2649,"totalTrials":146,"cells":2811},{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2818,"PHASE4":2824,"NA":2830},{"trials":2813,"activeCount":112},[],{"trials":2815,"activeCount":112},[],{"trials":2817,"activeCount":112},[],{"trials":2819,"activeCount":112},[2820],{"nctId":2640,"briefTitle":2641,"status":131,"phases":2821,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":186,"conditions":2822,"interventions":2823},[88],[2646,2647],[2619,2649,2650,2651],{"trials":2825,"activeCount":112},[2826],{"nctId":2655,"briefTitle":2656,"status":131,"phases":2827,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":2660,"conditions":2828,"interventions":2829},[89],[2662,2663],[2619,2665],{"trials":2831,"activeCount":112},[],{"intervention":2833,"totalTrials":146,"cells":2834},"Precedex",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2843,"NA":2866},{"trials":2836,"activeCount":112},[],{"trials":2838,"activeCount":112},[],{"trials":2840,"activeCount":112},[],{"trials":2842,"activeCount":112},[],{"trials":2844,"activeCount":112},[2845,2858],{"nctId":2846,"briefTitle":2847,"status":131,"phases":2848,"primaryCompletion":2849,"completion":2849,"start":2850,"enrollment":2851,"conditions":2852,"interventions":2857},"NCT00561678","Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve",[89],"2014-05","2008-02",404,[2853,2854,2855,2856],"Postoperative Delirium","PD","Postoperative Cognitive Dysfunction","POCD",[2833],{"nctId":2859,"briefTitle":2860,"status":246,"phases":2861,"primaryCompletion":2862,"completion":2862,"start":2863,"enrollment":2632,"conditions":2864,"interventions":2865},"NCT00455143","Cognitive Protection - Dexmedetomidine and Cognitive Reserve",[89],"2009-04","2006-09",[2853,2854,2855,2856],[2833],{"trials":2867,"activeCount":112},[],{"intervention":2869,"totalTrials":109,"cells":2870},"Atenolol",{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2875,"PHASE3":2877,"PHASE4":2879,"NA":2891},{"trials":2872,"activeCount":112},[],{"trials":2874,"activeCount":112},[],{"trials":2876,"activeCount":112},[],{"trials":2878,"activeCount":112},[],{"trials":2880,"activeCount":112},[2881],{"nctId":2882,"briefTitle":2883,"status":131,"phases":2884,"primaryCompletion":2885,"completion":2885,"start":2886,"enrollment":2887,"conditions":2888,"interventions":2890},"NCT00507663","Elder Surgery - Functional Recovery Following Beta Blockade",[89],"2007-11","2002-09",359,[2889],"Post Operative Cognitive Dysfunction",[2869],{"trials":2892,"activeCount":112},[],{"intervention":2894,"totalTrials":109,"cells":2895},"Ingenol Mebutate",{"EARLY_PHASE1":2896,"PHASE1":2898,"PHASE2":2900,"PHASE3":2902,"PHASE4":2904,"NA":2916},{"trials":2897,"activeCount":112},[],{"trials":2899,"activeCount":112},[],{"trials":2901,"activeCount":112},[],{"trials":2903,"activeCount":112},[],{"trials":2905,"activeCount":112},[2906],{"nctId":2907,"briefTitle":2908,"status":131,"phases":2909,"primaryCompletion":2910,"completion":2911,"start":2912,"enrollment":16,"conditions":2913,"interventions":2915},"NCT02251652","Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses",[89],"2014-12","2015-08","2013-04",[2914],"Actinic Keratoses",[2894],{"trials":2917,"activeCount":112},[],{"intervention":2919,"totalTrials":109,"cells":2920},"ACTHar",{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2927,"PHASE4":2929,"NA":2940},{"trials":2922,"activeCount":112},[],{"trials":2924,"activeCount":112},[],{"trials":2926,"activeCount":112},[],{"trials":2928,"activeCount":112},[],{"trials":2930,"activeCount":112},[2931],{"nctId":2932,"briefTitle":2933,"status":131,"phases":2934,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":93,"conditions":2937,"interventions":2939},"NCT03025828","Adrenocorticotropic Hormone in Membranous Nephropathy",[89],"2020-12-16","2018-03-19",[2938],"Membranous Nephropathy",[2919],{"trials":2941,"activeCount":112},[],{"intervention":2943,"totalTrials":109,"cells":2944},"Guanfacine Hydrochloride XR",{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2951,"PHASE4":2953,"NA":2963},{"trials":2946,"activeCount":112},[],{"trials":2948,"activeCount":112},[],{"trials":2950,"activeCount":112},[],{"trials":2952,"activeCount":112},[],{"trials":2954,"activeCount":112},[2955],{"nctId":2956,"briefTitle":2957,"status":131,"phases":2958,"primaryCompletion":2959,"completion":2959,"start":2960,"enrollment":2632,"conditions":2961,"interventions":2962},"NCT01709695","Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD",[89],"2013-12","2011-03",[125,126],[2943],{"trials":2964,"activeCount":112},[],{"intervention":2966,"totalTrials":109,"cells":2967},"Tranexamic Acid",{"EARLY_PHASE1":2968,"PHASE1":2970,"PHASE2":2972,"PHASE3":2974,"PHASE4":2976,"NA":2987},{"trials":2969,"activeCount":112},[],{"trials":2971,"activeCount":112},[],{"trials":2973,"activeCount":112},[],{"trials":2975,"activeCount":112},[],{"trials":2977,"activeCount":112},[2978],{"nctId":2979,"briefTitle":2980,"status":131,"phases":2981,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":459,"conditions":2982,"interventions":2985},"NCT03653429","Efficacy of Tranexamic Acid in Foot and Ankle Surgeries",[89],[2983,2984],"Foot and Ankle Surgeries","Bunion",[2966,2986],"Normal saline",{"trials":2988,"activeCount":112},[],{"intervention":2990,"totalTrials":109,"cells":2991},"Nebivolol",{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":2998,"PHASE4":3000,"NA":3012},{"trials":2993,"activeCount":112},[],{"trials":2995,"activeCount":112},[],{"trials":2997,"activeCount":112},[],{"trials":2999,"activeCount":112},[],{"trials":3001,"activeCount":112},[3002],{"nctId":3003,"briefTitle":3004,"status":131,"phases":3005,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":186,"conditions":3008,"interventions":3011},"NCT01961323","Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart",[89],"2016-03","2012-03",[3009,3010],"Hypertension","Left Ventricular Diastolic Dysfunction",[2990],{"trials":3013,"activeCount":112},[],{"intervention":3015,"totalTrials":109,"cells":3016},"lithium and Venlafaxine",{"EARLY_PHASE1":3017,"PHASE1":3019,"PHASE2":3021,"PHASE3":3023,"PHASE4":3025,"NA":3036},{"trials":3018,"activeCount":112},[],{"trials":3020,"activeCount":112},[],{"trials":3022,"activeCount":112},[],{"trials":3024,"activeCount":112},[],{"trials":3026,"activeCount":112},[3027],{"nctId":3028,"briefTitle":3029,"status":131,"phases":3030,"primaryCompletion":3031,"completion":3006,"start":3032,"enrollment":3033,"conditions":3034,"interventions":3035},"NCT01028508","Prolonging Remission in Depressed Elderly (PRIDE)",[89],"2015-09","2010-01",247,[21],[3015],{"trials":3037,"activeCount":112},[],{"intervention":3039,"totalTrials":109,"cells":3040},"Phenazopyridine",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3047,"PHASE4":3049,"NA":3061},{"trials":3042,"activeCount":112},[],{"trials":3044,"activeCount":112},[],{"trials":3046,"activeCount":112},[],{"trials":3048,"activeCount":112},[],{"trials":3050,"activeCount":112},[3051],{"nctId":3052,"briefTitle":3053,"status":131,"phases":3054,"primaryCompletion":3055,"completion":3055,"start":3056,"enrollment":3057,"conditions":3058,"interventions":3060},"NCT03302936","Assessing Pyridium for Post-Sling Urinary Retention",[89],"2019-07-01","2017-10-24",98,[3059],"Urinary Retention",[3039],{"trials":3062,"activeCount":112},[],{"intervention":3064,"totalTrials":109,"cells":3065},"Terbutaline",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3085},{"trials":3067,"activeCount":112},[],{"trials":3069,"activeCount":112},[],{"trials":3071,"activeCount":112},[],{"trials":3073,"activeCount":112},[],{"trials":3075,"activeCount":112},[3076],{"nctId":3077,"briefTitle":3078,"status":246,"phases":3079,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":206,"conditions":3082,"interventions":3084},"NCT03106753","Success of External Cephalic Version Study",[89],"2018-05-05","2017-04-12",[3083],"External Cephalic Version",[2485,3064],{"trials":3086,"activeCount":112},[],{"intervention":3088,"totalTrials":109,"cells":3089},"Minocycline",{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3094,"PHASE3":3096,"PHASE4":3098,"NA":3109},{"trials":3091,"activeCount":112},[],{"trials":3093,"activeCount":112},[],{"trials":3095,"activeCount":112},[],{"trials":3097,"activeCount":112},[],{"trials":3099,"activeCount":112},[3100],{"nctId":3101,"briefTitle":3102,"status":131,"phases":3103,"primaryCompletion":3104,"completion":3104,"start":3105,"enrollment":283,"conditions":3106,"interventions":3108},"NCT01514422","Minocycline for Bipolar Depression",[89],"2013-08","2011-05",[3107],"Bipolar Depression",[3088],{"trials":3110,"activeCount":112},[],{"intervention":3112,"totalTrials":109,"cells":3113},"Procardia XL 30Mg",{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3120,"PHASE4":3122,"NA":3135},{"trials":3115,"activeCount":112},[],{"trials":3117,"activeCount":112},[],{"trials":3119,"activeCount":112},[],{"trials":3121,"activeCount":112},[],{"trials":3123,"activeCount":112},[3124],{"nctId":3125,"briefTitle":3126,"status":246,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":93,"conditions":3130,"interventions":3133},"NCT03595982","Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily?",[89],"2020-02-20","2018-09-15",[3131,3132],"Hypertension in Pregnancy","Hypertension in Postpartum",[3112,3134],"Procardia XL 60Mg",{"trials":3136,"activeCount":112},[],{"intervention":3134,"totalTrials":109,"cells":3138},{"EARLY_PHASE1":3139,"PHASE1":3141,"PHASE2":3143,"PHASE3":3145,"PHASE4":3147,"NA":3153},{"trials":3140,"activeCount":112},[],{"trials":3142,"activeCount":112},[],{"trials":3144,"activeCount":112},[],{"trials":3146,"activeCount":112},[],{"trials":3148,"activeCount":112},[3149],{"nctId":3125,"briefTitle":3126,"status":246,"phases":3150,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":93,"conditions":3151,"interventions":3152},[89],[3131,3132],[3112,3134],{"trials":3154,"activeCount":112},[],{"intervention":3156,"totalTrials":109,"cells":3157},"5mg Oxycodone, Q6 PRN",{"EARLY_PHASE1":3158,"PHASE1":3160,"PHASE2":3162,"PHASE3":3164,"PHASE4":3166,"NA":3178},{"trials":3159,"activeCount":112},[],{"trials":3161,"activeCount":112},[],{"trials":3163,"activeCount":112},[],{"trials":3165,"activeCount":112},[],{"trials":3167,"activeCount":112},[3168],{"nctId":3169,"briefTitle":3170,"status":131,"phases":3171,"primaryCompletion":3172,"completion":3172,"start":3173,"enrollment":1524,"conditions":3174,"interventions":3176},"NCT05924165","Narcotic-Free Percutaneous Nephrolithotomy",[89],"2025-01-07","2023-05-19",[3175],"Nephrolithiasis",[3156,3177],"10mg Ketorolac, Q6 PRN",{"trials":3179,"activeCount":112},[],{"intervention":3177,"totalTrials":109,"cells":3181},{"EARLY_PHASE1":3182,"PHASE1":3184,"PHASE2":3186,"PHASE3":3188,"PHASE4":3190,"NA":3196},{"trials":3183,"activeCount":112},[],{"trials":3185,"activeCount":112},[],{"trials":3187,"activeCount":112},[],{"trials":3189,"activeCount":112},[],{"trials":3191,"activeCount":112},[3192],{"nctId":3169,"briefTitle":3170,"status":131,"phases":3193,"primaryCompletion":3172,"completion":3172,"start":3173,"enrollment":1524,"conditions":3194,"interventions":3195},[89],[3175],[3156,3177],{"trials":3197,"activeCount":112},[],{"intervention":3199,"totalTrials":109,"cells":3200},"Ticagrelor loading dose",{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3205,"PHASE3":3207,"PHASE4":3209,"NA":3222},{"trials":3202,"activeCount":112},[],{"trials":3204,"activeCount":112},[],{"trials":3206,"activeCount":112},[],{"trials":3208,"activeCount":112},[],{"trials":3210,"activeCount":112},[3211],{"nctId":3212,"briefTitle":3213,"status":131,"phases":3214,"primaryCompletion":3215,"completion":3215,"start":3216,"enrollment":283,"conditions":3217,"interventions":3218},"NCT02201394","Reversing Ticagrelor's Effects With Fresh Platelets",[89],"2016-06","2014-07",[15],[3199,3219,3220,3221],"Aspirin loading dose","Ticagrelor maintenance dose","Aspirin maintenance dose",{"trials":3223,"activeCount":112},[],{"intervention":3219,"totalTrials":109,"cells":3225},{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3232,"PHASE4":3234,"NA":3240},{"trials":3227,"activeCount":112},[],{"trials":3229,"activeCount":112},[],{"trials":3231,"activeCount":112},[],{"trials":3233,"activeCount":112},[],{"trials":3235,"activeCount":112},[3236],{"nctId":3212,"briefTitle":3213,"status":131,"phases":3237,"primaryCompletion":3215,"completion":3215,"start":3216,"enrollment":283,"conditions":3238,"interventions":3239},[89],[15],[3199,3219,3220,3221],{"trials":3241,"activeCount":112},[],{"intervention":3220,"totalTrials":109,"cells":3243},{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3250,"PHASE4":3252,"NA":3258},{"trials":3245,"activeCount":112},[],{"trials":3247,"activeCount":112},[],{"trials":3249,"activeCount":112},[],{"trials":3251,"activeCount":112},[],{"trials":3253,"activeCount":112},[3254],{"nctId":3212,"briefTitle":3213,"status":131,"phases":3255,"primaryCompletion":3215,"completion":3215,"start":3216,"enrollment":283,"conditions":3256,"interventions":3257},[89],[15],[3199,3219,3220,3221],{"trials":3259,"activeCount":112},[],{"intervention":3221,"totalTrials":109,"cells":3261},{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3266,"PHASE3":3268,"PHASE4":3270,"NA":3276},{"trials":3263,"activeCount":112},[],{"trials":3265,"activeCount":112},[],{"trials":3267,"activeCount":112},[],{"trials":3269,"activeCount":112},[],{"trials":3271,"activeCount":112},[3272],{"nctId":3212,"briefTitle":3213,"status":131,"phases":3273,"primaryCompletion":3215,"completion":3215,"start":3216,"enrollment":283,"conditions":3274,"interventions":3275},[89],[15],[3199,3219,3220,3221],{"trials":3277,"activeCount":112},[],{"intervention":3279,"totalTrials":109,"cells":3280},"Amoxicillin",{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3285,"PHASE3":3287,"PHASE4":3289,"NA":3302},{"trials":3282,"activeCount":112},[],{"trials":3284,"activeCount":112},[],{"trials":3286,"activeCount":112},[],{"trials":3288,"activeCount":112},[],{"trials":3290,"activeCount":112},[3291],{"nctId":3292,"briefTitle":3293,"status":131,"phases":3294,"primaryCompletion":3295,"completion":3295,"start":193,"enrollment":3296,"conditions":3297,"interventions":3299},"NCT05342532","High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population",[89],"2022-01-01",112,[3298],"Helicobacter Pylori Infection",[3279,3300,3301],"Omeprazole","Clarithromycin",{"trials":3303,"activeCount":112},[],{"intervention":3300,"totalTrials":109,"cells":3305},{"EARLY_PHASE1":3306,"PHASE1":3308,"PHASE2":3310,"PHASE3":3312,"PHASE4":3314,"NA":3320},{"trials":3307,"activeCount":112},[],{"trials":3309,"activeCount":112},[],{"trials":3311,"activeCount":112},[],{"trials":3313,"activeCount":112},[],{"trials":3315,"activeCount":112},[3316],{"nctId":3292,"briefTitle":3293,"status":131,"phases":3317,"primaryCompletion":3295,"completion":3295,"start":193,"enrollment":3296,"conditions":3318,"interventions":3319},[89],[3298],[3279,3300,3301],{"trials":3321,"activeCount":112},[],{"intervention":3301,"totalTrials":109,"cells":3323},{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3328,"PHASE3":3330,"PHASE4":3332,"NA":3338},{"trials":3325,"activeCount":112},[],{"trials":3327,"activeCount":112},[],{"trials":3329,"activeCount":112},[],{"trials":3331,"activeCount":112},[],{"trials":3333,"activeCount":112},[3334],{"nctId":3292,"briefTitle":3293,"status":131,"phases":3335,"primaryCompletion":3295,"completion":3295,"start":193,"enrollment":3296,"conditions":3336,"interventions":3337},[89],[3298],[3279,3300,3301],{"trials":3339,"activeCount":112},[],{"intervention":3341,"totalTrials":109,"cells":3342},"Duobrii®",{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3347,"PHASE3":3349,"PHASE4":3351,"NA":3363},{"trials":3344,"activeCount":112},[],{"trials":3346,"activeCount":112},[],{"trials":3348,"activeCount":112},[],{"trials":3350,"activeCount":112},[],{"trials":3352,"activeCount":112},[3353],{"nctId":3354,"briefTitle":3355,"status":131,"phases":3356,"primaryCompletion":3357,"completion":3357,"start":3358,"enrollment":2102,"conditions":3359,"interventions":3362},"NCT04720105","Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis",[89],"2022-03-29","2020-11-19",[3360,3361],"Palmoplantar Psoriasis","Plaque Psoriasis",[3341],{"trials":3364,"activeCount":112},[],{"intervention":3366,"totalTrials":109,"cells":3367},"Ondansetron 4 MG",{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3372,"PHASE3":3374,"PHASE4":3376,"NA":3388},{"trials":3369,"activeCount":112},[],{"trials":3371,"activeCount":112},[],{"trials":3373,"activeCount":112},[],{"trials":3375,"activeCount":112},[],{"trials":3377,"activeCount":112},[3378],{"nctId":3379,"briefTitle":3380,"status":131,"phases":3381,"primaryCompletion":913,"completion":913,"start":3382,"enrollment":3383,"conditions":3384,"interventions":3386},"NCT03297021","Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting",[89],"2017-10-23",141,[3385],"Post-operative Nausea and Vomiting",[3366,3387],"Ondansetron 8mg",{"trials":3389,"activeCount":112},[],{"intervention":3387,"totalTrials":109,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3398,"PHASE4":3400,"NA":3406},{"trials":3393,"activeCount":112},[],{"trials":3395,"activeCount":112},[],{"trials":3397,"activeCount":112},[],{"trials":3399,"activeCount":112},[],{"trials":3401,"activeCount":112},[3402],{"nctId":3379,"briefTitle":3380,"status":131,"phases":3403,"primaryCompletion":913,"completion":913,"start":3382,"enrollment":3383,"conditions":3404,"interventions":3405},[89],[3385],[3366,3387],{"trials":3407,"activeCount":112},[],{"intervention":3409,"totalTrials":109,"cells":3410},"Low-dose epinephrine",{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3417,"PHASE4":3419,"NA":3433},{"trials":3412,"activeCount":112},[],{"trials":3414,"activeCount":112},[],{"trials":3416,"activeCount":112},[],{"trials":3418,"activeCount":112},[],{"trials":3420,"activeCount":112},[3421],{"nctId":3422,"briefTitle":3423,"status":131,"phases":3424,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":3427,"conditions":3428,"interventions":3430},"NCT02369510","Does the Addition of Epinephrine Prolong the Duration of Spinal Anesthesia for Repeat Cesarean Section?",[89],"2016-05","2015-02",68,[3429,397],"Spinal Anesthesia",[3409,3431,3432],"High-dose epinephrine","No epinephrine",{"trials":3434,"activeCount":112},[],{"intervention":3431,"totalTrials":109,"cells":3436},{"EARLY_PHASE1":3437,"PHASE1":3439,"PHASE2":3441,"PHASE3":3443,"PHASE4":3445,"NA":3451},{"trials":3438,"activeCount":112},[],{"trials":3440,"activeCount":112},[],{"trials":3442,"activeCount":112},[],{"trials":3444,"activeCount":112},[],{"trials":3446,"activeCount":112},[3447],{"nctId":3422,"briefTitle":3423,"status":131,"phases":3448,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":3427,"conditions":3449,"interventions":3450},[89],[3429,397],[3409,3431,3432],{"trials":3452,"activeCount":112},[],{"intervention":3432,"totalTrials":109,"cells":3454},{"EARLY_PHASE1":3455,"PHASE1":3457,"PHASE2":3459,"PHASE3":3461,"PHASE4":3463,"NA":3469},{"trials":3456,"activeCount":112},[],{"trials":3458,"activeCount":112},[],{"trials":3460,"activeCount":112},[],{"trials":3462,"activeCount":112},[],{"trials":3464,"activeCount":112},[3465],{"nctId":3422,"briefTitle":3423,"status":131,"phases":3466,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":3427,"conditions":3467,"interventions":3468},[89],[3429,397],[3409,3431,3432],{"trials":3470,"activeCount":112},[],{"intervention":3472,"totalTrials":109,"cells":3473},"Ertugliflozin",{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3482,"NA":3494},{"trials":3475,"activeCount":112},[],{"trials":3477,"activeCount":112},[],{"trials":3479,"activeCount":112},[],{"trials":3481,"activeCount":112},[],{"trials":3483,"activeCount":112},[3484],{"nctId":3485,"briefTitle":3486,"status":131,"phases":3487,"primaryCompletion":3488,"completion":3488,"start":3489,"enrollment":2463,"conditions":3490,"interventions":3493},"NCT05152940","ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF",[89],"2023-10-27","2023-02-02",[3491,3492],"Heart Failure With Reduced Ejection Fraction","Congestion",[3472],{"trials":3495,"activeCount":112},[],{"intervention":3497,"totalTrials":109,"cells":3498},"Galantamine-ER",{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3505,"PHASE4":3507,"NA":3518},{"trials":3500,"activeCount":112},[],{"trials":3502,"activeCount":112},[],{"trials":3504,"activeCount":112},[],{"trials":3506,"activeCount":112},[],{"trials":3508,"activeCount":112},[3509],{"nctId":3510,"briefTitle":3511,"status":131,"phases":3512,"primaryCompletion":2849,"completion":2849,"start":3513,"enrollment":3514,"conditions":3515,"interventions":3516},"NCT00741598","Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder",[89],"2008-09",72,[251],[3497,3517],"Galantamine placebo",{"trials":3519,"activeCount":112},[],{"intervention":3517,"totalTrials":109,"cells":3521},{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3536},{"trials":3523,"activeCount":112},[],{"trials":3525,"activeCount":112},[],{"trials":3527,"activeCount":112},[],{"trials":3529,"activeCount":112},[],{"trials":3531,"activeCount":112},[3532],{"nctId":3510,"briefTitle":3511,"status":131,"phases":3533,"primaryCompletion":2849,"completion":2849,"start":3513,"enrollment":3514,"conditions":3534,"interventions":3535},[89],[251],[3497,3517],{"trials":3537,"activeCount":112},[],{"intervention":3539,"totalTrials":109,"cells":3540},"Escitalopram",{"EARLY_PHASE1":3541,"PHASE1":3543,"PHASE2":3545,"PHASE3":3547,"PHASE4":3549,"NA":3561},{"trials":3542,"activeCount":112},[],{"trials":3544,"activeCount":112},[],{"trials":3546,"activeCount":112},[],{"trials":3548,"activeCount":112},[],{"trials":3550,"activeCount":112},[3551],{"nctId":3552,"briefTitle":3553,"status":131,"phases":3554,"completion":3555,"start":3556,"enrollment":3557,"conditions":3558,"interventions":3560},"NCT00565422","Efficacy of Escitalopram in the Treatment of Internet Addiction",[89],"2004-10","2002-12",31,[3559],"Internet Addiction",[3539],{"trials":3562,"activeCount":112},[],{"intervention":3564,"totalTrials":109,"cells":3565},"Bimekizumab",{"EARLY_PHASE1":3566,"PHASE1":3568,"PHASE2":3570,"PHASE3":3572,"PHASE4":3574,"NA":3583},{"trials":3567,"activeCount":112},[],{"trials":3569,"activeCount":112},[],{"trials":3571,"activeCount":112},[],{"trials":3573,"activeCount":112},[],{"trials":3575,"activeCount":112},[3576],{"nctId":3577,"briefTitle":3578,"status":131,"phases":3579,"primaryCompletion":2146,"completion":2146,"start":3580,"enrollment":990,"conditions":3581,"interventions":3582},"NCT06336343","Bimekizumab in Plaque Psoriasis",[89],"2024-06-03",[3361],[3564],{"trials":3584,"activeCount":112},[],{"intervention":3586,"totalTrials":109,"cells":3587},"Acitretin",{"EARLY_PHASE1":3588,"PHASE1":3590,"PHASE2":3592,"PHASE3":3594,"PHASE4":3596,"NA":3606},{"trials":3589,"activeCount":112},[],{"trials":3591,"activeCount":112},[],{"trials":3593,"activeCount":112},[],{"trials":3595,"activeCount":112},[],{"trials":3597,"activeCount":112},[3598],{"nctId":3599,"briefTitle":3600,"status":246,"phases":3601,"primaryCompletion":2910,"completion":2910,"start":3602,"enrollment":146,"conditions":3603,"interventions":3605},"NCT02181790","Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles",[89],"2014-06",[3604],"Psoriasis, Skin or Nails",[3586],{"trials":3607,"activeCount":112},[],{"intervention":337,"totalTrials":109,"cells":3609},{"EARLY_PHASE1":3610,"PHASE1":3612,"PHASE2":3614,"PHASE3":3616,"PHASE4":3618,"NA":3624},{"trials":3611,"activeCount":112},[],{"trials":3613,"activeCount":112},[],{"trials":3615,"activeCount":112},[],{"trials":3617,"activeCount":112},[],{"trials":3619,"activeCount":112},[3620],{"nctId":327,"briefTitle":328,"status":131,"phases":3621,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":3622,"interventions":3623},[89],[334],[336,314,337,338,339],{"trials":3625,"activeCount":112},[],{"intervention":338,"totalTrials":109,"cells":3627},{"EARLY_PHASE1":3628,"PHASE1":3630,"PHASE2":3632,"PHASE3":3634,"PHASE4":3636,"NA":3642},{"trials":3629,"activeCount":112},[],{"trials":3631,"activeCount":112},[],{"trials":3633,"activeCount":112},[],{"trials":3635,"activeCount":112},[],{"trials":3637,"activeCount":112},[3638],{"nctId":327,"briefTitle":328,"status":131,"phases":3639,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":3640,"interventions":3641},[89],[334],[336,314,337,338,339],{"trials":3643,"activeCount":112},[],{"intervention":339,"totalTrials":109,"cells":3645},{"EARLY_PHASE1":3646,"PHASE1":3648,"PHASE2":3650,"PHASE3":3652,"PHASE4":3654,"NA":3660},{"trials":3647,"activeCount":112},[],{"trials":3649,"activeCount":112},[],{"trials":3651,"activeCount":112},[],{"trials":3653,"activeCount":112},[],{"trials":3655,"activeCount":112},[3656],{"nctId":327,"briefTitle":328,"status":131,"phases":3657,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":3658,"interventions":3659},[89],[334],[336,314,337,338,339],{"trials":3661,"activeCount":112},[],{"intervention":3663,"totalTrials":109,"cells":3664},"Atomoxetine arm",{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3671,"PHASE4":3673,"NA":3685},{"trials":3666,"activeCount":112},[],{"trials":3668,"activeCount":112},[],{"trials":3670,"activeCount":112},[],{"trials":3672,"activeCount":112},[],{"trials":3674,"activeCount":112},[3675],{"nctId":3676,"briefTitle":3677,"status":131,"phases":3678,"primaryCompletion":3679,"completion":3679,"start":3680,"enrollment":3681,"conditions":3682,"interventions":3683},"NCT01678209","Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach",[89],"2018-04-30","2012-10",127,[126,125],[3663,3684],"Methylphenidate arm",{"trials":3686,"activeCount":112},[],{"intervention":3684,"totalTrials":109,"cells":3688},{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3695,"PHASE4":3697,"NA":3703},{"trials":3690,"activeCount":112},[],{"trials":3692,"activeCount":112},[],{"trials":3694,"activeCount":112},[],{"trials":3696,"activeCount":112},[],{"trials":3698,"activeCount":112},[3699],{"nctId":3676,"briefTitle":3677,"status":131,"phases":3700,"primaryCompletion":3679,"completion":3679,"start":3680,"enrollment":3681,"conditions":3701,"interventions":3702},[89],[126,125],[3663,3684],{"trials":3704,"activeCount":112},[],{"intervention":3706,"totalTrials":109,"cells":3707},"BOTOX®",{"EARLY_PHASE1":3708,"PHASE1":3710,"PHASE2":3712,"PHASE3":3714,"PHASE4":3716,"NA":3728},{"trials":3709,"activeCount":112},[],{"trials":3711,"activeCount":112},[],{"trials":3713,"activeCount":112},[],{"trials":3715,"activeCount":112},[],{"trials":3717,"activeCount":112},[3718],{"nctId":3719,"briefTitle":3720,"status":131,"phases":3721,"completion":2863,"start":3722,"enrollment":3723,"conditions":3724,"interventions":3726},"NCT00430196","BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity",[89],"2003-12",135,[3725],"Upper Limb Spasticity",[3706,3727],"Zanaflex®",{"trials":3729,"activeCount":112},[],{"intervention":3727,"totalTrials":109,"cells":3731},{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3736,"PHASE3":3738,"PHASE4":3740,"NA":3746},{"trials":3733,"activeCount":112},[],{"trials":3735,"activeCount":112},[],{"trials":3737,"activeCount":112},[],{"trials":3739,"activeCount":112},[],{"trials":3741,"activeCount":112},[3742],{"nctId":3719,"briefTitle":3720,"status":131,"phases":3743,"completion":2863,"start":3722,"enrollment":3723,"conditions":3744,"interventions":3745},[89],[3725],[3706,3727],{"trials":3747,"activeCount":112},[],{"intervention":3749,"totalTrials":109,"cells":3750},"Rimegepant",{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3755,"PHASE3":3757,"PHASE4":3759,"NA":3772},{"trials":3752,"activeCount":112},[],{"trials":3754,"activeCount":112},[],{"trials":3756,"activeCount":112},[],{"trials":3758,"activeCount":112},[],{"trials":3760,"activeCount":112},[3761],{"nctId":3762,"briefTitle":3763,"status":246,"phases":3764,"primaryCompletion":3765,"completion":3766,"start":3767,"enrollment":161,"conditions":3768,"interventions":3770},"NCT06985342","Acute Migraine Treatment in the ED With Gepants",[89],"2026-01-06","2026-02-04","2025-06-05",[3769],"Migraine Headaches",[3749,3771],"Zavegepant",{"trials":3773,"activeCount":112},[],{"intervention":3771,"totalTrials":109,"cells":3775},{"EARLY_PHASE1":3776,"PHASE1":3778,"PHASE2":3780,"PHASE3":3782,"PHASE4":3784,"NA":3790},{"trials":3777,"activeCount":112},[],{"trials":3779,"activeCount":112},[],{"trials":3781,"activeCount":112},[],{"trials":3783,"activeCount":112},[],{"trials":3785,"activeCount":112},[3786],{"nctId":3762,"briefTitle":3763,"status":246,"phases":3787,"primaryCompletion":3765,"completion":3766,"start":3767,"enrollment":161,"conditions":3788,"interventions":3789},[89],[3769],[3749,3771],{"trials":3791,"activeCount":112},[],{"intervention":3793,"totalTrials":109,"cells":3794},"Pimozide",{"EARLY_PHASE1":3795,"PHASE1":3797,"PHASE2":3799,"PHASE3":3801,"PHASE4":3803,"NA":3813},{"trials":3796,"activeCount":112},[],{"trials":3798,"activeCount":112},[],{"trials":3800,"activeCount":112},[],{"trials":3802,"activeCount":112},[],{"trials":3804,"activeCount":112},[3805],{"nctId":3806,"briefTitle":3807,"status":131,"phases":3808,"primaryCompletion":3809,"completion":3809,"start":3555,"enrollment":979,"conditions":3810,"interventions":3812},"NCT00158223","Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia",[89],"2009-02",[334,3811],"Psychotic Disorders",[3793],{"trials":3814,"activeCount":112},[],{"intervention":3816,"totalTrials":109,"cells":3817},"Mifepristone",{"EARLY_PHASE1":3818,"PHASE1":3820,"PHASE2":3822,"PHASE3":3824,"PHASE4":3826,"NA":3838},{"trials":3819,"activeCount":112},[],{"trials":3821,"activeCount":112},[],{"trials":3823,"activeCount":112},[],{"trials":3825,"activeCount":112},[],{"trials":3827,"activeCount":112},[3828],{"nctId":3829,"briefTitle":3830,"status":131,"phases":3831,"primaryCompletion":3832,"completion":3832,"start":3833,"enrollment":3834,"conditions":3835,"interventions":3837},"NCT01990560","Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism",[89],"2016-09","2013-11",8,[3836],"Mild Hypercortisolism",[3816],{"trials":3839,"activeCount":112},[],{"intervention":3841,"totalTrials":109,"cells":3842},"Nintedanib",{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3849,"PHASE4":3851,"NA":3866},{"trials":3844,"activeCount":112},[],{"trials":3846,"activeCount":112},[],{"trials":3848,"activeCount":112},[],{"trials":3850,"activeCount":112},[],{"trials":3852,"activeCount":112},[3853],{"nctId":3854,"briefTitle":3855,"status":131,"phases":3856,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":3860,"conditions":3861,"interventions":3865},"NCT04619680","The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19",[89],"2024-02-01","2024-03-02","2020-11-18",103,[3862,3863,3864],"Pulmonary Fibrosis","Interstitial Lung Disease","Respiratory Disease",[3841],{"trials":3867,"activeCount":112},[],{"intervention":3869,"totalTrials":109,"cells":3870},"L-theanine",{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3875,"PHASE3":3877,"PHASE4":3879,"NA":3891},{"trials":3872,"activeCount":112},[],{"trials":3874,"activeCount":112},[],{"trials":3876,"activeCount":112},[],{"trials":3878,"activeCount":112},[],{"trials":3880,"activeCount":112},[3881],{"nctId":3882,"briefTitle":3883,"status":246,"phases":3884,"primaryCompletion":3885,"completion":3885,"start":3886,"enrollment":3887,"conditions":3888,"interventions":3890},"NCT04056650","Assessing the Effectiveness of an N-of-1 Platform Using Study of Cognitive Enhancers",[89],"2020-12-22","2019-10-18",57,[3889],"Cognitive Performance",[3869],{"trials":3892,"activeCount":112},[],{"intervention":3894,"totalTrials":109,"cells":3895},"Venlafaxine",{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3900,"PHASE3":3902,"PHASE4":3904,"NA":3914},{"trials":3897,"activeCount":112},[],{"trials":3899,"activeCount":112},[],{"trials":3901,"activeCount":112},[],{"trials":3903,"activeCount":112},[],{"trials":3905,"activeCount":112},[3906],{"nctId":3907,"briefTitle":3908,"status":246,"phases":3909,"primaryCompletion":3910,"completion":3910,"start":3513,"enrollment":914,"conditions":3911,"interventions":3913},"NCT00211809","CBT as an Adjunct to SRIs in the Treatment of BDD",[89],"2009-06",[3912],"Body Dysmorphic Disorder",[3894],{"trials":3915,"activeCount":112},[],{"intervention":2590,"totalTrials":109,"cells":3917},{"EARLY_PHASE1":3918,"PHASE1":3920,"PHASE2":3922,"PHASE3":3924,"PHASE4":3926,"NA":3932},{"trials":3919,"activeCount":112},[],{"trials":3921,"activeCount":112},[],{"trials":3923,"activeCount":112},[],{"trials":3925,"activeCount":112},[],{"trials":3927,"activeCount":112},[3928],{"nctId":2579,"briefTitle":2580,"status":246,"phases":3929,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":2102,"conditions":3930,"interventions":3931},[89],[24,2585,2586,2587,2588],[2590,2591,1907],{"trials":3933,"activeCount":112},[],{"intervention":2591,"totalTrials":109,"cells":3935},{"EARLY_PHASE1":3936,"PHASE1":3938,"PHASE2":3940,"PHASE3":3942,"PHASE4":3944,"NA":3950},{"trials":3937,"activeCount":112},[],{"trials":3939,"activeCount":112},[],{"trials":3941,"activeCount":112},[],{"trials":3943,"activeCount":112},[],{"trials":3945,"activeCount":112},[3946],{"nctId":2579,"briefTitle":2580,"status":246,"phases":3947,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":2102,"conditions":3948,"interventions":3949},[89],[24,2585,2586,2587,2588],[2590,2591,1907],{"trials":3951,"activeCount":112},[],{"intervention":3953,"totalTrials":109,"cells":3954},"Nifedipine",{"EARLY_PHASE1":3955,"PHASE1":3957,"PHASE2":3959,"PHASE3":3961,"PHASE4":3963,"NA":3975},{"trials":3956,"activeCount":112},[],{"trials":3958,"activeCount":112},[],{"trials":3960,"activeCount":112},[],{"trials":3962,"activeCount":112},[],{"trials":3964,"activeCount":112},[3965],{"nctId":3966,"briefTitle":3967,"status":131,"phases":3968,"primaryCompletion":913,"completion":913,"start":3969,"enrollment":3970,"conditions":3971,"interventions":3973},"NCT03506724","Response to Anti-hypertensives in Pregnant and Postpartum Patients",[89],"2017-09-11",109,[3131,3972],"Preeclampsia",[3953,3974],"Labetalol",{"trials":3976,"activeCount":112},[],{"intervention":3974,"totalTrials":109,"cells":3978},{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":3985,"PHASE4":3987,"NA":3993},{"trials":3980,"activeCount":112},[],{"trials":3982,"activeCount":112},[],{"trials":3984,"activeCount":112},[],{"trials":3986,"activeCount":112},[],{"trials":3988,"activeCount":112},[3989],{"nctId":3966,"briefTitle":3967,"status":131,"phases":3990,"primaryCompletion":913,"completion":913,"start":3969,"enrollment":3970,"conditions":3991,"interventions":3992},[89],[3131,3972],[3953,3974],{"trials":3994,"activeCount":112},[],{"intervention":2603,"totalTrials":109,"cells":3996},{"EARLY_PHASE1":3997,"PHASE1":3999,"PHASE2":4001,"PHASE3":4003,"PHASE4":4005,"NA":4011},{"trials":3998,"activeCount":112},[],{"trials":4000,"activeCount":112},[],{"trials":4002,"activeCount":112},[],{"trials":4004,"activeCount":112},[],{"trials":4006,"activeCount":112},[4007],{"nctId":2593,"briefTitle":2594,"status":131,"phases":4008,"primaryCompletion":2596,"completion":2596,"start":2597,"enrollment":598,"conditions":4009,"interventions":4010},[89],[2599,2600,2601],[2603,1907],{"trials":4012,"activeCount":112},[],{"intervention":4014,"totalTrials":109,"cells":4015},"Elagolix",{"EARLY_PHASE1":4016,"PHASE1":4018,"PHASE2":4020,"PHASE3":4022,"PHASE4":4024,"NA":4035},{"trials":4017,"activeCount":112},[],{"trials":4019,"activeCount":112},[],{"trials":4021,"activeCount":112},[],{"trials":4023,"activeCount":112},[],{"trials":4025,"activeCount":112},[4026],{"nctId":4027,"briefTitle":4028,"status":246,"phases":4029,"primaryCompletion":4030,"completion":4030,"start":4031,"enrollment":268,"conditions":4032,"interventions":4034},"NCT05038878","An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women",[89],"2022-06-24","2021-07-06",[4033],"Mild Autonomous Cortisol Excess",[4014],{"trials":4036,"activeCount":112},[],{"intervention":4038,"totalTrials":109,"cells":4039},"Enstilar® foam",{"EARLY_PHASE1":4040,"PHASE1":4042,"PHASE2":4044,"PHASE3":4046,"PHASE4":4048,"NA":4059},{"trials":4041,"activeCount":112},[],{"trials":4043,"activeCount":112},[],{"trials":4045,"activeCount":112},[],{"trials":4047,"activeCount":112},[],{"trials":4049,"activeCount":112},[4050],{"nctId":4051,"briefTitle":4052,"status":131,"phases":4053,"primaryCompletion":4054,"completion":4054,"start":1054,"enrollment":155,"conditions":4055,"interventions":4057},"NCT03506477","Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color",[89],"2019-09-25",[3361,4056],"Psoriasis",[4038,4058],"Vehicle foam",{"trials":4060,"activeCount":112},[],{"intervention":4058,"totalTrials":109,"cells":4062},{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4067,"PHASE3":4069,"PHASE4":4071,"NA":4077},{"trials":4064,"activeCount":112},[],{"trials":4066,"activeCount":112},[],{"trials":4068,"activeCount":112},[],{"trials":4070,"activeCount":112},[],{"trials":4072,"activeCount":112},[4073],{"nctId":4051,"briefTitle":4052,"status":131,"phases":4074,"primaryCompletion":4054,"completion":4054,"start":1054,"enrollment":155,"conditions":4075,"interventions":4076},[89],[3361,4056],[4038,4058],{"trials":4078,"activeCount":112},[],{"intervention":4080,"totalTrials":109,"cells":4081},"Lac-Hydrin lotion",{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4086,"PHASE3":4088,"PHASE4":4090,"NA":4102},{"trials":4083,"activeCount":112},[],{"trials":4085,"activeCount":112},[],{"trials":4087,"activeCount":112},[],{"trials":4089,"activeCount":112},[],{"trials":4091,"activeCount":112},[4092],{"nctId":4093,"briefTitle":4094,"status":131,"phases":4095,"primaryCompletion":4096,"completion":4096,"start":4097,"enrollment":4098,"conditions":4099,"interventions":4100},"NCT01111123","Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis",[89],"2010-03","2009-01",55,[3361],[4080,4101],"Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment",{"trials":4103,"activeCount":112},[],{"intervention":4101,"totalTrials":109,"cells":4105},{"EARLY_PHASE1":4106,"PHASE1":4108,"PHASE2":4110,"PHASE3":4112,"PHASE4":4114,"NA":4120},{"trials":4107,"activeCount":112},[],{"trials":4109,"activeCount":112},[],{"trials":4111,"activeCount":112},[],{"trials":4113,"activeCount":112},[],{"trials":4115,"activeCount":112},[4116],{"nctId":4093,"briefTitle":4094,"status":131,"phases":4117,"primaryCompletion":4096,"completion":4096,"start":4097,"enrollment":4098,"conditions":4118,"interventions":4119},[89],[3361],[4080,4101],{"trials":4121,"activeCount":112},[],{"intervention":2614,"totalTrials":109,"cells":4123},{"EARLY_PHASE1":4124,"PHASE1":4126,"PHASE2":4128,"PHASE3":4130,"PHASE4":4132,"NA":4138},{"trials":4125,"activeCount":112},[],{"trials":4127,"activeCount":112},[],{"trials":4129,"activeCount":112},[],{"trials":4131,"activeCount":112},[],{"trials":4133,"activeCount":112},[4134],{"nctId":2605,"briefTitle":2606,"status":131,"phases":4135,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":990,"conditions":4136,"interventions":4137},[89],[2611,2612],[2614,2615,1907],{"trials":4139,"activeCount":112},[],{"intervention":2615,"totalTrials":109,"cells":4141},{"EARLY_PHASE1":4142,"PHASE1":4144,"PHASE2":4146,"PHASE3":4148,"PHASE4":4150,"NA":4156},{"trials":4143,"activeCount":112},[],{"trials":4145,"activeCount":112},[],{"trials":4147,"activeCount":112},[],{"trials":4149,"activeCount":112},[],{"trials":4151,"activeCount":112},[4152],{"nctId":2605,"briefTitle":2606,"status":131,"phases":4153,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":990,"conditions":4154,"interventions":4155},[89],[2611,2612],[2614,2615,1907],{"trials":4157,"activeCount":112},[],{"intervention":4159,"totalTrials":109,"cells":4160},"Latanoprost 0.005%",{"EARLY_PHASE1":4161,"PHASE1":4163,"PHASE2":4165,"PHASE3":4167,"PHASE4":4169,"NA":4183},{"trials":4162,"activeCount":112},[],{"trials":4164,"activeCount":112},[],{"trials":4166,"activeCount":112},[],{"trials":4168,"activeCount":112},[],{"trials":4170,"activeCount":112},[4171],{"nctId":4172,"briefTitle":4173,"status":131,"phases":4174,"primaryCompletion":4175,"completion":4175,"start":4176,"enrollment":4177,"conditions":4178,"interventions":4180},"NCT03949244","Nailfold Capillary Blood Flow With Latanoprost Bunod",[89],"2020-10-01","2019-08-15",47,[4179],"Glaucoma, Open-Angle",[4159,4181,4182],"Latanoprost bunod 0.024%","Normal saline 0.9%",{"trials":4184,"activeCount":112},[],{"intervention":4181,"totalTrials":109,"cells":4186},{"EARLY_PHASE1":4187,"PHASE1":4189,"PHASE2":4191,"PHASE3":4193,"PHASE4":4195,"NA":4201},{"trials":4188,"activeCount":112},[],{"trials":4190,"activeCount":112},[],{"trials":4192,"activeCount":112},[],{"trials":4194,"activeCount":112},[],{"trials":4196,"activeCount":112},[4197],{"nctId":4172,"briefTitle":4173,"status":131,"phases":4198,"primaryCompletion":4175,"completion":4175,"start":4176,"enrollment":4177,"conditions":4199,"interventions":4200},[89],[4179],[4159,4181,4182],{"trials":4202,"activeCount":112},[],{"intervention":4182,"totalTrials":109,"cells":4204},{"EARLY_PHASE1":4205,"PHASE1":4207,"PHASE2":4209,"PHASE3":4211,"PHASE4":4213,"NA":4219},{"trials":4206,"activeCount":112},[],{"trials":4208,"activeCount":112},[],{"trials":4210,"activeCount":112},[],{"trials":4212,"activeCount":112},[],{"trials":4214,"activeCount":112},[4215],{"nctId":4172,"briefTitle":4173,"status":131,"phases":4216,"primaryCompletion":4175,"completion":4175,"start":4176,"enrollment":4177,"conditions":4217,"interventions":4218},[89],[4179],[4159,4181,4182],{"trials":4220,"activeCount":112},[],{"intervention":2718,"totalTrials":109,"cells":4222},{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4227,"PHASE3":4229,"PHASE4":4231,"NA":4237},{"trials":4224,"activeCount":112},[],{"trials":4226,"activeCount":112},[],{"trials":4228,"activeCount":112},[],{"trials":4230,"activeCount":112},[],{"trials":4232,"activeCount":112},[4233],{"nctId":2711,"briefTitle":2712,"status":246,"phases":4234,"primaryCompletion":2714,"completion":2714,"start":2715,"enrollment":109,"conditions":4235,"interventions":4236},[89],[1938],[689,2718],{"trials":4238,"activeCount":112},[],{"intervention":4240,"totalTrials":109,"cells":4241},"Brodalumab",{"EARLY_PHASE1":4242,"PHASE1":4244,"PHASE2":4246,"PHASE3":4248,"PHASE4":4250,"NA":4260},{"trials":4243,"activeCount":112},[],{"trials":4245,"activeCount":112},[],{"trials":4247,"activeCount":112},[],{"trials":4249,"activeCount":112},[],{"trials":4251,"activeCount":112},[4252],{"nctId":4253,"briefTitle":4254,"status":131,"phases":4255,"primaryCompletion":2479,"completion":2479,"start":4256,"enrollment":4257,"conditions":4258,"interventions":4259},"NCT03403036","Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies",[89],"2017-10-31",39,[4056],[4240],{"trials":4261,"activeCount":112},[],{"intervention":4263,"totalTrials":109,"cells":4264},"Aczone Gel",{"EARLY_PHASE1":4265,"PHASE1":4267,"PHASE2":4269,"PHASE3":4271,"PHASE4":4273,"NA":4284},{"trials":4266,"activeCount":112},[],{"trials":4268,"activeCount":112},[],{"trials":4270,"activeCount":112},[],{"trials":4272,"activeCount":112},[],{"trials":4274,"activeCount":112},[4275],{"nctId":4276,"briefTitle":4277,"status":131,"phases":4278,"primaryCompletion":4279,"completion":4279,"start":4280,"enrollment":283,"conditions":4281,"interventions":4283},"NCT03681470","Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color",[89],"2021-05-06","2019-04-09",[4282],"Acne Vulgaris",[4263],{"trials":4285,"activeCount":112},[],{"intervention":4287,"totalTrials":109,"cells":4288},"Harvoni",{"EARLY_PHASE1":4289,"PHASE1":4291,"PHASE2":4293,"PHASE3":4295,"PHASE4":4308,"NA":4310},{"trials":4290,"activeCount":112},[],{"trials":4292,"activeCount":112},[],{"trials":4294,"activeCount":112},[],{"trials":4296,"activeCount":112},[4297],{"nctId":4298,"briefTitle":4299,"status":131,"phases":4300,"primaryCompletion":4301,"completion":4301,"start":4302,"enrollment":32,"conditions":4303,"interventions":4306},"NCT02825212","Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia",[87,88],"2019-07-19","2016-02",[4304,4305],"Hepatitis C","Cryoglobulinemia",[4287,4307],"Epclusa",{"trials":4309,"activeCount":112},[],{"trials":4311,"activeCount":112},[],{"intervention":4307,"totalTrials":109,"cells":4313},{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4318,"PHASE3":4320,"PHASE4":4326,"NA":4328},{"trials":4315,"activeCount":112},[],{"trials":4317,"activeCount":112},[],{"trials":4319,"activeCount":112},[],{"trials":4321,"activeCount":112},[4322],{"nctId":4298,"briefTitle":4299,"status":131,"phases":4323,"primaryCompletion":4301,"completion":4301,"start":4302,"enrollment":32,"conditions":4324,"interventions":4325},[87,88],[4304,4305],[4287,4307],{"trials":4327,"activeCount":112},[],{"trials":4329,"activeCount":112},[],{"intervention":4331,"totalTrials":109,"cells":4332},"Duobrii",{"EARLY_PHASE1":4333,"PHASE1":4335,"PHASE2":4337,"PHASE3":4339,"PHASE4":4352,"NA":4354},{"trials":4334,"activeCount":112},[],{"trials":4336,"activeCount":112},[],{"trials":4338,"activeCount":112},[],{"trials":4340,"activeCount":112},[4341],{"nctId":4342,"briefTitle":4343,"status":246,"phases":4344,"primaryCompletion":4345,"completion":4345,"start":4346,"enrollment":19,"conditions":4347,"interventions":4350},"NCT05608499","Duobrii Treatment of Acne Keloidalis Nuchae (AKN)",[88],"2024-04-15","2022-10-26",[4348,4349],"Acne Keloidalis Nuchae","AKN",[4331,4351],"Bryhali",{"trials":4353,"activeCount":112},[],{"trials":4355,"activeCount":112},[],{"intervention":4351,"totalTrials":109,"cells":4357},{"EARLY_PHASE1":4358,"PHASE1":4360,"PHASE2":4362,"PHASE3":4364,"PHASE4":4370,"NA":4372},{"trials":4359,"activeCount":112},[],{"trials":4361,"activeCount":112},[],{"trials":4363,"activeCount":112},[],{"trials":4365,"activeCount":112},[4366],{"nctId":4342,"briefTitle":4343,"status":246,"phases":4367,"primaryCompletion":4345,"completion":4345,"start":4346,"enrollment":19,"conditions":4368,"interventions":4369},[88],[4348,4349],[4331,4351],{"trials":4371,"activeCount":112},[],{"trials":4373,"activeCount":112},[],{"intervention":2232,"totalTrials":109,"cells":4375},{"EARLY_PHASE1":4376,"PHASE1":4378,"PHASE2":4380,"PHASE3":4382,"PHASE4":4388,"NA":4390},{"trials":4377,"activeCount":112},[],{"trials":4379,"activeCount":112},[],{"trials":4381,"activeCount":112},[],{"trials":4383,"activeCount":112},[4384],{"nctId":2221,"briefTitle":2222,"status":131,"phases":4385,"primaryCompletion":2224,"completion":2224,"start":2225,"enrollment":2226,"conditions":4386,"interventions":4387},[88],[2228,2229,2230],[69,2232,2233],{"trials":4389,"activeCount":112},[],{"trials":4391,"activeCount":112},[],{"intervention":2233,"totalTrials":109,"cells":4393},{"EARLY_PHASE1":4394,"PHASE1":4396,"PHASE2":4398,"PHASE3":4400,"PHASE4":4406,"NA":4408},{"trials":4395,"activeCount":112},[],{"trials":4397,"activeCount":112},[],{"trials":4399,"activeCount":112},[],{"trials":4401,"activeCount":112},[4402],{"nctId":2221,"briefTitle":2222,"status":131,"phases":4403,"primaryCompletion":2224,"completion":2224,"start":2225,"enrollment":2226,"conditions":4404,"interventions":4405},[88],[2228,2229,2230],[69,2232,2233],{"trials":4407,"activeCount":112},[],{"trials":4409,"activeCount":112},[],{"intervention":4411,"totalTrials":109,"cells":4412},"Nitroglycerin Paste",{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4417,"PHASE3":4419,"PHASE4":4432,"NA":4434},{"trials":4414,"activeCount":112},[],{"trials":4416,"activeCount":112},[],{"trials":4418,"activeCount":112},[],{"trials":4420,"activeCount":112},[4421],{"nctId":4422,"briefTitle":4423,"status":222,"phases":4424,"primaryCompletion":4425,"completion":4425,"start":4426,"enrollment":112,"conditions":4427,"interventions":4430},"NCT04321967","Nitropaste in Breast Reduction",[88],"2022-11-01","2019-08-20",[4428,4429],"Gynecomastia","Delayed Wound Healing",[4411,4431],"Dermabond",{"trials":4433,"activeCount":112},[],{"trials":4435,"activeCount":112},[],{"intervention":4431,"totalTrials":109,"cells":4437},{"EARLY_PHASE1":4438,"PHASE1":4440,"PHASE2":4442,"PHASE3":4444,"PHASE4":4450,"NA":4452},{"trials":4439,"activeCount":112},[],{"trials":4441,"activeCount":112},[],{"trials":4443,"activeCount":112},[],{"trials":4445,"activeCount":112},[4446],{"nctId":4422,"briefTitle":4423,"status":222,"phases":4447,"primaryCompletion":4425,"completion":4425,"start":4426,"enrollment":112,"conditions":4448,"interventions":4449},[88],[4428,4429],[4411,4431],{"trials":4451,"activeCount":112},[],{"trials":4453,"activeCount":112},[],{"intervention":4455,"totalTrials":109,"cells":4456},"0.25% Bupivacaine",{"EARLY_PHASE1":4457,"PHASE1":4459,"PHASE2":4461,"PHASE3":4463,"PHASE4":4474,"NA":4476},{"trials":4458,"activeCount":112},[],{"trials":4460,"activeCount":112},[],{"trials":4462,"activeCount":112},[],{"trials":4464,"activeCount":112},[4465],{"nctId":4466,"briefTitle":4467,"status":131,"phases":4468,"primaryCompletion":4469,"completion":4469,"start":4470,"enrollment":459,"conditions":4471,"interventions":4473},"NCT05672680","Transabdominal Plane (TAP) Blocks for Inguinal Hernia Repairs",[87,88],"2023-08-03","2019-12-09",[4472],"Inguinal Hernia",[4455],{"trials":4475,"activeCount":112},[],{"trials":4477,"activeCount":112},[],{"intervention":2650,"totalTrials":109,"cells":4479},{"EARLY_PHASE1":4480,"PHASE1":4482,"PHASE2":4484,"PHASE3":4486,"PHASE4":4492,"NA":4494},{"trials":4481,"activeCount":112},[],{"trials":4483,"activeCount":112},[],{"trials":4485,"activeCount":112},[],{"trials":4487,"activeCount":112},[4488],{"nctId":2640,"briefTitle":2641,"status":131,"phases":4489,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":186,"conditions":4490,"interventions":4491},[88],[2646,2647],[2619,2649,2650,2651],{"trials":4493,"activeCount":112},[],{"trials":4495,"activeCount":112},[],{"intervention":2651,"totalTrials":109,"cells":4497},{"EARLY_PHASE1":4498,"PHASE1":4500,"PHASE2":4502,"PHASE3":4504,"PHASE4":4510,"NA":4512},{"trials":4499,"activeCount":112},[],{"trials":4501,"activeCount":112},[],{"trials":4503,"activeCount":112},[],{"trials":4505,"activeCount":112},[4506],{"nctId":2640,"briefTitle":2641,"status":131,"phases":4507,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":186,"conditions":4508,"interventions":4509},[88],[2646,2647],[2619,2649,2650,2651],{"trials":4511,"activeCount":112},[],{"trials":4513,"activeCount":112},[],{"intervention":4515,"totalTrials":109,"cells":4516},"Ricrolin+",{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4521,"PHASE3":4523,"PHASE4":4535,"NA":4537},{"trials":4518,"activeCount":112},[],{"trials":4520,"activeCount":112},[],{"trials":4522,"activeCount":112},[],{"trials":4524,"activeCount":112},[4525],{"nctId":4526,"briefTitle":4527,"status":668,"phases":4528,"primaryCompletion":4529,"completion":4529,"start":3215,"enrollment":3834,"conditions":4530,"interventions":4533},"NCT03080077","Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia",[88],"2019-06",[4531,4532],"Keratoconus","Ectasia",[4515,4534],"Epi-Off",{"trials":4536,"activeCount":112},[],{"trials":4538,"activeCount":112},[],{"intervention":4534,"totalTrials":109,"cells":4540},{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4545,"PHASE3":4547,"PHASE4":4553,"NA":4555},{"trials":4542,"activeCount":112},[],{"trials":4544,"activeCount":112},[],{"trials":4546,"activeCount":112},[],{"trials":4548,"activeCount":112},[4549],{"nctId":4526,"briefTitle":4527,"status":668,"phases":4550,"primaryCompletion":4529,"completion":4529,"start":3215,"enrollment":3834,"conditions":4551,"interventions":4552},[88],[4531,4532],[4515,4534],{"trials":4554,"activeCount":112},[],{"trials":4556,"activeCount":112},[],{"intervention":4558,"totalTrials":109,"cells":4559},"Remestemcel-L",{"EARLY_PHASE1":4560,"PHASE1":4562,"PHASE2":4564,"PHASE3":4566,"PHASE4":4581,"NA":4583},{"trials":4561,"activeCount":112},[],{"trials":4563,"activeCount":112},[],{"trials":4565,"activeCount":112},[],{"trials":4567,"activeCount":112},[4568],{"nctId":4569,"briefTitle":4570,"status":246,"phases":4571,"primaryCompletion":4572,"completion":4573,"start":4574,"enrollment":4575,"conditions":4576,"interventions":4580},"NCT04371393","MSCs in COVID-19 ARDS",[88],"2021-01-14","2022-01-02","2020-04-30",223,[4577,4558,4578,4579],"Mesenchymal Stromal Cells","Acute Respiratory Distress Syndrome","COVID",[4558],{"trials":4582,"activeCount":112},[],{"trials":4584,"activeCount":112},[],{"intervention":4586,"totalTrials":109,"cells":4587},"Low dose methotrexate",{"EARLY_PHASE1":4588,"PHASE1":4590,"PHASE2":4592,"PHASE3":4594,"PHASE4":4606,"NA":4608},{"trials":4589,"activeCount":112},[],{"trials":4591,"activeCount":112},[],{"trials":4593,"activeCount":112},[],{"trials":4595,"activeCount":112},[4596],{"nctId":4597,"briefTitle":4598,"status":131,"phases":4599,"primaryCompletion":4600,"completion":4600,"start":4601,"enrollment":4602,"conditions":4603,"interventions":4605},"NCT02576067","Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study",[88],"2019-03-29","2015-12-18",123,[4604,821],"Vascular Inflammation",[4586],{"trials":4607,"activeCount":112},[],{"trials":4609,"activeCount":112},[],{"intervention":4611,"totalTrials":109,"cells":4612},"Rate Control",{"EARLY_PHASE1":4613,"PHASE1":4615,"PHASE2":4617,"PHASE3":4619,"PHASE4":4630,"NA":4632},{"trials":4614,"activeCount":112},[],{"trials":4616,"activeCount":112},[],{"trials":4618,"activeCount":112},[],{"trials":4620,"activeCount":112},[4621],{"nctId":4622,"briefTitle":4623,"status":131,"phases":4624,"primaryCompletion":3031,"completion":3031,"start":2849,"enrollment":4625,"conditions":4626,"interventions":4628},"NCT02132767","Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation",[88],523,[4627],"Postoperative Atrial Fibrillation",[4629,4611],"Amiodarone",{"trials":4631,"activeCount":112},[],{"trials":4633,"activeCount":112},[],{"intervention":4635,"totalTrials":109,"cells":4636},"Topiramate",{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4641,"PHASE3":4643,"PHASE4":4654,"NA":4656},{"trials":4638,"activeCount":112},[],{"trials":4640,"activeCount":112},[],{"trials":4642,"activeCount":112},[],{"trials":4644,"activeCount":112},[4645],{"nctId":4646,"briefTitle":4647,"status":246,"phases":4648,"primaryCompletion":4649,"completion":4649,"start":4650,"enrollment":1367,"conditions":4651,"interventions":4653},"NCT00245583","Topiramate in the Treatment of Pathological Gambling",[88],"2009-05","2005-10",[4652],"Pathological Gambling",[4635],{"trials":4655,"activeCount":112},[],{"trials":4657,"activeCount":112},[],{"intervention":4659,"totalTrials":109,"cells":4660},"AndroGel 5 Grams",{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4665,"PHASE3":4667,"PHASE4":4677,"NA":4679},{"trials":4662,"activeCount":112},[],{"trials":4664,"activeCount":112},[],{"trials":4666,"activeCount":112},[],{"trials":4668,"activeCount":112},[4669],{"nctId":4670,"briefTitle":4671,"status":131,"phases":4672,"primaryCompletion":2782,"completion":4673,"start":4674,"enrollment":104,"conditions":4675,"interventions":4676},"NCT00413244","The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery",[88],"2014-11","2007-01",[15],[4659],{"trials":4678,"activeCount":112},[],{"trials":4680,"activeCount":112},[],{"intervention":675,"totalTrials":956,"cells":4682},{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4707,"PHASE4":4709,"NA":4711},{"trials":4684,"activeCount":112},[],{"trials":4686,"activeCount":112},[],{"trials":4688,"activeCount":112},[4689,4693,4697],{"nctId":666,"briefTitle":667,"status":668,"phases":4690,"primaryCompletion":54,"completion":54,"start":670,"enrollment":9,"conditions":4691,"interventions":4692},[87],[672,673],[675,40,676,677,678,679],{"nctId":694,"briefTitle":695,"status":246,"phases":4694,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":4695,"interventions":4696},[87],[701],[703,40,704,705,706,704,675,707,708,675],{"nctId":4698,"briefTitle":4699,"status":222,"phases":4700,"primaryCompletion":4701,"completion":4702,"start":4175,"enrollment":112,"conditions":4703,"interventions":4705},"NCT04561817","To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer",[87],"2022-10-01","2023-10-01",[4704],"Ovarian Neoplasms",[4706,675],"Ipatasertib",{"trials":4708,"activeCount":112},[],{"trials":4710,"activeCount":112},[],{"trials":4712,"activeCount":112},[],{"intervention":708,"totalTrials":956,"cells":4714},{"EARLY_PHASE1":4715,"PHASE1":4717,"PHASE2":4719,"PHASE3":4736,"PHASE4":4738,"NA":4740},{"trials":4716,"activeCount":112},[],{"trials":4718,"activeCount":112},[],{"trials":4720,"activeCount":112},[4721,4725,4732],{"nctId":694,"briefTitle":695,"status":246,"phases":4722,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":4723,"interventions":4724},[87],[701],[703,40,704,705,706,704,675,707,708,675],{"nctId":4726,"briefTitle":4727,"status":246,"phases":4728,"primaryCompletion":2959,"completion":2910,"start":3680,"enrollment":32,"conditions":4729,"interventions":4731},"NCT01740401","CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma",[87],[4730],"Melanoma",[708],{"nctId":2458,"briefTitle":2459,"status":131,"phases":4733,"primaryCompletion":2461,"completion":2461,"start":2462,"enrollment":2463,"conditions":4734,"interventions":4735},[86,87],[2465],[2467,708,676],{"trials":4737,"activeCount":112},[],{"trials":4739,"activeCount":112},[],{"trials":4741,"activeCount":112},[],{"intervention":2636,"totalTrials":146,"cells":4743},{"EARLY_PHASE1":4744,"PHASE1":4746,"PHASE2":4748,"PHASE3":4763,"PHASE4":4765,"NA":4767},{"trials":4745,"activeCount":112},[],{"trials":4747,"activeCount":112},[],{"trials":4749,"activeCount":112},[4750,4759],{"nctId":4751,"briefTitle":4752,"status":131,"phases":4753,"primaryCompletion":4754,"completion":4754,"start":4755,"enrollment":2288,"conditions":4756,"interventions":4757},"NCT01960296","Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?",[87],"2013-05","2012-01",[2636],[2636,4758],"Discontinue Clopidogrel",{"nctId":2628,"briefTitle":2629,"status":131,"phases":4760,"primaryCompletion":204,"completion":204,"start":2631,"enrollment":2632,"conditions":4761,"interventions":4762},[87],[2634],[2636,2619],{"trials":4764,"activeCount":112},[],{"trials":4766,"activeCount":112},[],{"trials":4768,"activeCount":112},[],{"intervention":688,"totalTrials":146,"cells":4770},{"EARLY_PHASE1":4771,"PHASE1":4773,"PHASE2":4775,"PHASE3":4789,"PHASE4":4791,"NA":4793},{"trials":4772,"activeCount":112},[],{"trials":4774,"activeCount":112},[],{"trials":4776,"activeCount":112},[4777,4781],{"nctId":681,"briefTitle":682,"status":131,"phases":4778,"primaryCompletion":684,"completion":684,"start":685,"enrollment":195,"conditions":4779,"interventions":4780},[87],[26],[688,689,690,691,40,692],{"nctId":4782,"briefTitle":4783,"status":246,"phases":4784,"primaryCompletion":3006,"completion":3006,"start":4785,"enrollment":294,"conditions":4786,"interventions":4787},"NCT01735396","Abiraterone Acetate Trial in African American Prostate Cancer Patients",[87],"2012-12",[26],[4788],"Abiraterone Acetate",{"trials":4790,"activeCount":112},[],{"trials":4792,"activeCount":112},[],{"trials":4794,"activeCount":112},[],{"intervention":4796,"totalTrials":146,"cells":4797},"Secukinumab",{"EARLY_PHASE1":4798,"PHASE1":4800,"PHASE2":4802,"PHASE3":4818,"PHASE4":4820,"NA":4822},{"trials":4799,"activeCount":112},[],{"trials":4801,"activeCount":112},[],{"trials":4803,"activeCount":112},[4804,4812],{"nctId":4805,"briefTitle":4806,"status":131,"phases":4807,"primaryCompletion":4808,"completion":4808,"start":1108,"enrollment":4809,"conditions":4810,"interventions":4811},"NCT02594098","Secukinumab for Treatment of Atopic Dermatitis",[87],"2018-01-30",41,[1312],[4796],{"nctId":4813,"briefTitle":4814,"status":246,"phases":4815,"primaryCompletion":204,"completion":204,"start":1108,"enrollment":294,"conditions":4816,"interventions":4817},"NCT02599129","A Study of Secukinumab for the Treatment of Alopecia Areata",[87],[981],[4796],{"trials":4819,"activeCount":112},[],{"trials":4821,"activeCount":112},[],{"trials":4823,"activeCount":112},[],{"intervention":4825,"totalTrials":146,"cells":4826},"Infliximab",{"EARLY_PHASE1":4827,"PHASE1":4829,"PHASE2":4831,"PHASE3":4850,"PHASE4":4852,"NA":4854},{"trials":4828,"activeCount":112},[],{"trials":4830,"activeCount":112},[],{"trials":4832,"activeCount":112},[4833,4842],{"nctId":4834,"briefTitle":4835,"status":668,"phases":4836,"primaryCompletion":4837,"completion":4837,"start":4838,"enrollment":32,"conditions":4839,"interventions":4841},"NCT00959725","Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema",[86,87],"2011-08","2009-08",[4840],"Diabetic Macular Edema",[4825],{"nctId":4843,"briefTitle":4844,"status":222,"phases":4845,"completion":248,"start":4838,"enrollment":32,"conditions":4846,"interventions":4849},"NCT00958906","Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema",[86,87],[4847,4848],"Uveitic Macular Edema","Intraocular Inflammation",[4825],{"trials":4851,"activeCount":112},[],{"trials":4853,"activeCount":112},[],{"trials":4855,"activeCount":112},[],{"intervention":1144,"totalTrials":109,"cells":4857},{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4862,"PHASE3":4868,"PHASE4":4870,"NA":4872},{"trials":4859,"activeCount":112},[],{"trials":4861,"activeCount":112},[],{"trials":4863,"activeCount":112},[4864],{"nctId":1136,"briefTitle":1137,"status":131,"phases":4865,"completion":1139,"start":1140,"conditions":4866,"interventions":4867},[87],[1142],[1144,1127],{"trials":4869,"activeCount":112},[],{"trials":4871,"activeCount":112},[],{"trials":4873,"activeCount":112},[],{"intervention":4875,"totalTrials":109,"cells":4876},"Peginterferon Lambda-1A",{"EARLY_PHASE1":4877,"PHASE1":4879,"PHASE2":4881,"PHASE3":4892,"PHASE4":4894,"NA":4896},{"trials":4878,"activeCount":112},[],{"trials":4880,"activeCount":112},[],{"trials":4882,"activeCount":112},[4883],{"nctId":4884,"briefTitle":4885,"status":222,"phases":4886,"primaryCompletion":4887,"completion":4887,"start":4888,"enrollment":112,"conditions":4889,"interventions":4891},"NCT04388709","Interferon Lambda Therapy for COVID-19",[87],"2021-02-05","2020-09",[4890],"SARS-CoV-2",[4875],{"trials":4893,"activeCount":112},[],{"trials":4895,"activeCount":112},[],{"trials":4897,"activeCount":112},[],{"intervention":4899,"totalTrials":109,"cells":4900},"Spesolimab",{"EARLY_PHASE1":4901,"PHASE1":4903,"PHASE2":4905,"PHASE3":4916,"PHASE4":4918,"NA":4920},{"trials":4902,"activeCount":112},[],{"trials":4904,"activeCount":112},[],{"trials":4906,"activeCount":112},[4907],{"nctId":4908,"briefTitle":4909,"status":246,"phases":4910,"primaryCompletion":4911,"completion":4911,"start":4912,"enrollment":93,"conditions":4913,"interventions":4915},"NCT06092216","Spesolimab in Pyoderma Gangrenosum",[87],"2025-01-14","2023-09-23",[4914],"Pyoderma Gangrenosum",[4899],{"trials":4917,"activeCount":112},[],{"trials":4919,"activeCount":112},[],{"trials":4921,"activeCount":112},[],{"intervention":4923,"totalTrials":109,"cells":4924},"Riluzole",{"EARLY_PHASE1":4925,"PHASE1":4927,"PHASE2":4929,"PHASE3":4940,"PHASE4":4942,"NA":4944},{"trials":4926,"activeCount":112},[],{"trials":4928,"activeCount":112},[],{"trials":4930,"activeCount":112},[4931],{"nctId":4932,"briefTitle":4933,"status":131,"phases":4934,"primaryCompletion":4935,"completion":4935,"start":3833,"enrollment":4936,"conditions":4937,"interventions":4939},"NCT01703117","Riluzole in Mild Alzheimer's Disease",[87],"2020-05-26",50,[4938],"Alzheimer's Disease",[4923],{"trials":4941,"activeCount":112},[],{"trials":4943,"activeCount":112},[],{"trials":4945,"activeCount":112},[],{"intervention":4758,"totalTrials":109,"cells":4947},{"EARLY_PHASE1":4948,"PHASE1":4950,"PHASE2":4952,"PHASE3":4958,"PHASE4":4960,"NA":4962},{"trials":4949,"activeCount":112},[],{"trials":4951,"activeCount":112},[],{"trials":4953,"activeCount":112},[4954],{"nctId":4751,"briefTitle":4752,"status":131,"phases":4955,"primaryCompletion":4754,"completion":4754,"start":4755,"enrollment":2288,"conditions":4956,"interventions":4957},[87],[2636],[2636,4758],{"trials":4959,"activeCount":112},[],{"trials":4961,"activeCount":112},[],{"trials":4963,"activeCount":112},[],{"intervention":4965,"totalTrials":109,"cells":4966},"Propranolol",{"EARLY_PHASE1":4967,"PHASE1":4969,"PHASE2":4971,"PHASE3":4982,"PHASE4":4984,"NA":4986},{"trials":4968,"activeCount":112},[],{"trials":4970,"activeCount":112},[],{"trials":4972,"activeCount":112},[4973],{"nctId":4974,"briefTitle":4975,"status":131,"phases":4976,"primaryCompletion":4977,"completion":4977,"start":2609,"enrollment":4978,"conditions":4979,"interventions":4981},"NCT03348683","Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients",[87],"2018-12-11",240,[4980],"Induction of Labor Affected Fetus \u002F Newborn",[4965],{"trials":4983,"activeCount":112},[],{"trials":4985,"activeCount":112},[],{"trials":4987,"activeCount":112},[],{"intervention":4989,"totalTrials":109,"cells":4990},"Ixekizumab",{"EARLY_PHASE1":4991,"PHASE1":4993,"PHASE2":4995,"PHASE3":5005,"PHASE4":5007,"NA":5009},{"trials":4992,"activeCount":112},[],{"trials":4994,"activeCount":112},[],{"trials":4996,"activeCount":112},[4997],{"nctId":4998,"briefTitle":4999,"status":131,"phases":5000,"primaryCompletion":5001,"completion":5001,"start":5002,"enrollment":699,"conditions":5003,"interventions":5004},"NCT04979910","Targeting IL-17A for Treatment-Resistant Depression",[87],"2024-04-12","2021-08-27",[18],[4989],{"trials":5006,"activeCount":112},[],{"trials":5008,"activeCount":112},[],{"trials":5010,"activeCount":112},[],{"intervention":5012,"totalTrials":109,"cells":5013},"Modified-release morphine",{"EARLY_PHASE1":5014,"PHASE1":5016,"PHASE2":5018,"PHASE3":5029,"PHASE4":5031,"NA":5033},{"trials":5015,"activeCount":112},[],{"trials":5017,"activeCount":112},[],{"trials":5019,"activeCount":112},[5020],{"nctId":5021,"briefTitle":5022,"status":131,"phases":5023,"primaryCompletion":205,"completion":205,"start":5024,"enrollment":914,"conditions":5025,"interventions":5028},"NCT00488969","Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury",[87],"2007-07",[5026,5027],"Neuropathic Pain","Spinal Cord Injury",[5012],{"trials":5030,"activeCount":112},[],{"trials":5032,"activeCount":112},[],{"trials":5034,"activeCount":112},[],{"intervention":5036,"totalTrials":109,"cells":5037},"Exendin 9-39 and Sitagliptin",{"EARLY_PHASE1":5038,"PHASE1":5040,"PHASE2":5042,"PHASE3":5052,"PHASE4":5054,"NA":5056},{"trials":5039,"activeCount":112},[],{"trials":5041,"activeCount":112},[],{"trials":5043,"activeCount":112},[5044],{"nctId":5045,"briefTitle":5046,"status":222,"phases":5047,"primaryCompletion":5048,"completion":5048,"start":5049,"enrollment":112,"conditions":5050,"interventions":5051},"NCT02697253","Mechanisms Underlying Predictors of Success From Obesity Surgery",[87],"2021-07-29","2016-01",[24],[5036],{"trials":5053,"activeCount":112},[],{"trials":5055,"activeCount":112},[],{"trials":5057,"activeCount":112},[],{"intervention":677,"totalTrials":109,"cells":5059},{"EARLY_PHASE1":5060,"PHASE1":5062,"PHASE2":5064,"PHASE3":5070,"PHASE4":5072,"NA":5074},{"trials":5061,"activeCount":112},[],{"trials":5063,"activeCount":112},[],{"trials":5065,"activeCount":112},[5066],{"nctId":666,"briefTitle":667,"status":668,"phases":5067,"primaryCompletion":54,"completion":54,"start":670,"enrollment":9,"conditions":5068,"interventions":5069},[87],[672,673],[675,40,676,677,678,679],{"trials":5071,"activeCount":112},[],{"trials":5073,"activeCount":112},[],{"trials":5075,"activeCount":112},[],{"intervention":678,"totalTrials":109,"cells":5077},{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5088,"PHASE4":5090,"NA":5092},{"trials":5079,"activeCount":112},[],{"trials":5081,"activeCount":112},[],{"trials":5083,"activeCount":112},[5084],{"nctId":666,"briefTitle":667,"status":668,"phases":5085,"primaryCompletion":54,"completion":54,"start":670,"enrollment":9,"conditions":5086,"interventions":5087},[87],[672,673],[675,40,676,677,678,679],{"trials":5089,"activeCount":112},[],{"trials":5091,"activeCount":112},[],{"trials":5093,"activeCount":112},[],{"intervention":679,"totalTrials":109,"cells":5095},{"EARLY_PHASE1":5096,"PHASE1":5098,"PHASE2":5100,"PHASE3":5106,"PHASE4":5108,"NA":5110},{"trials":5097,"activeCount":112},[],{"trials":5099,"activeCount":112},[],{"trials":5101,"activeCount":112},[5102],{"nctId":666,"briefTitle":667,"status":668,"phases":5103,"primaryCompletion":54,"completion":54,"start":670,"enrollment":9,"conditions":5104,"interventions":5105},[87],[672,673],[675,40,676,677,678,679],{"trials":5107,"activeCount":112},[],{"trials":5109,"activeCount":112},[],{"trials":5111,"activeCount":112},[],{"intervention":690,"totalTrials":109,"cells":5113},{"EARLY_PHASE1":5114,"PHASE1":5116,"PHASE2":5118,"PHASE3":5124,"PHASE4":5126,"NA":5128},{"trials":5115,"activeCount":112},[],{"trials":5117,"activeCount":112},[],{"trials":5119,"activeCount":112},[5120],{"nctId":681,"briefTitle":682,"status":131,"phases":5121,"primaryCompletion":684,"completion":684,"start":685,"enrollment":195,"conditions":5122,"interventions":5123},[87],[26],[688,689,690,691,40,692],{"trials":5125,"activeCount":112},[],{"trials":5127,"activeCount":112},[],{"trials":5129,"activeCount":112},[],{"intervention":691,"totalTrials":109,"cells":5131},{"EARLY_PHASE1":5132,"PHASE1":5134,"PHASE2":5136,"PHASE3":5142,"PHASE4":5144,"NA":5146},{"trials":5133,"activeCount":112},[],{"trials":5135,"activeCount":112},[],{"trials":5137,"activeCount":112},[5138],{"nctId":681,"briefTitle":682,"status":131,"phases":5139,"primaryCompletion":684,"completion":684,"start":685,"enrollment":195,"conditions":5140,"interventions":5141},[87],[26],[688,689,690,691,40,692],{"trials":5143,"activeCount":112},[],{"trials":5145,"activeCount":112},[],{"trials":5147,"activeCount":112},[],{"intervention":692,"totalTrials":109,"cells":5149},{"EARLY_PHASE1":5150,"PHASE1":5152,"PHASE2":5154,"PHASE3":5160,"PHASE4":5162,"NA":5164},{"trials":5151,"activeCount":112},[],{"trials":5153,"activeCount":112},[],{"trials":5155,"activeCount":112},[5156],{"nctId":681,"briefTitle":682,"status":131,"phases":5157,"primaryCompletion":684,"completion":684,"start":685,"enrollment":195,"conditions":5158,"interventions":5159},[87],[26],[688,689,690,691,40,692],{"trials":5161,"activeCount":112},[],{"trials":5163,"activeCount":112},[],{"trials":5165,"activeCount":112},[],{"intervention":5167,"totalTrials":109,"cells":5168},"Lenalidomide",{"EARLY_PHASE1":5169,"PHASE1":5171,"PHASE2":5173,"PHASE3":5183,"PHASE4":5185,"NA":5187},{"trials":5170,"activeCount":112},[],{"trials":5172,"activeCount":112},[],{"trials":5174,"activeCount":112},[5175],{"nctId":5176,"briefTitle":5177,"status":246,"phases":5178,"primaryCompletion":5179,"completion":5179,"start":2960,"enrollment":161,"conditions":5180,"interventions":5182},"NCT01342172","Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma",[86,87],"2013-06",[5181],"Urinary Bladder Neoplasms",[5167],{"trials":5184,"activeCount":112},[],{"trials":5186,"activeCount":112},[],{"trials":5188,"activeCount":112},[],{"intervention":2280,"totalTrials":109,"cells":5190},{"EARLY_PHASE1":5191,"PHASE1":5193,"PHASE2":5195,"PHASE3":5201,"PHASE4":5203,"NA":5205},{"trials":5192,"activeCount":112},[],{"trials":5194,"activeCount":112},[],{"trials":5196,"activeCount":112},[5197],{"nctId":2270,"briefTitle":2271,"status":131,"phases":5198,"primaryCompletion":2273,"completion":2273,"start":2274,"enrollment":155,"conditions":5199,"interventions":5200},[86,87],[2276,2277,2278],[2280,2239],{"trials":5202,"activeCount":112},[],{"trials":5204,"activeCount":112},[],{"trials":5206,"activeCount":112},[],{"intervention":703,"totalTrials":109,"cells":5208},{"EARLY_PHASE1":5209,"PHASE1":5211,"PHASE2":5213,"PHASE3":5219,"PHASE4":5221,"NA":5223},{"trials":5210,"activeCount":112},[],{"trials":5212,"activeCount":112},[],{"trials":5214,"activeCount":112},[5215],{"nctId":694,"briefTitle":695,"status":246,"phases":5216,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":5217,"interventions":5218},[87],[701],[703,40,704,705,706,704,675,707,708,675],{"trials":5220,"activeCount":112},[],{"trials":5222,"activeCount":112},[],{"trials":5224,"activeCount":112},[],{"intervention":706,"totalTrials":109,"cells":5226},{"EARLY_PHASE1":5227,"PHASE1":5229,"PHASE2":5231,"PHASE3":5237,"PHASE4":5239,"NA":5241},{"trials":5228,"activeCount":112},[],{"trials":5230,"activeCount":112},[],{"trials":5232,"activeCount":112},[5233],{"nctId":694,"briefTitle":695,"status":246,"phases":5234,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":5235,"interventions":5236},[87],[701],[703,40,704,705,706,704,675,707,708,675],{"trials":5238,"activeCount":112},[],{"trials":5240,"activeCount":112},[],{"trials":5242,"activeCount":112},[],{"intervention":707,"totalTrials":109,"cells":5244},{"EARLY_PHASE1":5245,"PHASE1":5247,"PHASE2":5249,"PHASE3":5255,"PHASE4":5257,"NA":5259},{"trials":5246,"activeCount":112},[],{"trials":5248,"activeCount":112},[],{"trials":5250,"activeCount":112},[5251],{"nctId":694,"briefTitle":695,"status":246,"phases":5252,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":5253,"interventions":5254},[87],[701],[703,40,704,705,706,704,675,707,708,675],{"trials":5256,"activeCount":112},[],{"trials":5258,"activeCount":112},[],{"trials":5260,"activeCount":112},[],{"intervention":5262,"totalTrials":109,"cells":5263},"rosuvastatin",{"EARLY_PHASE1":5264,"PHASE1":5266,"PHASE2":5268,"PHASE3":5278,"PHASE4":5280,"NA":5282},{"trials":5265,"activeCount":112},[],{"trials":5267,"activeCount":112},[],{"trials":5269,"activeCount":112},[5270],{"nctId":5271,"briefTitle":5272,"status":131,"phases":5273,"primaryCompletion":2644,"completion":2644,"start":205,"enrollment":5274,"conditions":5275,"interventions":5277},"NCT01837823","YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering",[87],91,[5276,15],"Obstructive Coronary Artery Disease",[5262],{"trials":5279,"activeCount":112},[],{"trials":5281,"activeCount":112},[],{"trials":5283,"activeCount":112},[],{"intervention":5285,"totalTrials":109,"cells":5286},"Ibrutinib",{"EARLY_PHASE1":5287,"PHASE1":5289,"PHASE2":5291,"PHASE3":5302,"PHASE4":5304,"NA":5306},{"trials":5288,"activeCount":112},[],{"trials":5290,"activeCount":112},[],{"trials":5292,"activeCount":112},[5293],{"nctId":5294,"briefTitle":5295,"status":246,"phases":5296,"primaryCompletion":5297,"completion":5297,"start":5298,"enrollment":161,"conditions":5299,"interventions":5301},"NCT02943473","Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients",[87],"2019-09-10","2017-05-18",[5300],"High Risk Smoldering Multiple Myeloma",[5285],{"trials":5303,"activeCount":112},[],{"trials":5305,"activeCount":112},[],{"trials":5307,"activeCount":112},[],{"intervention":5309,"totalTrials":109,"cells":5310},"Omega-3 Fatty Acid Supplement",{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5315,"PHASE3":5328,"PHASE4":5330,"NA":5332},{"trials":5312,"activeCount":112},[],{"trials":5314,"activeCount":112},[],{"trials":5316,"activeCount":112},[5317],{"nctId":5318,"briefTitle":5319,"status":131,"phases":5320,"primaryCompletion":5321,"completion":5321,"start":5322,"enrollment":5323,"conditions":5324,"interventions":5327},"NCT04495816","COVID-19 Anosmia Study",[87],"2021-12-31","2020-07-15",139,[5325,5326],"Anosmia","Covid19",[5309],{"trials":5329,"activeCount":112},[],{"trials":5331,"activeCount":112},[],{"trials":5333,"activeCount":112},[],{"intervention":920,"totalTrials":109,"cells":5335},{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5340,"PHASE3":5346,"PHASE4":5348,"NA":5350},{"trials":5337,"activeCount":112},[],{"trials":5339,"activeCount":112},[],{"trials":5341,"activeCount":112},[5342],{"nctId":908,"briefTitle":909,"status":131,"phases":5343,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":5344,"interventions":5345},[86,87],[916,917,918],[899,920,921],{"trials":5347,"activeCount":112},[],{"trials":5349,"activeCount":112},[],{"trials":5351,"activeCount":112},[],{"intervention":921,"totalTrials":109,"cells":5353},{"EARLY_PHASE1":5354,"PHASE1":5356,"PHASE2":5358,"PHASE3":5364,"PHASE4":5366,"NA":5368},{"trials":5355,"activeCount":112},[],{"trials":5357,"activeCount":112},[],{"trials":5359,"activeCount":112},[5360],{"nctId":908,"briefTitle":909,"status":131,"phases":5361,"primaryCompletion":911,"completion":912,"start":913,"enrollment":914,"conditions":5362,"interventions":5363},[86,87],[916,917,918],[899,920,921],{"trials":5365,"activeCount":112},[],{"trials":5367,"activeCount":112},[],{"trials":5369,"activeCount":112},[],{"intervention":4706,"totalTrials":109,"cells":5371},{"EARLY_PHASE1":5372,"PHASE1":5374,"PHASE2":5376,"PHASE3":5382,"PHASE4":5384,"NA":5386},{"trials":5373,"activeCount":112},[],{"trials":5375,"activeCount":112},[],{"trials":5377,"activeCount":112},[5378],{"nctId":4698,"briefTitle":4699,"status":222,"phases":5379,"primaryCompletion":4701,"completion":4702,"start":4175,"enrollment":112,"conditions":5380,"interventions":5381},[87],[4704],[4706,675],{"trials":5383,"activeCount":112},[],{"trials":5385,"activeCount":112},[],{"trials":5387,"activeCount":112},[],{"intervention":5389,"totalTrials":109,"cells":5390},"Ropivicaine",{"EARLY_PHASE1":5391,"PHASE1":5393,"PHASE2":5395,"PHASE3":5408,"PHASE4":5410,"NA":5412},{"trials":5392,"activeCount":112},[],{"trials":5394,"activeCount":112},[],{"trials":5396,"activeCount":112},[5397],{"nctId":5398,"briefTitle":5399,"status":131,"phases":5400,"primaryCompletion":5401,"completion":5401,"start":5402,"enrollment":175,"conditions":5403,"interventions":5406},"NCT03349034","Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps",[87],"2019-09-30","2017-09-13",[5404,5405],"Head and Neck Cancer","Free Tissue Transfer",[5389,5407],"Local Saline",{"trials":5409,"activeCount":112},[],{"trials":5411,"activeCount":112},[],{"trials":5413,"activeCount":112},[],{"intervention":5407,"totalTrials":109,"cells":5415},{"EARLY_PHASE1":5416,"PHASE1":5418,"PHASE2":5420,"PHASE3":5426,"PHASE4":5428,"NA":5430},{"trials":5417,"activeCount":112},[],{"trials":5419,"activeCount":112},[],{"trials":5421,"activeCount":112},[5422],{"nctId":5398,"briefTitle":5399,"status":131,"phases":5423,"primaryCompletion":5401,"completion":5401,"start":5402,"enrollment":175,"conditions":5424,"interventions":5425},[87],[5404,5405],[5389,5407],{"trials":5427,"activeCount":112},[],{"trials":5429,"activeCount":112},[],{"trials":5431,"activeCount":112},[],{"intervention":5433,"totalTrials":109,"cells":5434},"Mesenchymal Precursor cells",{"EARLY_PHASE1":5435,"PHASE1":5437,"PHASE2":5439,"PHASE3":5451,"PHASE4":5453,"NA":5455},{"trials":5436,"activeCount":112},[],{"trials":5438,"activeCount":112},[],{"trials":5440,"activeCount":112},[5441],{"nctId":5442,"briefTitle":5443,"status":246,"phases":5444,"primaryCompletion":5445,"completion":5446,"start":4838,"enrollment":32,"conditions":5447,"interventions":5449},"NCT00927784","Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD",[87],"2010-05","2011-02",[5448],"Heart Failure",[5433,5450],"Cryoprotective media alone",{"trials":5452,"activeCount":112},[],{"trials":5454,"activeCount":112},[],{"trials":5456,"activeCount":112},[],{"intervention":5450,"totalTrials":109,"cells":5458},{"EARLY_PHASE1":5459,"PHASE1":5461,"PHASE2":5463,"PHASE3":5469,"PHASE4":5471,"NA":5473},{"trials":5460,"activeCount":112},[],{"trials":5462,"activeCount":112},[],{"trials":5464,"activeCount":112},[5465],{"nctId":5442,"briefTitle":5443,"status":246,"phases":5466,"primaryCompletion":5445,"completion":5446,"start":4838,"enrollment":32,"conditions":5467,"interventions":5468},[87],[5448],[5433,5450],{"trials":5470,"activeCount":112},[],{"trials":5472,"activeCount":112},[],{"trials":5474,"activeCount":112},[],{"intervention":5476,"totalTrials":109,"cells":5477},"cetirizine",{"EARLY_PHASE1":5478,"PHASE1":5480,"PHASE2":5482,"PHASE3":5492,"PHASE4":5494,"NA":5496},{"trials":5479,"activeCount":112},[],{"trials":5481,"activeCount":112},[],{"trials":5483,"activeCount":112},[5484],{"nctId":5485,"briefTitle":5486,"status":131,"phases":5487,"primaryCompletion":4302,"completion":4302,"start":5488,"enrollment":16,"conditions":5489,"interventions":5491},"NCT02865018","Neuromyelitis Optica (NMO) & Cetirizine",[86,87],"2014-04",[5490],"Neuromyelitis Optica",[5476],{"trials":5493,"activeCount":112},[],{"trials":5495,"activeCount":112},[],{"trials":5497,"activeCount":112},[],{"intervention":2552,"totalTrials":109,"cells":5499},{"EARLY_PHASE1":5500,"PHASE1":5502,"PHASE2":5504,"PHASE3":5510,"PHASE4":5512,"NA":5514},{"trials":5501,"activeCount":112},[],{"trials":5503,"activeCount":112},[],{"trials":5505,"activeCount":112},[5506],{"nctId":2541,"briefTitle":2542,"status":131,"phases":5507,"primaryCompletion":2544,"completion":2545,"start":2546,"enrollment":2547,"conditions":5508,"interventions":5509},[87],[2549,2550],[2552,1907],{"trials":5511,"activeCount":112},[],{"trials":5513,"activeCount":112},[],{"trials":5515,"activeCount":112},[],{"intervention":718,"totalTrials":109,"cells":5517},{"EARLY_PHASE1":5518,"PHASE1":5520,"PHASE2":5522,"PHASE3":5528,"PHASE4":5530,"NA":5532},{"trials":5519,"activeCount":112},[],{"trials":5521,"activeCount":112},[],{"trials":5523,"activeCount":112},[5524],{"nctId":710,"briefTitle":711,"status":222,"phases":5525,"primaryCompletion":713,"completion":713,"start":713,"enrollment":112,"conditions":5526,"interventions":5527},[87],[715,716],[40,718,719],{"trials":5529,"activeCount":112},[],{"trials":5531,"activeCount":112},[],{"trials":5533,"activeCount":112},[],{"intervention":719,"totalTrials":109,"cells":5535},{"EARLY_PHASE1":5536,"PHASE1":5538,"PHASE2":5540,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5537,"activeCount":112},[],{"trials":5539,"activeCount":112},[],{"trials":5541,"activeCount":112},[5542],{"nctId":710,"briefTitle":711,"status":222,"phases":5543,"primaryCompletion":713,"completion":713,"start":713,"enrollment":112,"conditions":5544,"interventions":5545},[87],[715,716],[40,718,719],{"trials":5547,"activeCount":112},[],{"trials":5549,"activeCount":112},[],{"trials":5551,"activeCount":112},[],{"intervention":5553,"totalTrials":109,"cells":5554},"Polyenylphosphatidylcholine",{"EARLY_PHASE1":5555,"PHASE1":5557,"PHASE2":5559,"PHASE3":5571,"PHASE4":5573,"NA":5575},{"trials":5556,"activeCount":112},[],{"trials":5558,"activeCount":112},[],{"trials":5560,"activeCount":112},[5561],{"nctId":5562,"briefTitle":5563,"status":131,"phases":5564,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":1038,"conditions":5567,"interventions":5568},"NCT00211848","Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers",[87],"2005-12","2000-06",[4304],[5553,5569,5570],"Pegylated Interferon","Ribavirin",{"trials":5572,"activeCount":112},[],{"trials":5574,"activeCount":112},[],{"trials":5576,"activeCount":112},[],{"intervention":5569,"totalTrials":109,"cells":5578},{"EARLY_PHASE1":5579,"PHASE1":5581,"PHASE2":5583,"PHASE3":5589,"PHASE4":5591,"NA":5593},{"trials":5580,"activeCount":112},[],{"trials":5582,"activeCount":112},[],{"trials":5584,"activeCount":112},[5585],{"nctId":5562,"briefTitle":5563,"status":131,"phases":5586,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":1038,"conditions":5587,"interventions":5588},[87],[4304],[5553,5569,5570],{"trials":5590,"activeCount":112},[],{"trials":5592,"activeCount":112},[],{"trials":5594,"activeCount":112},[],{"intervention":5570,"totalTrials":109,"cells":5596},{"EARLY_PHASE1":5597,"PHASE1":5599,"PHASE2":5601,"PHASE3":5607,"PHASE4":5609,"NA":5611},{"trials":5598,"activeCount":112},[],{"trials":5600,"activeCount":112},[],{"trials":5602,"activeCount":112},[5603],{"nctId":5562,"briefTitle":5563,"status":131,"phases":5604,"primaryCompletion":5565,"completion":5565,"start":5566,"enrollment":1038,"conditions":5605,"interventions":5606},[87],[4304],[5553,5569,5570],{"trials":5608,"activeCount":112},[],{"trials":5610,"activeCount":112},[],{"trials":5612,"activeCount":112},[],{"intervention":5614,"totalTrials":109,"cells":5615},"Transabdominal Plane Block",{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5620,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5617,"activeCount":112},[],{"trials":5619,"activeCount":112},[],{"trials":5621,"activeCount":112},[5622],{"nctId":5623,"briefTitle":5624,"status":131,"phases":5625,"primaryCompletion":5626,"completion":5626,"start":5627,"enrollment":3681,"conditions":5628,"interventions":5633},"NCT02007096","Does a Transabdominal Plane Block Decrease Patient Pain After Ventral Hernia Repair?",[87],"2014-10","2012-08",[5629,5630,5631,5632,2228],"Ventral Hernia","Umbilical Hernia","Incisional Hernia","Postoperative Complications",[5614,5634],"Non Transabdominal Plane Block",{"trials":5636,"activeCount":112},[],{"trials":5638,"activeCount":112},[],{"trials":5640,"activeCount":112},[],{"intervention":5634,"totalTrials":109,"cells":5642},{"EARLY_PHASE1":5643,"PHASE1":5645,"PHASE2":5647,"PHASE3":5653,"PHASE4":5655,"NA":5657},{"trials":5644,"activeCount":112},[],{"trials":5646,"activeCount":112},[],{"trials":5648,"activeCount":112},[5649],{"nctId":5623,"briefTitle":5624,"status":131,"phases":5650,"primaryCompletion":5626,"completion":5626,"start":5627,"enrollment":3681,"conditions":5651,"interventions":5652},[87],[5629,5630,5631,5632,2228],[5614,5634],{"trials":5654,"activeCount":112},[],{"trials":5656,"activeCount":112},[],{"trials":5658,"activeCount":112},[],{"intervention":5660,"totalTrials":109,"cells":5661},"ASHMI 4",{"EARLY_PHASE1":5662,"PHASE1":5664,"PHASE2":5666,"PHASE3":5679,"PHASE4":5681,"NA":5683},{"trials":5663,"activeCount":112},[],{"trials":5665,"activeCount":112},[],{"trials":5667,"activeCount":112},[5668],{"nctId":5669,"briefTitle":5670,"status":246,"phases":5671,"primaryCompletion":5672,"completion":5672,"start":5673,"enrollment":5674,"conditions":5675,"interventions":5677},"NCT00712296","Effectiveness of Chinese Herbal Therapy for Asthma",[86,87],"2009-09-29","2008-08",66,[5676],"Asthma",[5660,5678],"ASHMI 12",{"trials":5680,"activeCount":112},[],{"trials":5682,"activeCount":112},[],{"trials":5684,"activeCount":112},[],{"intervention":5678,"totalTrials":109,"cells":5686},{"EARLY_PHASE1":5687,"PHASE1":5689,"PHASE2":5691,"PHASE3":5697,"PHASE4":5699,"NA":5701},{"trials":5688,"activeCount":112},[],{"trials":5690,"activeCount":112},[],{"trials":5692,"activeCount":112},[5693],{"nctId":5669,"briefTitle":5670,"status":246,"phases":5694,"primaryCompletion":5672,"completion":5672,"start":5673,"enrollment":5674,"conditions":5695,"interventions":5696},[86,87],[5676],[5660,5678],{"trials":5698,"activeCount":112},[],{"trials":5700,"activeCount":112},[],{"trials":5702,"activeCount":112},[],{"intervention":5704,"totalTrials":109,"cells":5705},"Botulinum Toxin A",{"EARLY_PHASE1":5706,"PHASE1":5708,"PHASE2":5710,"PHASE3":5720,"PHASE4":5722,"NA":5724},{"trials":5707,"activeCount":112},[],{"trials":5709,"activeCount":112},[],{"trials":5711,"activeCount":112},[5712],{"nctId":5713,"briefTitle":5714,"status":246,"phases":5715,"primaryCompletion":5716,"completion":5716,"start":3006,"enrollment":3834,"conditions":5717,"interventions":5719},"NCT02736890","Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury",[87],"2018-07-17",[5718,5027],"Neuropathic Back Pain",[5704],{"trials":5721,"activeCount":112},[],{"trials":5723,"activeCount":112},[],{"trials":5725,"activeCount":112},[],{"intervention":5727,"totalTrials":109,"cells":5728},"TACE",{"EARLY_PHASE1":5729,"PHASE1":5731,"PHASE2":5733,"PHASE3":5741,"PHASE4":5743,"NA":5745},{"trials":5730,"activeCount":112},[],{"trials":5732,"activeCount":112},[],{"trials":5734,"activeCount":112},[5735],{"nctId":5736,"briefTitle":5737,"status":131,"phases":5738,"primaryCompletion":3295,"completion":3295,"start":4673,"enrollment":2547,"conditions":5739,"interventions":5740},"NCT02513199","Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma",[87],[541],[5727],{"trials":5742,"activeCount":112},[],{"trials":5744,"activeCount":112},[],{"trials":5746,"activeCount":112},[],{"intervention":5748,"totalTrials":109,"cells":5749},"Ruxolitinib 1.5% Cream",{"EARLY_PHASE1":5750,"PHASE1":5752,"PHASE2":5754,"PHASE3":5765,"PHASE4":5767,"NA":5769},{"trials":5751,"activeCount":112},[],{"trials":5753,"activeCount":112},[],{"trials":5755,"activeCount":112},[5756],{"nctId":5757,"briefTitle":5758,"status":131,"phases":5759,"primaryCompletion":5760,"completion":5760,"start":5761,"enrollment":928,"conditions":5762,"interventions":5764},"NCT05787860","Ruxolitinib in Seborrheic Dermatitis",[87],"2024-01-26","2022-11-15",[5763],"Seborrheic Dermatitis",[5748],{"trials":5766,"activeCount":112},[],{"trials":5768,"activeCount":112},[],{"trials":5770,"activeCount":112},[],{"intervention":5772,"totalTrials":109,"cells":5773},"Intrathecal morphine",{"EARLY_PHASE1":5774,"PHASE1":5776,"PHASE2":5778,"PHASE3":5789,"PHASE4":5791,"NA":5793},{"trials":5775,"activeCount":112},[],{"trials":5777,"activeCount":112},[],{"trials":5779,"activeCount":112},[5780],{"nctId":5781,"briefTitle":5782,"status":131,"phases":5783,"primaryCompletion":5784,"completion":5784,"start":2849,"enrollment":346,"conditions":5785,"interventions":5787},"NCT02096003","Intrathecal Hydromorphone for Pain Control After Cesarean Section",[87],"2017-05-05",[5786,397],"Pain",[5772,5788],"Intrathecal hydromorphone",{"trials":5790,"activeCount":112},[],{"trials":5792,"activeCount":112},[],{"trials":5794,"activeCount":112},[],{"intervention":5788,"totalTrials":109,"cells":5796},{"EARLY_PHASE1":5797,"PHASE1":5799,"PHASE2":5801,"PHASE3":5807,"PHASE4":5809,"NA":5811},{"trials":5798,"activeCount":112},[],{"trials":5800,"activeCount":112},[],{"trials":5802,"activeCount":112},[5803],{"nctId":5781,"briefTitle":5782,"status":131,"phases":5804,"primaryCompletion":5784,"completion":5784,"start":2849,"enrollment":346,"conditions":5805,"interventions":5806},[87],[5786,397],[5772,5788],{"trials":5808,"activeCount":112},[],{"trials":5810,"activeCount":112},[],{"trials":5812,"activeCount":112},[],{"intervention":2291,"totalTrials":109,"cells":5814},{"EARLY_PHASE1":5815,"PHASE1":5817,"PHASE2":5819,"PHASE3":5825,"PHASE4":5827,"NA":5829},{"trials":5816,"activeCount":112},[],{"trials":5818,"activeCount":112},[],{"trials":5820,"activeCount":112},[5821],{"nctId":2282,"briefTitle":2283,"status":131,"phases":5822,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":5823,"interventions":5824},[87],[2276,541],[2239,2291,2292],{"trials":5826,"activeCount":112},[],{"trials":5828,"activeCount":112},[],{"trials":5830,"activeCount":112},[],{"intervention":2292,"totalTrials":109,"cells":5832},{"EARLY_PHASE1":5833,"PHASE1":5835,"PHASE2":5837,"PHASE3":5843,"PHASE4":5845,"NA":5847},{"trials":5834,"activeCount":112},[],{"trials":5836,"activeCount":112},[],{"trials":5838,"activeCount":112},[5839],{"nctId":2282,"briefTitle":2283,"status":131,"phases":5840,"primaryCompletion":2285,"completion":2286,"start":2287,"enrollment":2288,"conditions":5841,"interventions":5842},[87],[2276,541],[2239,2291,2292],{"trials":5844,"activeCount":112},[],{"trials":5846,"activeCount":112},[],{"trials":5848,"activeCount":112},[],{"intervention":5850,"totalTrials":109,"cells":5851},"incobotulinumtoxin A",{"EARLY_PHASE1":5852,"PHASE1":5854,"PHASE2":5856,"PHASE3":5866,"PHASE4":5868,"NA":5870},{"trials":5853,"activeCount":112},[],{"trials":5855,"activeCount":112},[],{"trials":5857,"activeCount":112},[5858],{"nctId":5859,"briefTitle":5860,"status":131,"phases":5861,"primaryCompletion":235,"completion":235,"start":5862,"enrollment":1000,"conditions":5863,"interventions":5865},"NCT02107261","Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand",[87],"2014-03",[5864],"Dystonia",[5850],{"trials":5867,"activeCount":112},[],{"trials":5869,"activeCount":112},[],{"trials":5871,"activeCount":112},[],{"intervention":5873,"totalTrials":109,"cells":5874},"nab-paclitaxel",{"EARLY_PHASE1":5875,"PHASE1":5877,"PHASE2":5879,"PHASE3":5888,"PHASE4":5890,"NA":5892},{"trials":5876,"activeCount":112},[],{"trials":5878,"activeCount":112},[],{"trials":5880,"activeCount":112},[5881],{"nctId":5882,"briefTitle":5883,"status":246,"phases":5884,"primaryCompletion":2631,"completion":2631,"start":5862,"enrollment":146,"conditions":5885,"interventions":5887},"NCT02076243","Treatment With Nab-paclitaxel in Cutaneous SCC",[87],[5886],"Cutaneous Squamous Cell Carcinoma",[5873],{"trials":5889,"activeCount":112},[],{"trials":5891,"activeCount":112},[],{"trials":5893,"activeCount":112},[],{"intervention":5895,"totalTrials":109,"cells":5896},"Omega-3 Fatty Acids",{"EARLY_PHASE1":5897,"PHASE1":5899,"PHASE2":5901,"PHASE3":5911,"PHASE4":5913,"NA":5915},{"trials":5898,"activeCount":112},[],{"trials":5900,"activeCount":112},[],{"trials":5902,"activeCount":112},[5903],{"nctId":5904,"briefTitle":5905,"status":131,"phases":5906,"primaryCompletion":5179,"completion":5179,"start":5565,"enrollment":3887,"conditions":5907,"interventions":5909},"NCT00312897","Omega-3 Fatty Acids in Adolescent Depression",[87],[5908],"Adolescent Depression",[5895,5910],"corn oil",{"trials":5912,"activeCount":112},[],{"trials":5914,"activeCount":112},[],{"trials":5916,"activeCount":112},[],{"intervention":5910,"totalTrials":109,"cells":5918},{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5923,"PHASE3":5929,"PHASE4":5931,"NA":5933},{"trials":5920,"activeCount":112},[],{"trials":5922,"activeCount":112},[],{"trials":5924,"activeCount":112},[5925],{"nctId":5904,"briefTitle":5905,"status":131,"phases":5926,"primaryCompletion":5179,"completion":5179,"start":5565,"enrollment":3887,"conditions":5927,"interventions":5928},[87],[5908],[5895,5910],{"trials":5930,"activeCount":112},[],{"trials":5932,"activeCount":112},[],{"trials":5934,"activeCount":112},[],{"intervention":5936,"totalTrials":109,"cells":5937},"Omega 3 Fatty Acids",{"EARLY_PHASE1":5938,"PHASE1":5940,"PHASE2":5942,"PHASE3":5952,"PHASE4":5954,"NA":5956},{"trials":5939,"activeCount":112},[],{"trials":5941,"activeCount":112},[],{"trials":5943,"activeCount":112},[5944],{"nctId":5945,"briefTitle":5946,"status":131,"phases":5947,"primaryCompletion":5179,"completion":5179,"start":5948,"enrollment":16,"conditions":5949,"interventions":5951},"NCT00962598","The Role Of Omega-3 Fatty Acids In Adolescent Depression",[87],"2006-01",[5950],"Depressive Disorder, Major",[5936],{"trials":5953,"activeCount":112},[],{"trials":5955,"activeCount":112},[],{"trials":5957,"activeCount":112},[],{"intervention":199,"totalTrials":109,"cells":5959},{"EARLY_PHASE1":5960,"PHASE1":5962,"PHASE2":5964,"PHASE3":5970,"PHASE4":5972,"NA":5974},{"trials":5961,"activeCount":112},[],{"trials":5963,"activeCount":112},[],{"trials":5965,"activeCount":112},[5966],{"nctId":190,"briefTitle":191,"status":131,"phases":5967,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":5968,"interventions":5969},[87],[21],[198,160,199],{"trials":5971,"activeCount":112},[],{"trials":5973,"activeCount":112},[],{"trials":5975,"activeCount":112},[],{"intervention":5977,"totalTrials":109,"cells":5978},"ezogabine",{"EARLY_PHASE1":5979,"PHASE1":5981,"PHASE2":5983,"PHASE3":5993,"PHASE4":5995,"NA":5997},{"trials":5980,"activeCount":112},[],{"trials":5982,"activeCount":112},[],{"trials":5984,"activeCount":112},[5985],{"nctId":5986,"briefTitle":5987,"status":131,"phases":5988,"primaryCompletion":5989,"completion":5989,"start":5990,"enrollment":2783,"conditions":5991,"interventions":5992},"NCT02149836","Study to Treat Major Depressive Disorder (MDD) With a New Medication",[87],"2016-12","2014-08",[18,21],[5977],{"trials":5994,"activeCount":112},[],{"trials":5996,"activeCount":112},[],{"trials":5998,"activeCount":112},[],{"intervention":209,"totalTrials":109,"cells":6000},{"EARLY_PHASE1":6001,"PHASE1":6003,"PHASE2":6005,"PHASE3":6011,"PHASE4":6013,"NA":6015},{"trials":6002,"activeCount":112},[],{"trials":6004,"activeCount":112},[],{"trials":6006,"activeCount":112},[6007],{"nctId":201,"briefTitle":202,"status":131,"phases":6008,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":6009,"interventions":6010},[87],[21],[209,160],{"trials":6012,"activeCount":112},[],{"trials":6014,"activeCount":112},[],{"trials":6016,"activeCount":112},[],{"intervention":6018,"totalTrials":109,"cells":6019},"Chinese Herbal Medicine (CHM) supplement",{"EARLY_PHASE1":6020,"PHASE1":6022,"PHASE2":6024,"PHASE3":6035,"PHASE4":6037,"NA":6039},{"trials":6021,"activeCount":112},[],{"trials":6023,"activeCount":112},[],{"trials":6025,"activeCount":112},[6026],{"nctId":6027,"briefTitle":6028,"status":222,"phases":6029,"primaryCompletion":6030,"completion":6030,"start":6031,"enrollment":112,"conditions":6032,"interventions":6034},"NCT06187376","Chinese Herbal Medicine for Gynecologic Patients",[87],"2024-07-16","2024-07",[6033],"Dysmenorrhea",[6018],{"trials":6036,"activeCount":112},[],{"trials":6038,"activeCount":112},[],{"trials":6040,"activeCount":112},[],{"intervention":6042,"totalTrials":109,"cells":6043},"Insulin-Like Growth Factor-1",{"EARLY_PHASE1":6044,"PHASE1":6046,"PHASE2":6048,"PHASE3":6060,"PHASE4":6062,"NA":6064},{"trials":6045,"activeCount":112},[],{"trials":6047,"activeCount":112},[],{"trials":6049,"activeCount":112},[6050],{"nctId":6051,"briefTitle":6052,"status":131,"phases":6053,"primaryCompletion":6054,"completion":6054,"start":6055,"enrollment":6056,"conditions":6057,"interventions":6059},"NCT01525901","Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)",[87],"2016-08-23","2012-02",19,[6058,2549],"22q13 Deletion Syndrome",[6042,2986],{"trials":6061,"activeCount":112},[],{"trials":6063,"activeCount":112},[],{"trials":6065,"activeCount":112},[],{"intervention":6067,"totalTrials":109,"cells":6068},"Danazol",{"EARLY_PHASE1":6069,"PHASE1":6071,"PHASE2":6073,"PHASE3":6084,"PHASE4":6086,"NA":6088},{"trials":6070,"activeCount":112},[],{"trials":6072,"activeCount":112},[],{"trials":6074,"activeCount":112},[6075],{"nctId":6076,"briefTitle":6077,"status":246,"phases":6078,"primaryCompletion":6079,"completion":6079,"start":6080,"enrollment":161,"conditions":6081,"interventions":6083},"NCT00953771","Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)",[87],"2015-11-19","2008-10",[6082],"Thrombotic Thrombocytopenic Purpura",[6067],{"trials":6085,"activeCount":112},[],{"trials":6087,"activeCount":112},[],{"trials":6089,"activeCount":112},[],{"intervention":6091,"totalTrials":109,"cells":6092},"PF-07038124",{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6107,"PHASE4":6109,"NA":6111},{"trials":6094,"activeCount":112},[],{"trials":6096,"activeCount":112},[],{"trials":6098,"activeCount":112},[6099],{"nctId":6100,"briefTitle":6101,"status":246,"phases":6102,"primaryCompletion":6103,"completion":6103,"start":6104,"enrollment":2547,"conditions":6105,"interventions":6106},"NCT06013371","PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea",[87],"2025-02-18","2023-07-19",[5763,1192],[6091],{"trials":6108,"activeCount":112},[],{"trials":6110,"activeCount":112},[],{"trials":6112,"activeCount":112},[],{"intervention":6114,"totalTrials":109,"cells":6115},"lidamycin phosphate and benzoyl peroxide 1.2%\u002F3.75% combination",{"EARLY_PHASE1":6116,"PHASE1":6118,"PHASE2":6120,"PHASE3":6131,"PHASE4":6133,"NA":6135},{"trials":6117,"activeCount":112},[],{"trials":6119,"activeCount":112},[],{"trials":6121,"activeCount":112},[6122],{"nctId":6123,"briefTitle":6124,"status":131,"phases":6125,"primaryCompletion":6126,"completion":6126,"start":6127,"enrollment":2102,"conditions":6128,"interventions":6130},"NCT03122457","Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide",[87],"2018-07-19","2017-01-01",[6129],"Actinic Keratosis",[6114],{"trials":6132,"activeCount":112},[],{"trials":6134,"activeCount":112},[],{"trials":6136,"activeCount":112},[],{"intervention":2562,"totalTrials":109,"cells":6138},{"EARLY_PHASE1":6139,"PHASE1":6141,"PHASE2":6143,"PHASE3":6149,"PHASE4":6151,"NA":6153},{"trials":6140,"activeCount":112},[],{"trials":6142,"activeCount":112},[],{"trials":6144,"activeCount":112},[6145],{"nctId":2554,"briefTitle":2555,"status":131,"phases":6146,"primaryCompletion":2557,"completion":2557,"start":2558,"enrollment":1367,"conditions":6147,"interventions":6148},[87],[2560],[2562,1907],{"trials":6150,"activeCount":112},[],{"trials":6152,"activeCount":112},[],{"trials":6154,"activeCount":112},[],{"intervention":6156,"totalTrials":109,"cells":6157},"IGF-1",{"EARLY_PHASE1":6158,"PHASE1":6160,"PHASE2":6162,"PHASE3":6171,"PHASE4":6173,"NA":6175},{"trials":6159,"activeCount":112},[],{"trials":6161,"activeCount":112},[],{"trials":6163,"activeCount":112},[6164],{"nctId":6165,"briefTitle":6166,"status":246,"phases":6167,"primaryCompletion":5402,"completion":5402,"start":2849,"enrollment":956,"conditions":6168,"interventions":6170},"NCT01970345","A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder",[87],[6169],"Autism Spectrum Disorder",[6156],{"trials":6172,"activeCount":112},[],{"trials":6174,"activeCount":112},[],{"trials":6176,"activeCount":112},[],{"intervention":6178,"totalTrials":109,"cells":6179},"sunitinib malate",{"EARLY_PHASE1":6180,"PHASE1":6182,"PHASE2":6184,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6181,"activeCount":112},[],{"trials":6183,"activeCount":112},[],{"trials":6185,"activeCount":112},[6186],{"nctId":6187,"briefTitle":6188,"status":131,"phases":6189,"primaryCompletion":3216,"completion":3216,"start":4674,"enrollment":4177,"conditions":6190,"interventions":6192},"NCT00463060","Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer",[86,87],[6191],"Cancer",[6178],{"trials":6194,"activeCount":112},[],{"trials":6196,"activeCount":112},[],{"trials":6198,"activeCount":112},[],{"intervention":6200,"totalTrials":109,"cells":6201},"Esomeprazole",{"EARLY_PHASE1":6202,"PHASE1":6204,"PHASE2":6206,"PHASE3":6219,"PHASE4":6221,"NA":6223},{"trials":6203,"activeCount":112},[],{"trials":6205,"activeCount":112},[],{"trials":6207,"activeCount":112},[6208],{"nctId":6209,"briefTitle":6210,"status":222,"phases":6211,"primaryCompletion":6212,"completion":6212,"start":6213,"enrollment":112,"conditions":6214,"interventions":6218},"NCT03488147","Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and\u002For Severity of Difficulty Swallowing Foods and\u002For Liquids,Following Anterior Cervical Surgery",[87],"2020-07-02","2020-07",[6215,6216,6217],"Dysphagia","GERD","Degenerative Joint Disease",[6200],{"trials":6220,"activeCount":112},[],{"trials":6222,"activeCount":112},[],{"trials":6224,"activeCount":112},[],{"intervention":6226,"totalTrials":109,"cells":6227},"Intravenous Glycoprotein inhibitor + ASA, Clopidogrel",{"EARLY_PHASE1":6228,"PHASE1":6230,"PHASE2":6232,"PHASE3":6244,"PHASE4":6246,"NA":6248},{"trials":6229,"activeCount":112},[],{"trials":6231,"activeCount":112},[],{"trials":6233,"activeCount":112},[6234],{"nctId":6235,"briefTitle":6236,"status":131,"phases":6237,"primaryCompletion":3910,"completion":3910,"start":6238,"enrollment":6239,"conditions":6240,"interventions":6242},"NCT01103440","Aspirin Resistance and Percutaneous Coronary Intervention (PCI)",[87],"2007-04",36,[6241],"Stable Angina",[6226,6243],"Antiplatelet Therapy",{"trials":6245,"activeCount":112},[],{"trials":6247,"activeCount":112},[],{"trials":6249,"activeCount":112},[],{"intervention":6243,"totalTrials":109,"cells":6251},{"EARLY_PHASE1":6252,"PHASE1":6254,"PHASE2":6256,"PHASE3":6262,"PHASE4":6264,"NA":6266},{"trials":6253,"activeCount":112},[],{"trials":6255,"activeCount":112},[],{"trials":6257,"activeCount":112},[6258],{"nctId":6235,"briefTitle":6236,"status":131,"phases":6259,"primaryCompletion":3910,"completion":3910,"start":6238,"enrollment":6239,"conditions":6260,"interventions":6261},[87],[6241],[6226,6243],{"trials":6263,"activeCount":112},[],{"trials":6265,"activeCount":112},[],{"trials":6267,"activeCount":112},[],{"intervention":6269,"totalTrials":109,"cells":6270},"Imiquimod 3.75% Cream",{"EARLY_PHASE1":6271,"PHASE1":6273,"PHASE2":6275,"PHASE3":6285,"PHASE4":6287,"NA":6289},{"trials":6272,"activeCount":112},[],{"trials":6274,"activeCount":112},[],{"trials":6276,"activeCount":112},[6277],{"nctId":6278,"briefTitle":6279,"status":131,"phases":6280,"primaryCompletion":6281,"completion":6281,"start":6282,"enrollment":1000,"conditions":6283,"interventions":6284},"NCT03914417","Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream",[87],"2015-04-30","2013-01",[6129],[6269],{"trials":6286,"activeCount":112},[],{"trials":6288,"activeCount":112},[],{"trials":6290,"activeCount":112},[],{"intervention":6292,"totalTrials":109,"cells":6293},"5-Aminolevulinic acid Hydrochloride",{"EARLY_PHASE1":6294,"PHASE1":6296,"PHASE2":6298,"PHASE3":6310,"PHASE4":6312,"NA":6314},{"trials":6295,"activeCount":112},[],{"trials":6297,"activeCount":112},[],{"trials":6299,"activeCount":112},[6300],{"nctId":6301,"briefTitle":6302,"status":246,"phases":6303,"primaryCompletion":6304,"completion":6304,"start":6305,"enrollment":699,"conditions":6306,"interventions":6309},"NCT05101798","The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial",[87],"2022-12-25","2021-09-14",[6307,6308],"Neoplasm","Skull Base Neoplasm",[6292],{"trials":6311,"activeCount":112},[],{"trials":6313,"activeCount":112},[],{"trials":6315,"activeCount":112},[],{"intervention":6317,"totalTrials":109,"cells":6318},"Sertraline",{"EARLY_PHASE1":6319,"PHASE1":6321,"PHASE2":6323,"PHASE3":6332,"PHASE4":6334,"NA":6336},{"trials":6320,"activeCount":112},[],{"trials":6322,"activeCount":112},[],{"trials":6324,"activeCount":112},[6325],{"nctId":6326,"briefTitle":6327,"status":131,"phases":6328,"primaryCompletion":3513,"completion":3513,"start":6329,"enrollment":588,"conditions":6330,"interventions":6331},"NCT00233103","Treatment of Post-Traumatic Brain Injury (TBI) Depression",[87],"2003-06",[21],[6317],{"trials":6333,"activeCount":112},[],{"trials":6335,"activeCount":112},[],{"trials":6337,"activeCount":112},[],{"intervention":2467,"totalTrials":109,"cells":6339},{"EARLY_PHASE1":6340,"PHASE1":6342,"PHASE2":6344,"PHASE3":6350,"PHASE4":6352,"NA":6354},{"trials":6341,"activeCount":112},[],{"trials":6343,"activeCount":112},[],{"trials":6345,"activeCount":112},[6346],{"nctId":2458,"briefTitle":2459,"status":131,"phases":6347,"primaryCompletion":2461,"completion":2461,"start":2462,"enrollment":2463,"conditions":6348,"interventions":6349},[86,87],[2465],[2467,708,676],{"trials":6351,"activeCount":112},[],{"trials":6353,"activeCount":112},[],{"trials":6355,"activeCount":112},[],{"intervention":1343,"totalTrials":109,"cells":6357},{"EARLY_PHASE1":6358,"PHASE1":6360,"PHASE2":6362,"PHASE3":6368,"PHASE4":6370,"NA":6372},{"trials":6359,"activeCount":112},[],{"trials":6361,"activeCount":112},[],{"trials":6363,"activeCount":112},[6364],{"nctId":1333,"briefTitle":1334,"status":131,"phases":6365,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":22,"conditions":6366,"interventions":6367},[87],[1340,1341,26],[1343,1344,955],{"trials":6369,"activeCount":112},[],{"trials":6371,"activeCount":112},[],{"trials":6373,"activeCount":112},[],{"intervention":1344,"totalTrials":109,"cells":6375},{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6386,"PHASE4":6388,"NA":6390},{"trials":6377,"activeCount":112},[],{"trials":6379,"activeCount":112},[],{"trials":6381,"activeCount":112},[6382],{"nctId":1333,"briefTitle":1334,"status":131,"phases":6383,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":22,"conditions":6384,"interventions":6385},[87],[1340,1341,26],[1343,1344,955],{"trials":6387,"activeCount":112},[],{"trials":6389,"activeCount":112},[],{"trials":6391,"activeCount":112},[],{"intervention":6393,"totalTrials":109,"cells":6394},"Doxycycline",{"EARLY_PHASE1":6395,"PHASE1":6397,"PHASE2":6399,"PHASE3":6415,"PHASE4":6417,"NA":6419},{"trials":6396,"activeCount":112},[],{"trials":6398,"activeCount":112},[],{"trials":6400,"activeCount":112},[6401],{"nctId":6402,"briefTitle":6403,"status":246,"phases":6404,"primaryCompletion":6405,"completion":6405,"start":6406,"enrollment":6407,"conditions":6408,"interventions":6410},"NCT02569437","Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps",[87],"2016-08","2014-09",49,[6409],"Polyp of Nasal Sinus",[6393,6411,6412,6413,6414],"methylprednisolone","nasal saline spray","Flonase","sugar pill",{"trials":6416,"activeCount":112},[],{"trials":6418,"activeCount":112},[],{"trials":6420,"activeCount":112},[],{"intervention":6411,"totalTrials":109,"cells":6422},{"EARLY_PHASE1":6423,"PHASE1":6425,"PHASE2":6427,"PHASE3":6433,"PHASE4":6435,"NA":6437},{"trials":6424,"activeCount":112},[],{"trials":6426,"activeCount":112},[],{"trials":6428,"activeCount":112},[6429],{"nctId":6402,"briefTitle":6403,"status":246,"phases":6430,"primaryCompletion":6405,"completion":6405,"start":6406,"enrollment":6407,"conditions":6431,"interventions":6432},[87],[6409],[6393,6411,6412,6413,6414],{"trials":6434,"activeCount":112},[],{"trials":6436,"activeCount":112},[],{"trials":6438,"activeCount":112},[],{"intervention":6412,"totalTrials":109,"cells":6440},{"EARLY_PHASE1":6441,"PHASE1":6443,"PHASE2":6445,"PHASE3":6451,"PHASE4":6453,"NA":6455},{"trials":6442,"activeCount":112},[],{"trials":6444,"activeCount":112},[],{"trials":6446,"activeCount":112},[6447],{"nctId":6402,"briefTitle":6403,"status":246,"phases":6448,"primaryCompletion":6405,"completion":6405,"start":6406,"enrollment":6407,"conditions":6449,"interventions":6450},[87],[6409],[6393,6411,6412,6413,6414],{"trials":6452,"activeCount":112},[],{"trials":6454,"activeCount":112},[],{"trials":6456,"activeCount":112},[],{"intervention":6413,"totalTrials":109,"cells":6458},{"EARLY_PHASE1":6459,"PHASE1":6461,"PHASE2":6463,"PHASE3":6469,"PHASE4":6471,"NA":6473},{"trials":6460,"activeCount":112},[],{"trials":6462,"activeCount":112},[],{"trials":6464,"activeCount":112},[6465],{"nctId":6402,"briefTitle":6403,"status":246,"phases":6466,"primaryCompletion":6405,"completion":6405,"start":6406,"enrollment":6407,"conditions":6467,"interventions":6468},[87],[6409],[6393,6411,6412,6413,6414],{"trials":6470,"activeCount":112},[],{"trials":6472,"activeCount":112},[],{"trials":6474,"activeCount":112},[],{"intervention":6414,"totalTrials":109,"cells":6476},{"EARLY_PHASE1":6477,"PHASE1":6479,"PHASE2":6481,"PHASE3":6487,"PHASE4":6489,"NA":6491},{"trials":6478,"activeCount":112},[],{"trials":6480,"activeCount":112},[],{"trials":6482,"activeCount":112},[6483],{"nctId":6402,"briefTitle":6403,"status":246,"phases":6484,"primaryCompletion":6405,"completion":6405,"start":6406,"enrollment":6407,"conditions":6485,"interventions":6486},[87],[6409],[6393,6411,6412,6413,6414],{"trials":6488,"activeCount":112},[],{"trials":6490,"activeCount":112},[],{"trials":6492,"activeCount":112},[],{"intervention":6494,"totalTrials":146,"cells":6495},"ingenol mebutate 0.015%",{"EARLY_PHASE1":6496,"PHASE1":6498,"PHASE2":6515,"PHASE3":6517,"PHASE4":6519,"NA":6521},{"trials":6497,"activeCount":112},[],{"trials":6499,"activeCount":112},[6500,6507],{"nctId":6501,"briefTitle":6502,"status":131,"phases":6503,"primaryCompletion":3215,"completion":3215,"start":6504,"enrollment":283,"conditions":6505,"interventions":6506},"NCT02411851","Treatment of Actinic Keratoses (AK) on the Face",[86],"2015-03",[2914],[6494],{"nctId":6508,"briefTitle":6509,"status":131,"phases":6510,"primaryCompletion":3104,"completion":3104,"start":6511,"enrollment":283,"conditions":6512,"interventions":6513},"NCT01836367","Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp",[86],"2013-03",[6129],[6514],"Ingenol Mebutate 0.015%",{"trials":6516,"activeCount":112},[],{"trials":6518,"activeCount":112},[],{"trials":6520,"activeCount":112},[],{"trials":6522,"activeCount":112},[],{"intervention":6524,"totalTrials":109,"cells":6525},"MSSM\u002FBIIR HDC Vax-001",{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6539,"PHASE3":6541,"PHASE4":6543,"NA":6545},{"trials":6527,"activeCount":112},[],{"trials":6529,"activeCount":112},[6530],{"nctId":6531,"briefTitle":6532,"status":668,"phases":6533,"primaryCompletion":205,"start":4838,"enrollment":155,"conditions":6534,"interventions":6538},"NCT00935597","Host Dendritic Cells in Allograft Patients",[86],[6535,6536,2332,6537],"Relapsed Non-Hodgkin's Lymphoma","Hodgkin's Disease","Chronic Lymphocytic Lymphoma",[6524],{"trials":6540,"activeCount":112},[],{"trials":6542,"activeCount":112},[],{"trials":6544,"activeCount":112},[],{"trials":6546,"activeCount":112},[],{"intervention":6548,"totalTrials":109,"cells":6549},"Colchicine",{"EARLY_PHASE1":6550,"PHASE1":6552,"PHASE2":6564,"PHASE3":6566,"PHASE4":6568,"NA":6570},{"trials":6551,"activeCount":112},[],{"trials":6553,"activeCount":112},[6554],{"nctId":6555,"briefTitle":6556,"status":131,"phases":6557,"primaryCompletion":6558,"completion":6558,"start":6559,"enrollment":16,"conditions":6560,"interventions":6563},"NCT05279690","Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors",[86],"2024-12-16","2022-02-14",[6561,6562],"Urothelial Cancer","Metastatic Solid Tumor",[6548],{"trials":6565,"activeCount":112},[],{"trials":6567,"activeCount":112},[],{"trials":6569,"activeCount":112},[],{"trials":6571,"activeCount":112},[],{"intervention":6573,"totalTrials":109,"cells":6574},"Oxytocin",{"EARLY_PHASE1":6575,"PHASE1":6577,"PHASE2":6588,"PHASE3":6590,"PHASE4":6592,"NA":6594},{"trials":6576,"activeCount":112},[],{"trials":6578,"activeCount":112},[6579],{"nctId":6580,"briefTitle":6581,"status":131,"phases":6582,"primaryCompletion":6583,"completion":6583,"start":4673,"enrollment":6584,"conditions":6585,"interventions":6587},"NCT02098421","Foley Labor Induction Trial at Term and in PROM",[86],"2016-04-18",312,[6586],"Induction of Labor",[6573],{"trials":6589,"activeCount":112},[],{"trials":6591,"activeCount":112},[],{"trials":6593,"activeCount":112},[],{"trials":6595,"activeCount":112},[],{"intervention":6597,"totalTrials":109,"cells":6598},"Emergency Department Initiated Oral Naltrexone",{"EARLY_PHASE1":6599,"PHASE1":6601,"PHASE2":6613,"PHASE3":6615,"PHASE4":6617,"NA":6619},{"trials":6600,"activeCount":112},[],{"trials":6602,"activeCount":112},[6603],{"nctId":6604,"briefTitle":6605,"status":131,"phases":6606,"primaryCompletion":6607,"completion":6608,"start":6609,"enrollment":237,"conditions":6610,"interventions":6612},"NCT04817410","ED Initiated Oral Naltrexone for AUD",[86],"2023-10-31","2023-11-02","2021-09-28",[6611],"Alcohol Use Disorder",[6597],{"trials":6614,"activeCount":112},[],{"trials":6616,"activeCount":112},[],{"trials":6618,"activeCount":112},[],{"trials":6620,"activeCount":112},[],{"intervention":6622,"totalTrials":109,"cells":6623},"Sevelamer Carbonate",{"EARLY_PHASE1":6624,"PHASE1":6626,"PHASE2":6637,"PHASE3":6639,"PHASE4":6641,"NA":6643},{"trials":6625,"activeCount":112},[],{"trials":6627,"activeCount":112},[6628],{"nctId":6629,"briefTitle":6630,"status":131,"phases":6631,"primaryCompletion":6632,"completion":6632,"start":3910,"enrollment":283,"conditions":6633,"interventions":6635},"NCT00967629","Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy",[86],"2010-02",[6634],"Diabetic Nephropathy",[6622,6636],"Calcium Carbonate",{"trials":6638,"activeCount":112},[],{"trials":6640,"activeCount":112},[],{"trials":6642,"activeCount":112},[],{"trials":6644,"activeCount":112},[],{"intervention":6636,"totalTrials":109,"cells":6646},{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6655,"PHASE3":6657,"PHASE4":6659,"NA":6661},{"trials":6648,"activeCount":112},[],{"trials":6650,"activeCount":112},[6651],{"nctId":6629,"briefTitle":6630,"status":131,"phases":6652,"primaryCompletion":6632,"completion":6632,"start":3910,"enrollment":283,"conditions":6653,"interventions":6654},[86],[6634],[6622,6636],{"trials":6656,"activeCount":112},[],{"trials":6658,"activeCount":112},[],{"trials":6660,"activeCount":112},[],{"trials":6662,"activeCount":112},[],{"intervention":6664,"totalTrials":109,"cells":6665},"ondansetron",{"EARLY_PHASE1":6666,"PHASE1":6668,"PHASE2":6679,"PHASE3":6681,"PHASE4":6683,"NA":6685},{"trials":6667,"activeCount":112},[],{"trials":6669,"activeCount":112},[6670],{"nctId":6671,"briefTitle":6672,"status":131,"phases":6673,"primaryCompletion":6674,"completion":6674,"start":2911,"enrollment":1152,"conditions":6675,"interventions":6678},"NCT02460341","The Effects of Ondansetron on Brain Function",[86],"2017-02-03",[6676,6677],"Brain Function","Healthy Adults",[6664],{"trials":6680,"activeCount":112},[],{"trials":6682,"activeCount":112},[],{"trials":6684,"activeCount":112},[],{"trials":6686,"activeCount":112},[],{"intervention":6688,"totalTrials":109,"cells":6689},"Fulvestrant",{"EARLY_PHASE1":6690,"PHASE1":6692,"PHASE2":6703,"PHASE3":6705,"PHASE4":6707,"NA":6709},{"trials":6691,"activeCount":112},[],{"trials":6693,"activeCount":112},[6694],{"nctId":6695,"briefTitle":6696,"status":246,"phases":6697,"primaryCompletion":6698,"completion":6698,"start":6699,"enrollment":146,"conditions":6700,"interventions":6701},"NCT02936206","Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.",[86],"2020-05-01","2016-10",[31],[6688,6702],"Tamoxifen",{"trials":6704,"activeCount":112},[],{"trials":6706,"activeCount":112},[],{"trials":6708,"activeCount":112},[],{"trials":6710,"activeCount":112},[],{"intervention":6712,"totalTrials":109,"cells":6713},"Avelumab",{"EARLY_PHASE1":6714,"PHASE1":6716,"PHASE2":6730,"PHASE3":6732,"PHASE4":6734,"NA":6736},{"trials":6715,"activeCount":112},[],{"trials":6717,"activeCount":112},[6718],{"nctId":6719,"briefTitle":6720,"status":131,"phases":6721,"primaryCompletion":6722,"completion":6722,"start":6723,"enrollment":6724,"conditions":6725,"interventions":6728},"NCT03341806","Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma",[86],"2021-10-13","2018-06-13",13,[6726,6727],"Glioblastoma","GBM",[6712,6729],"MRI-guided LITT therapy",{"trials":6731,"activeCount":112},[],{"trials":6733,"activeCount":112},[],{"trials":6735,"activeCount":112},[],{"trials":6737,"activeCount":112},[],{"intervention":6729,"totalTrials":109,"cells":6739},{"EARLY_PHASE1":6740,"PHASE1":6742,"PHASE2":6748,"PHASE3":6750,"PHASE4":6752,"NA":6754},{"trials":6741,"activeCount":112},[],{"trials":6743,"activeCount":112},[6744],{"nctId":6719,"briefTitle":6720,"status":131,"phases":6745,"primaryCompletion":6722,"completion":6722,"start":6723,"enrollment":6724,"conditions":6746,"interventions":6747},[86],[6726,6727],[6712,6729],{"trials":6749,"activeCount":112},[],{"trials":6751,"activeCount":112},[],{"trials":6753,"activeCount":112},[],{"trials":6755,"activeCount":112},[],{"intervention":6757,"totalTrials":109,"cells":6758},"pamidronate",{"EARLY_PHASE1":6759,"PHASE1":6761,"PHASE2":6772,"PHASE3":6774,"PHASE4":6776,"NA":6778},{"trials":6760,"activeCount":112},[],{"trials":6762,"activeCount":112},[6763],{"nctId":6764,"briefTitle":6765,"status":668,"phases":6766,"primaryCompletion":6767,"completion":6767,"start":6768,"enrollment":143,"conditions":6769,"interventions":6771},"NCT00101790","A Pilot Trial of Intravenous (IV) Pamidronate for Low Back Pain",[86],"2010-06","2003-09",[6770],"Low Back Pain",[6757],{"trials":6773,"activeCount":112},[],{"trials":6775,"activeCount":112},[],{"trials":6777,"activeCount":112},[],{"trials":6779,"activeCount":112},[],{"intervention":6781,"totalTrials":109,"cells":6782},"Definity",{"EARLY_PHASE1":6783,"PHASE1":6785,"PHASE2":6794,"PHASE3":6796,"PHASE4":6798,"NA":6800},{"trials":6784,"activeCount":112},[],{"trials":6786,"activeCount":112},[6787],{"nctId":6788,"briefTitle":6789,"status":131,"phases":6790,"primaryCompletion":6055,"completion":6055,"start":4674,"enrollment":6791,"conditions":6792,"interventions":6793},"NCT00626873","Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary",[86],67,[1154],[6781],{"trials":6795,"activeCount":112},[],{"trials":6797,"activeCount":112},[],{"trials":6799,"activeCount":112},[],{"trials":6801,"activeCount":112},[],{"intervention":6803,"totalTrials":109,"cells":6804},"High Dose Tranexamic acid",{"EARLY_PHASE1":6805,"PHASE1":6819,"PHASE2":6821,"PHASE3":6823,"PHASE4":6825,"NA":6827},{"trials":6806,"activeCount":112},[6807],{"nctId":6808,"briefTitle":6809,"status":131,"phases":6810,"primaryCompletion":6811,"completion":6811,"start":6812,"enrollment":2740,"conditions":6813,"interventions":6816},"NCT04797156","Combined IV and Topical TXA in Major Spine Surgery",[85],"2024-08-15","2021-03-03",[6814,6815],"Spine Surgery","Back Pain",[6803,6817,6818,2986],"Low Dose Tranexamic acid","Tranexamic acid Topical",{"trials":6820,"activeCount":112},[],{"trials":6822,"activeCount":112},[],{"trials":6824,"activeCount":112},[],{"trials":6826,"activeCount":112},[],{"trials":6828,"activeCount":112},[],{"intervention":6817,"totalTrials":109,"cells":6830},{"EARLY_PHASE1":6831,"PHASE1":6837,"PHASE2":6839,"PHASE3":6841,"PHASE4":6843,"NA":6845},{"trials":6832,"activeCount":112},[6833],{"nctId":6808,"briefTitle":6809,"status":131,"phases":6834,"primaryCompletion":6811,"completion":6811,"start":6812,"enrollment":2740,"conditions":6835,"interventions":6836},[85],[6814,6815],[6803,6817,6818,2986],{"trials":6838,"activeCount":112},[],{"trials":6840,"activeCount":112},[],{"trials":6842,"activeCount":112},[],{"trials":6844,"activeCount":112},[],{"trials":6846,"activeCount":112},[],{"intervention":6818,"totalTrials":109,"cells":6848},{"EARLY_PHASE1":6849,"PHASE1":6855,"PHASE2":6857,"PHASE3":6859,"PHASE4":6861,"NA":6863},{"trials":6850,"activeCount":112},[6851],{"nctId":6808,"briefTitle":6809,"status":131,"phases":6852,"primaryCompletion":6811,"completion":6811,"start":6812,"enrollment":2740,"conditions":6853,"interventions":6854},[85],[6814,6815],[6803,6817,6818,2986],{"trials":6856,"activeCount":112},[],{"trials":6858,"activeCount":112},[],{"trials":6860,"activeCount":112},[],{"trials":6862,"activeCount":112},[],{"trials":6864,"activeCount":112},[],{"intervention":6866,"totalTrials":109,"cells":6867},"Propranolol Hydrochloride",{"EARLY_PHASE1":6868,"PHASE1":6879,"PHASE2":6881,"PHASE3":6883,"PHASE4":6885,"NA":6887},{"trials":6869,"activeCount":112},[6870],{"nctId":6871,"briefTitle":6872,"status":131,"phases":6873,"primaryCompletion":6874,"completion":6874,"start":6875,"enrollment":3383,"conditions":6876,"interventions":6878},"NCT05928689","Behavioral and Pharmacological Reconsolidation Interference in Misophonia",[85],"2024-09-30","2023-06-02",[6877],"Misophonia",[6866],{"trials":6880,"activeCount":112},[],{"trials":6882,"activeCount":112},[],{"trials":6884,"activeCount":112},[],{"trials":6886,"activeCount":112},[],{"trials":6888,"activeCount":112},[],{"intervention":2485,"totalTrials":32,"cells":6890},{"EARLY_PHASE1":6891,"PHASE1":6893,"PHASE2":6895,"PHASE3":6897,"PHASE4":6911,"NA":6957},{"trials":6892,"activeCount":112},[],{"trials":6894,"activeCount":112},[],{"trials":6896,"activeCount":112},[],{"trials":6898,"activeCount":112},[6899],{"nctId":6900,"briefTitle":6901,"status":246,"phases":6902,"primaryCompletion":6903,"completion":6904,"start":6905,"enrollment":6906,"conditions":6907,"interventions":6910},"NCT06313632","Erector Spinae Plane Block With Bupivacaine for Medical Thoracoscopy",[88],"2025-03-19","2025-03-20","2024-03-28",33,[6908,6909],"Pleural Disease","Postoperative Pain",[2485],{"trials":6912,"activeCount":112},[6913,6922,6926,6930,6939,6943,6947],{"nctId":6914,"briefTitle":6915,"status":131,"phases":6916,"primaryCompletion":6917,"completion":6917,"start":2739,"enrollment":6918,"conditions":6919,"interventions":6921},"NCT03653416","Efficacy of Ipack Block and Surgeon's Joint Infiltration in Total Knee Arthroplasty",[89],"2019-08-01",99,[6920],"Osteo Arthritis Knee",[2485],{"nctId":3077,"briefTitle":3078,"status":246,"phases":6923,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":206,"conditions":6924,"interventions":6925},[89],[3083],[2485,3064],{"nctId":2735,"briefTitle":2736,"status":246,"phases":6927,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":2740,"conditions":6928,"interventions":6929},[89],[2742],[2485,2722],{"nctId":6931,"briefTitle":6932,"status":246,"phases":6933,"primaryCompletion":6934,"completion":6934,"start":6935,"enrollment":6724,"conditions":6936,"interventions":6938},"NCT05417113","Erector Spinae Block for Spine Surgery",[89],"2024-02-27","2022-08-31",[6937],"Lumbar Radiculopathy",[2484,2485],{"nctId":2745,"briefTitle":2746,"status":131,"phases":6940,"primaryCompletion":597,"completion":597,"start":2748,"enrollment":2749,"conditions":6941,"interventions":6942},[89],[2751],[2485,2722,2753],{"nctId":2568,"briefTitle":2569,"status":131,"phases":6944,"primaryCompletion":2571,"completion":2571,"start":2572,"enrollment":2573,"conditions":6945,"interventions":6946},[89],[2575,2576],[1907,2485],{"nctId":6948,"briefTitle":6949,"status":131,"phases":6950,"primaryCompletion":6951,"completion":6951,"start":6952,"enrollment":4809,"conditions":6953,"interventions":6956},"NCT04073056","Efficacy Of Quadratus Lumborum II Block For Laparoscopic Sleeve Gastrectomy",[89],"2021-02-23","2018-08-01",[6954,6955],"Morbid Obesity","High BMI",[2485],{"trials":6958,"activeCount":112},[6959,6963],{"nctId":2475,"briefTitle":2476,"status":131,"phases":6960,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":1524,"conditions":6961,"interventions":6962},[],[2481,2482],[2484,676,2485],{"nctId":6964,"briefTitle":6965,"status":131,"phases":6966,"primaryCompletion":6967,"completion":6967,"start":6968,"enrollment":6969,"conditions":6970,"interventions":6972},"NCT01534416","Effect of Paracervical Block on Post Operative Pain in Laparoscopic Gynecologic Surgery",[90],"2013-09","2011-09",132,[6909,1917,6971],"Laparoscopic Gynecologic Surgery",[2485,6973],"Normal Saline",{"intervention":2986,"totalTrials":2262,"cells":6975},{"EARLY_PHASE1":6976,"PHASE1":6982,"PHASE2":6984,"PHASE3":6990,"PHASE4":6992,"NA":7002},{"trials":6977,"activeCount":112},[6978],{"nctId":6808,"briefTitle":6809,"status":131,"phases":6979,"primaryCompletion":6811,"completion":6811,"start":6812,"enrollment":2740,"conditions":6980,"interventions":6981},[85],[6814,6815],[6803,6817,6818,2986],{"trials":6983,"activeCount":112},[],{"trials":6985,"activeCount":112},[6986],{"nctId":6051,"briefTitle":6052,"status":131,"phases":6987,"primaryCompletion":6054,"completion":6054,"start":6055,"enrollment":6056,"conditions":6988,"interventions":6989},[87],[6058,2549],[6042,2986],{"trials":6991,"activeCount":112},[],{"trials":6993,"activeCount":112},[6994,6998],{"nctId":2979,"briefTitle":2980,"status":131,"phases":6995,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":459,"conditions":6996,"interventions":6997},[89],[2983,2984],[2966,2986],{"nctId":2745,"briefTitle":2746,"status":131,"phases":6999,"primaryCompletion":597,"completion":597,"start":2748,"enrollment":2749,"conditions":7000,"interventions":7001},[89],[2751],[2485,2722,2753],{"trials":7003,"activeCount":112},[7004,7014],{"nctId":7005,"briefTitle":7006,"status":131,"phases":7007,"primaryCompletion":7008,"completion":7008,"start":7009,"enrollment":237,"conditions":7010,"interventions":7013},"NCT03689452","The Effect of Platelet Rich Plasma on Non-scarring Alopecia",[90],"2019-06-03","2018-10-01",[7011,7012],"Androgenetic Alopecia","Alopecia",[2986],{"nctId":6964,"briefTitle":6965,"status":131,"phases":7015,"primaryCompletion":6967,"completion":6967,"start":6968,"enrollment":6969,"conditions":7016,"interventions":7017},[90],[6909,1917,6971],[2485,6973],{"intervention":7019,"totalTrials":956,"cells":7020},"Apremilast",{"EARLY_PHASE1":7021,"PHASE1":7023,"PHASE2":7025,"PHASE3":7036,"PHASE4":7038,"NA":7048},{"trials":7022,"activeCount":112},[],{"trials":7024,"activeCount":112},[],{"trials":7026,"activeCount":112},[7027],{"nctId":7028,"briefTitle":7029,"status":131,"phases":7030,"primaryCompletion":7031,"completion":7031,"start":7032,"enrollment":726,"conditions":7033,"interventions":7035},"NCT03123016","Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo",[87],"2019-08-05","2017-04-14",[7034],"Vitiligo",[7019],{"trials":7037,"activeCount":112},[],{"trials":7039,"activeCount":112},[7040],{"nctId":7041,"briefTitle":7042,"status":131,"phases":7043,"primaryCompletion":7044,"completion":7044,"start":7045,"enrollment":283,"conditions":7046,"interventions":7047},"NCT03521687","Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)",[89],"2021-02-12","2018-11-15",[1182],[7019],{"trials":7049,"activeCount":112},[7050],{"nctId":7051,"briefTitle":7052,"status":131,"phases":7053,"primaryCompletion":7054,"completion":7054,"start":4302,"enrollment":237,"conditions":7055,"interventions":7056},"NCT02684123","Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata",[90],"2017-09-15",[981],[7019],{"intervention":7058,"totalTrials":956,"cells":7059},"Guanfacine",{"EARLY_PHASE1":7060,"PHASE1":7062,"PHASE2":7064,"PHASE3":7075,"PHASE4":7077,"NA":7088},{"trials":7061,"activeCount":112},[],{"trials":7063,"activeCount":112},[],{"trials":7065,"activeCount":112},[7066],{"nctId":7067,"briefTitle":7068,"status":131,"phases":7069,"primaryCompletion":7070,"completion":7070,"start":2782,"enrollment":928,"conditions":7071,"interventions":7074},"NCT02524899","CRT-Guanfacine for SPD",[87],"2017-01-10",[7072,7073],"Schizotypal Personality Disorder","SPD",[7058],{"trials":7076,"activeCount":112},[],{"trials":7078,"activeCount":112},[7079],{"nctId":7080,"briefTitle":7081,"status":246,"phases":7082,"primaryCompletion":7083,"completion":7083,"start":7084,"enrollment":9,"conditions":7085,"interventions":7087},"NCT00353379","Pharmacology of Cognition in Schizotypal Personality Disorder",[89],"1997-05","1995-09",[7072,7086],"Personality Disorders",[7058],{"trials":7089,"activeCount":112},[7090],{"nctId":7091,"briefTitle":7092,"status":668,"phases":7093,"start":7094,"conditions":7095,"interventions":7097},"NCT00358969","Guanfacine to Treat Borderline Personality Disorder",[90],"2006-07",[7096],"Borderline Personality Disorder",[7098],"guanfacine",{"intervention":336,"totalTrials":146,"cells":7100},{"EARLY_PHASE1":7101,"PHASE1":7103,"PHASE2":7105,"PHASE3":7107,"PHASE4":7109,"NA":7115},{"trials":7102,"activeCount":112},[],{"trials":7104,"activeCount":112},[],{"trials":7106,"activeCount":112},[],{"trials":7108,"activeCount":112},[],{"trials":7110,"activeCount":112},[7111],{"nctId":327,"briefTitle":328,"status":131,"phases":7112,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":7113,"interventions":7114},[89],[334],[336,314,337,338,339],{"trials":7116,"activeCount":112},[7117],{"nctId":7118,"briefTitle":7119,"status":131,"phases":7120,"primaryCompletion":7121,"completion":7121,"start":7122,"enrollment":155,"conditions":7123,"interventions":7124},"NCT00158028","Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder",[90],"2001-12","1995-11",[7072],[336],{"intervention":2484,"totalTrials":146,"cells":7126},{"EARLY_PHASE1":7127,"PHASE1":7129,"PHASE2":7131,"PHASE3":7133,"PHASE4":7135,"NA":7141},{"trials":7128,"activeCount":112},[],{"trials":7130,"activeCount":112},[],{"trials":7132,"activeCount":112},[],{"trials":7134,"activeCount":112},[],{"trials":7136,"activeCount":112},[7137],{"nctId":6931,"briefTitle":6932,"status":246,"phases":7138,"primaryCompletion":6934,"completion":6934,"start":6935,"enrollment":6724,"conditions":7139,"interventions":7140},[89],[6937],[2484,2485],{"trials":7142,"activeCount":112},[7143],{"nctId":2475,"briefTitle":2476,"status":131,"phases":7144,"primaryCompletion":2478,"completion":2478,"start":2479,"enrollment":1524,"conditions":7145,"interventions":7146},[],[2481,2482],[2484,676,2485],{"intervention":6702,"totalTrials":146,"cells":7148},{"EARLY_PHASE1":7149,"PHASE1":7151,"PHASE2":7157,"PHASE3":7159,"PHASE4":7161,"NA":7163},{"trials":7150,"activeCount":112},[],{"trials":7152,"activeCount":112},[7153],{"nctId":6695,"briefTitle":6696,"status":246,"phases":7154,"primaryCompletion":6698,"completion":6698,"start":6699,"enrollment":146,"conditions":7155,"interventions":7156},[86],[31],[6688,6702],{"trials":7158,"activeCount":112},[],{"trials":7160,"activeCount":112},[],{"trials":7162,"activeCount":112},[],{"trials":7164,"activeCount":112},[7165],{"nctId":7166,"briefTitle":7167,"status":131,"phases":7168,"primaryCompletion":4755,"completion":4755,"start":4097,"enrollment":7169,"conditions":7170,"interventions":7171},"NCT00900744","A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6",[],121,[31],[6702],{"intervention":7173,"totalTrials":146,"cells":7174},"fluoxetine",{"EARLY_PHASE1":7175,"PHASE1":7177,"PHASE2":7179,"PHASE3":7181,"PHASE4":7183,"NA":7185},{"trials":7176,"activeCount":112},[],{"trials":7178,"activeCount":112},[],{"trials":7180,"activeCount":112},[],{"trials":7182,"activeCount":112},[],{"trials":7184,"activeCount":112},[],{"trials":7186,"activeCount":112},[7187,7195],{"nctId":7188,"briefTitle":7189,"status":131,"phases":7190,"completion":3556,"start":7191,"enrollment":928,"conditions":7192,"interventions":7194},"NCT00004486","Randomized Study of Fluoxetine in Children and Adolescents With Autism",[90],"1998-09",[7193],"Autism",[7173],{"nctId":7196,"briefTitle":7197,"status":131,"phases":7198,"completion":7199,"start":7200,"enrollment":2288,"conditions":7201,"interventions":7203},"NCT00027404","Study of Fluoxetine in Adults With Autistic Disorder",[90],"2005-08","2001-09",[7202],"Autistic Disorder",[7204],"Fluoxetine",{"intervention":4629,"totalTrials":146,"cells":7206},{"EARLY_PHASE1":7207,"PHASE1":7209,"PHASE2":7211,"PHASE3":7213,"PHASE4":7219,"NA":7221},{"trials":7208,"activeCount":112},[],{"trials":7210,"activeCount":112},[],{"trials":7212,"activeCount":112},[],{"trials":7214,"activeCount":112},[7215],{"nctId":4622,"briefTitle":4623,"status":131,"phases":7216,"primaryCompletion":3031,"completion":3031,"start":2849,"enrollment":4625,"conditions":7217,"interventions":7218},[88],[4627],[4629,4611],{"trials":7220,"activeCount":112},[],{"trials":7222,"activeCount":112},[7223],{"nctId":7224,"briefTitle":7225,"status":246,"phases":7226,"primaryCompletion":3215,"completion":3832,"start":248,"enrollment":7227,"conditions":7228,"interventions":7230},"NCT02301390","INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events",[90],53,[7229],"Ventricular Tachycardia",[4629],{"intervention":7232,"totalTrials":109,"cells":7233},"cysteamine bitartrate",{"EARLY_PHASE1":7234,"PHASE1":7236,"PHASE2":7238,"PHASE3":7240,"PHASE4":7242,"NA":7244},{"trials":7235,"activeCount":112},[],{"trials":7237,"activeCount":112},[],{"trials":7239,"activeCount":112},[],{"trials":7241,"activeCount":112},[],{"trials":7243,"activeCount":112},[],{"trials":7245,"activeCount":112},[7246],{"nctId":7247,"briefTitle":7248,"status":246,"phases":7249,"primaryCompletion":4649,"completion":4649,"start":7250,"enrollment":956,"conditions":7251,"interventions":7252},"NCT00715559","Cysteamine Therapy for Major Depressive Disorder",[90],"2008-07",[18],[7232],{"intervention":7254,"totalTrials":109,"cells":7255},"40 IU Intranasal Oxytocin",{"EARLY_PHASE1":7256,"PHASE1":7258,"PHASE2":7260,"PHASE3":7262,"PHASE4":7264,"NA":7266},{"trials":7257,"activeCount":112},[],{"trials":7259,"activeCount":112},[],{"trials":7261,"activeCount":112},[],{"trials":7263,"activeCount":112},[],{"trials":7265,"activeCount":112},[],{"trials":7267,"activeCount":112},[7268],{"nctId":7269,"briefTitle":7270,"status":7271,"phases":7272,"primaryCompletion":7273,"completion":1409,"start":7274,"enrollment":195,"conditions":7275,"interventions":7276},"NCT02225600","The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults","SUSPENDED",[90],"2027-07","2014-08-26",[7096],[7254,7277],"24 IU intranasal Oxytocin",{"intervention":7277,"totalTrials":109,"cells":7279},{"EARLY_PHASE1":7280,"PHASE1":7282,"PHASE2":7284,"PHASE3":7286,"PHASE4":7288,"NA":7290},{"trials":7281,"activeCount":112},[],{"trials":7283,"activeCount":112},[],{"trials":7285,"activeCount":112},[],{"trials":7287,"activeCount":112},[],{"trials":7289,"activeCount":112},[],{"trials":7291,"activeCount":112},[7292],{"nctId":7269,"briefTitle":7270,"status":7271,"phases":7293,"primaryCompletion":7273,"completion":1409,"start":7274,"enrollment":195,"conditions":7294,"interventions":7295},[90],[7096],[7254,7277],{"intervention":7297,"totalTrials":109,"cells":7298},"isradipine",{"EARLY_PHASE1":7299,"PHASE1":7301,"PHASE2":7303,"PHASE3":7305,"PHASE4":7307,"NA":7309},{"trials":7300,"activeCount":112},[],{"trials":7302,"activeCount":112},[],{"trials":7304,"activeCount":112},[],{"trials":7306,"activeCount":112},[],{"trials":7308,"activeCount":112},[],{"trials":7310,"activeCount":112},[7311],{"nctId":7312,"briefTitle":7313,"status":131,"phases":7314,"primaryCompletion":7315,"completion":7315,"start":7316,"enrollment":294,"conditions":7317,"interventions":7319},"NCT01658150","Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder",[90],"2018-01-02","2012-09",[334,7318],"Schizoaffective Disorder",[7297],{"intervention":7321,"totalTrials":109,"cells":7322},"droxidopa",{"EARLY_PHASE1":7323,"PHASE1":7325,"PHASE2":7327,"PHASE3":7329,"PHASE4":7331,"NA":7333},{"trials":7324,"activeCount":112},[],{"trials":7326,"activeCount":112},[],{"trials":7328,"activeCount":112},[],{"trials":7330,"activeCount":112},[],{"trials":7332,"activeCount":112},[],{"trials":7334,"activeCount":112},[7335],{"nctId":7336,"briefTitle":7337,"status":131,"phases":7338,"primaryCompletion":7339,"completion":7339,"start":7340,"conditions":7341,"interventions":7344},"NCT00004478","Droxidopa in Treating Patients With Neurogenic Hypotension",[90],"2006-03","1999-03",[7342,7343],"Shy-Drager Syndrome","Orthostatic Hypotension",[7321],{"intervention":7346,"totalTrials":109,"cells":7347},"Oral Iron",{"EARLY_PHASE1":7348,"PHASE1":7350,"PHASE2":7352,"PHASE3":7354,"PHASE4":7356,"NA":7358},{"trials":7349,"activeCount":112},[],{"trials":7351,"activeCount":112},[],{"trials":7353,"activeCount":112},[],{"trials":7355,"activeCount":112},[],{"trials":7357,"activeCount":112},[],{"trials":7359,"activeCount":112},[7360],{"nctId":7361,"briefTitle":7362,"status":131,"phases":7363,"primaryCompletion":4301,"completion":4301,"start":5989,"enrollment":16,"conditions":7364,"interventions":7369},"NCT02979249","Oral Iron for Erythropoietic Protoporphyrias",[90],[7365,7366,7367,7368],"Erythropoietic Protoporphyria","EPP","X-linked Protoporphyria","XLP",[7346],{"intervention":7371,"totalTrials":109,"cells":7372},"midodrine",{"EARLY_PHASE1":7373,"PHASE1":7375,"PHASE2":7377,"PHASE3":7379,"PHASE4":7381,"NA":7383},{"trials":7374,"activeCount":112},[],{"trials":7376,"activeCount":112},[],{"trials":7378,"activeCount":112},[],{"trials":7380,"activeCount":112},[],{"trials":7382,"activeCount":112},[],{"trials":7384,"activeCount":112},[7385],{"nctId":7386,"briefTitle":7387,"status":131,"phases":7388,"start":7340,"conditions":7389,"interventions":7391},"NCT00004479","Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope",[90],[7390],"Syncope",[7371],{"intervention":7393,"totalTrials":109,"cells":7394},"Systane Ultra",{"EARLY_PHASE1":7395,"PHASE1":7397,"PHASE2":7399,"PHASE3":7401,"PHASE4":7403,"NA":7405},{"trials":7396,"activeCount":112},[],{"trials":7398,"activeCount":112},[],{"trials":7400,"activeCount":112},[],{"trials":7402,"activeCount":112},[],{"trials":7404,"activeCount":112},[],{"trials":7406,"activeCount":112},[7407],{"nctId":7408,"briefTitle":7409,"status":131,"phases":7410,"primaryCompletion":3680,"completion":3680,"start":7411,"enrollment":6239,"conditions":7412,"interventions":7414},"NCT01775540","Systane Ultra Versus Maxidex Versus Saline",[90],"2012-05",[7413],"Dry Eye Disease",[7393,7415,7416],"Saline solution","Maxidex",{"intervention":7415,"totalTrials":109,"cells":7418},{"EARLY_PHASE1":7419,"PHASE1":7421,"PHASE2":7423,"PHASE3":7425,"PHASE4":7427,"NA":7429},{"trials":7420,"activeCount":112},[],{"trials":7422,"activeCount":112},[],{"trials":7424,"activeCount":112},[],{"trials":7426,"activeCount":112},[],{"trials":7428,"activeCount":112},[],{"trials":7430,"activeCount":112},[7431],{"nctId":7408,"briefTitle":7409,"status":131,"phases":7432,"primaryCompletion":3680,"completion":3680,"start":7411,"enrollment":6239,"conditions":7433,"interventions":7434},[90],[7413],[7393,7415,7416],{"intervention":7416,"totalTrials":109,"cells":7436},{"EARLY_PHASE1":7437,"PHASE1":7439,"PHASE2":7441,"PHASE3":7443,"PHASE4":7445,"NA":7447},{"trials":7438,"activeCount":112},[],{"trials":7440,"activeCount":112},[],{"trials":7442,"activeCount":112},[],{"trials":7444,"activeCount":112},[],{"trials":7446,"activeCount":112},[],{"trials":7448,"activeCount":112},[7449],{"nctId":7408,"briefTitle":7409,"status":131,"phases":7450,"primaryCompletion":3680,"completion":3680,"start":7411,"enrollment":6239,"conditions":7451,"interventions":7452},[90],[7413],[7393,7415,7416],{"intervention":7454,"totalTrials":109,"cells":7455},"Desmopressin",{"EARLY_PHASE1":7456,"PHASE1":7458,"PHASE2":7460,"PHASE3":7462,"PHASE4":7464,"NA":7466},{"trials":7457,"activeCount":112},[],{"trials":7459,"activeCount":112},[],{"trials":7461,"activeCount":112},[],{"trials":7463,"activeCount":112},[],{"trials":7465,"activeCount":112},[],{"trials":7467,"activeCount":112},[7468],{"nctId":7469,"briefTitle":7470,"status":131,"phases":7471,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":6239,"conditions":7474,"interventions":7477},"NCT00816127","Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction",[90],"2007-05","2003-10",[7475,7476],"Liver Cirrhosis","Coagulopathy",[7454,7478],"blood transfusion",{"intervention":7478,"totalTrials":109,"cells":7480},{"EARLY_PHASE1":7481,"PHASE1":7483,"PHASE2":7485,"PHASE3":7487,"PHASE4":7489,"NA":7491},{"trials":7482,"activeCount":112},[],{"trials":7484,"activeCount":112},[],{"trials":7486,"activeCount":112},[],{"trials":7488,"activeCount":112},[],{"trials":7490,"activeCount":112},[],{"trials":7492,"activeCount":112},[7493],{"nctId":7469,"briefTitle":7470,"status":131,"phases":7494,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":6239,"conditions":7495,"interventions":7496},[90],[7475,7476],[7454,7478],{"intervention":7498,"totalTrials":109,"cells":7499},"Oxymorphone",{"EARLY_PHASE1":7500,"PHASE1":7502,"PHASE2":7504,"PHASE3":7506,"PHASE4":7508,"NA":7510},{"trials":7501,"activeCount":112},[],{"trials":7503,"activeCount":112},[],{"trials":7505,"activeCount":112},[],{"trials":7507,"activeCount":112},[],{"trials":7509,"activeCount":112},[],{"trials":7511,"activeCount":112},[7512],{"nctId":7513,"briefTitle":7514,"status":131,"phases":7515,"primaryCompletion":5673,"completion":5673,"start":2885,"enrollment":29,"conditions":7516,"interventions":7517},"NCT00580294","A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)",[90],[5786],[7498],{"intervention":7519,"totalTrials":109,"cells":7520},"botulinum toxin type A",{"EARLY_PHASE1":7521,"PHASE1":7523,"PHASE2":7525,"PHASE3":7527,"PHASE4":7529,"NA":7531},{"trials":7522,"activeCount":112},[],{"trials":7524,"activeCount":112},[],{"trials":7526,"activeCount":112},[],{"trials":7528,"activeCount":112},[],{"trials":7530,"activeCount":112},[],{"trials":7532,"activeCount":112},[7533],{"nctId":7534,"briefTitle":7535,"status":131,"phases":7536,"start":7537,"conditions":7538,"interventions":7540},"NCT00004480","Study of Botulinum Toxin in Patients With Primary Hyperhidrosis",[90],"1999-07",[7539],"Hyperhidrosis",[7519],{"intervention":7542,"totalTrials":109,"cells":7543},"seroquel xr",{"EARLY_PHASE1":7544,"PHASE1":7546,"PHASE2":7548,"PHASE3":7550,"PHASE4":7552,"NA":7554},{"trials":7545,"activeCount":112},[],{"trials":7547,"activeCount":112},[],{"trials":7549,"activeCount":112},[],{"trials":7551,"activeCount":112},[],{"trials":7553,"activeCount":112},[],{"trials":7555,"activeCount":112},[7556],{"nctId":7557,"briefTitle":7558,"status":131,"phases":7559,"primaryCompletion":5179,"completion":5179,"start":7560,"enrollment":395,"conditions":7561,"interventions":7563},"NCT01971203","Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat",[90],"2009-09",[18,7562],"Generalized Anxiety Disorder",[7542],{"intervention":7565,"totalTrials":109,"cells":7566},"Sinecatechins 15% Ointment",{"EARLY_PHASE1":7567,"PHASE1":7569,"PHASE2":7571,"PHASE3":7573,"PHASE4":7575,"NA":7577},{"trials":7568,"activeCount":112},[],{"trials":7570,"activeCount":112},[],{"trials":7572,"activeCount":112},[],{"trials":7574,"activeCount":112},[],{"trials":7576,"activeCount":112},[],{"trials":7578,"activeCount":112},[7579],{"nctId":7580,"briefTitle":7581,"status":131,"phases":7582,"primaryCompletion":4785,"completion":4785,"start":6968,"enrollment":1367,"conditions":7583,"interventions":7585},"NCT02147353","Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment",[90],[7584],"External Genital Warts",[7565,7586],"Cryotherapy alone",{"intervention":7586,"totalTrials":109,"cells":7588},{"EARLY_PHASE1":7589,"PHASE1":7591,"PHASE2":7593,"PHASE3":7595,"PHASE4":7597,"NA":7599},{"trials":7590,"activeCount":112},[],{"trials":7592,"activeCount":112},[],{"trials":7594,"activeCount":112},[],{"trials":7596,"activeCount":112},[],{"trials":7598,"activeCount":112},[],{"trials":7600,"activeCount":112},[7601],{"nctId":7580,"briefTitle":7581,"status":131,"phases":7602,"primaryCompletion":4785,"completion":4785,"start":6968,"enrollment":1367,"conditions":7603,"interventions":7604},[90],[7584],[7565,7586],{"intervention":7606,"totalTrials":109,"cells":7607},"Glycopyrrolate",{"EARLY_PHASE1":7608,"PHASE1":7610,"PHASE2":7612,"PHASE3":7614,"PHASE4":7616,"NA":7618},{"trials":7609,"activeCount":112},[],{"trials":7611,"activeCount":112},[],{"trials":7613,"activeCount":112},[],{"trials":7615,"activeCount":112},[],{"trials":7617,"activeCount":112},[],{"trials":7619,"activeCount":112},[7620],{"nctId":7621,"briefTitle":7622,"status":131,"phases":7623,"primaryCompletion":7624,"completion":7624,"start":7625,"enrollment":7626,"conditions":7627,"interventions":7629},"NCT03742141","Intraoperative Video Laryngoscopy as Adjunct for Nerve Monitoring",[90],"2022-01-18","2018-10-17",125,[7628],"Vocal Cord Function in Neck Procedures",[7606],{"intervention":7631,"totalTrials":109,"cells":7632},"PEG-interleukin-2",{"EARLY_PHASE1":7633,"PHASE1":7635,"PHASE2":7637,"PHASE3":7639,"PHASE4":7641,"NA":7643},{"trials":7634,"activeCount":112},[],{"trials":7636,"activeCount":112},[],{"trials":7638,"activeCount":112},[],{"trials":7640,"activeCount":112},[],{"trials":7642,"activeCount":112},[],{"trials":7644,"activeCount":112},[7645],{"nctId":7646,"briefTitle":7647,"status":131,"phases":7648,"completion":7649,"start":7650,"enrollment":2288,"conditions":7651,"interventions":7653},"NCT00004695","Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency",[90],"2000-03","1997-09",[7652],"Common Variable Immunodeficiency",[7631],{"intervention":7655,"totalTrials":109,"cells":7656},"Oxymorphone ER",{"EARLY_PHASE1":7657,"PHASE1":7659,"PHASE2":7661,"PHASE3":7663,"PHASE4":7665,"NA":7667},{"trials":7658,"activeCount":112},[],{"trials":7660,"activeCount":112},[],{"trials":7662,"activeCount":112},[],{"trials":7664,"activeCount":112},[],{"trials":7666,"activeCount":112},[],{"trials":7668,"activeCount":112},[7669],{"nctId":7670,"briefTitle":7671,"status":668,"phases":7672,"primaryCompletion":7673,"completion":3105,"start":249,"enrollment":29,"conditions":7674,"interventions":7677},"NCT00945919","A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone",[90],"2010-12",[7675,5026,7676],"Chronic Nociceptive Pain","Non-cancer Pain",[7655],{"intervention":7679,"totalTrials":109,"cells":7680},"Vayarin",{"EARLY_PHASE1":7681,"PHASE1":7683,"PHASE2":7685,"PHASE3":7687,"PHASE4":7689,"NA":7691},{"trials":7682,"activeCount":112},[],{"trials":7684,"activeCount":112},[],{"trials":7686,"activeCount":112},[],{"trials":7688,"activeCount":112},[],{"trials":7690,"activeCount":112},[],{"trials":7692,"activeCount":112},[7693],{"nctId":7694,"briefTitle":7695,"status":131,"phases":7696,"primaryCompletion":7697,"completion":7697,"start":7698,"enrollment":7699,"conditions":7700,"interventions":7701},"NCT02473419","Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment",[],"2017-03-02","2015-05",107,[125],[7679],{"intervention":7703,"totalTrials":109,"cells":7704},"Locoid Lipocream",{"EARLY_PHASE1":7705,"PHASE1":7707,"PHASE2":7709,"PHASE3":7711,"PHASE4":7713,"NA":7715},{"trials":7706,"activeCount":112},[],{"trials":7708,"activeCount":112},[],{"trials":7710,"activeCount":112},[],{"trials":7712,"activeCount":112},[],{"trials":7714,"activeCount":112},[],{"trials":7716,"activeCount":112},[7717],{"nctId":7718,"briefTitle":7719,"status":131,"phases":7720,"primaryCompletion":2782,"completion":2782,"start":2912,"enrollment":4809,"conditions":7721,"interventions":7722},"NCT02153762","Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream",[90],[1312],[7703,7723],"Hylatopic Plus",{"intervention":7723,"totalTrials":109,"cells":7725},{"EARLY_PHASE1":7726,"PHASE1":7728,"PHASE2":7730,"PHASE3":7732,"PHASE4":7734,"NA":7736},{"trials":7727,"activeCount":112},[],{"trials":7729,"activeCount":112},[],{"trials":7731,"activeCount":112},[],{"trials":7733,"activeCount":112},[],{"trials":7735,"activeCount":112},[],{"trials":7737,"activeCount":112},[7738],{"nctId":7718,"briefTitle":7719,"status":131,"phases":7739,"primaryCompletion":2782,"completion":2782,"start":2912,"enrollment":4809,"conditions":7740,"interventions":7741},[90],[1312],[7703,7723],{"intervention":7743,"totalTrials":109,"cells":7744},"Warfarin",{"EARLY_PHASE1":7745,"PHASE1":7747,"PHASE2":7749,"PHASE3":7751,"PHASE4":7753,"NA":7755},{"trials":7746,"activeCount":112},[],{"trials":7748,"activeCount":112},[],{"trials":7750,"activeCount":112},[],{"trials":7752,"activeCount":112},[],{"trials":7754,"activeCount":112},[],{"trials":7756,"activeCount":112},[7757],{"nctId":7758,"briefTitle":7759,"status":131,"phases":7760,"primaryCompletion":3105,"completion":3105,"start":3910,"enrollment":7761,"conditions":7762,"interventions":7763},"NCT01520402","Genetic Response to Warfarin in Healthy Subjects",[90],35,[578],[7743],{"intervention":7765,"totalTrials":109,"cells":7766},"statin",{"EARLY_PHASE1":7767,"PHASE1":7769,"PHASE2":7771,"PHASE3":7773,"PHASE4":7775,"NA":7777},{"trials":7768,"activeCount":112},[],{"trials":7770,"activeCount":112},[],{"trials":7772,"activeCount":112},[],{"trials":7774,"activeCount":112},[],{"trials":7776,"activeCount":112},[],{"trials":7778,"activeCount":112},[7779],{"nctId":7780,"briefTitle":7781,"status":131,"phases":7782,"primaryCompletion":7783,"completion":7783,"start":7784,"enrollment":7785,"conditions":7786,"interventions":7787},"NCT05984953","Rosuvastatin and Evolocumab for Coronary Artery Disease",[],"2022-10-28","2013-08-01",195,[15],[7765,7788],"evolocumab",{"intervention":7788,"totalTrials":109,"cells":7790},{"EARLY_PHASE1":7791,"PHASE1":7793,"PHASE2":7795,"PHASE3":7797,"PHASE4":7799,"NA":7801},{"trials":7792,"activeCount":112},[],{"trials":7794,"activeCount":112},[],{"trials":7796,"activeCount":112},[],{"trials":7798,"activeCount":112},[],{"trials":7800,"activeCount":112},[],{"trials":7802,"activeCount":112},[7803],{"nctId":7780,"briefTitle":7781,"status":131,"phases":7804,"primaryCompletion":7783,"completion":7783,"start":7784,"enrollment":7785,"conditions":7805,"interventions":7806},[],[15],[7765,7788],{"intervention":7808,"totalTrials":109,"cells":7809},"Tyrosine",{"EARLY_PHASE1":7810,"PHASE1":7812,"PHASE2":7814,"PHASE3":7816,"PHASE4":7818,"NA":7820},{"trials":7811,"activeCount":112},[],{"trials":7813,"activeCount":112},[],{"trials":7815,"activeCount":112},[],{"trials":7817,"activeCount":112},[],{"trials":7819,"activeCount":112},[],{"trials":7821,"activeCount":112},[7822],{"nctId":7823,"briefTitle":7824,"status":246,"phases":7825,"primaryCompletion":7826,"completion":7826,"start":3032,"enrollment":19,"conditions":7827,"interventions":7829},"NCT01219049","L-Tyrosine Supplementation in Patients With Fibromyalgia",[90],"2011-01",[7828],"Fibromyalgia",[7808,7808],{"intervention":7831,"totalTrials":109,"cells":7832},"pudendal block",{"EARLY_PHASE1":7833,"PHASE1":7835,"PHASE2":7837,"PHASE3":7839,"PHASE4":7841,"NA":7843},{"trials":7834,"activeCount":112},[],{"trials":7836,"activeCount":112},[],{"trials":7838,"activeCount":112},[],{"trials":7840,"activeCount":112},[],{"trials":7842,"activeCount":112},[],{"trials":7844,"activeCount":112},[7845],{"nctId":7846,"briefTitle":7847,"status":222,"phases":7848,"primaryCompletion":2631,"completion":2631,"start":2631,"enrollment":112,"conditions":7849,"interventions":7851},"NCT02409498","Use of Pre-Emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery",[90],[7850],"Pelvic Organ Prolapse",[7831,7852],"no pudendal block",{"intervention":7852,"totalTrials":109,"cells":7854},{"EARLY_PHASE1":7855,"PHASE1":7857,"PHASE2":7859,"PHASE3":7861,"PHASE4":7863,"NA":7865},{"trials":7856,"activeCount":112},[],{"trials":7858,"activeCount":112},[],{"trials":7860,"activeCount":112},[],{"trials":7862,"activeCount":112},[],{"trials":7864,"activeCount":112},[],{"trials":7866,"activeCount":112},[7867],{"nctId":7846,"briefTitle":7847,"status":222,"phases":7868,"primaryCompletion":2631,"completion":2631,"start":2631,"enrollment":112,"conditions":7869,"interventions":7870},[90],[7850],[7831,7852]]